0001844149
false
0001844149
2023-11-17
2023-11-17
0001844149
SPEC:CommonStockParValue0.0001PerShareMember
2023-11-17
2023-11-17
0001844149
SPEC:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member
2023-11-17
2023-11-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
November 17, 2023
Spectaire Holdings Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-40976 |
|
98-1578608 |
(State or other jurisdiction |
|
(Commission File Number) |
|
(I.R.S. Employer |
of incorporation) |
|
|
|
Identification No.) |
155 Arlington St., Watertown, MA |
|
02472 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (508) 213-8991
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common stock, par value $0.0001 per share |
|
SPEC |
|
The Nasdaq Stock Market LLC |
Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 |
|
SPECW |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.01 Entry into a Material Definitive Agreement
Equity Line of Credit
On November 17, 2023, Spectaire Holdings Inc.
(the “Company”) entered into a Common Stock Purchase Agreement (the “ELOC Purchase Agreement”) with the Equity Line investor (the “ELOC Purchaser”), whereby the Company has the right, but not the obligation, to sell to the ELOC Purchaser,
and the ELOC Purchaser is obligated to purchase, up to the lesser of (i) an aggregate of $20 million of newly issued shares (the “ELOC
Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”) and (ii) the Exchange Cap
(as defined in the ELOC Purchase Agreement).
The Company does not have a right to commence
any sales of Common Stock to the ELOC Purchaser under the ELOC Purchase Agreement until the time when all of the conditions to the Company’s
right to commence sales of Common Stock to the ELOC Purchaser set forth in the ELOC Purchase Agreement have been satisfied, including
that a registration statement of such shares is declared effective by the SEC and the final form of prospectus is filed with the SEC (the
“Commencement Date”). Over the 24-month period from and after the Commencement Date, the Company will control the timing and
amount of any sales of Common Stock to the ELOC Purchaser. Actual sales of shares of Common Stock to the ELOC Purchaser under the ELOC
Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market
conditions, the trading price of the Common Stock and determinations by us as to the appropriate sources of funding and our operations.
At any time after the Commencement Date, and so
long as the closing sale price of the Common Stock is equal to or greater than $1.00 per share, the Company may direct the ELOC Purchaser
to purchase a specified number of shares of Common Stock (a “Fixed Purchase”) at a purchase price equal to the lesser of ninety-five
percent (95.0%) of (i) the closing sale price on the applicable purchase date for such Fixed Purchase and (ii) the daily volume weighted
average price for the Common Stock on the NASDAQ for the five (5) consecutive trading days immediately preceding the applicable purchase
date for such Fixed Purchase. In addition, at any time after the Commencement Date, and so long as (i) the closing sale price of the Common
Stock is equal to or greater than $1.00 per share and (ii) such date is also a purchase date for a Fixed Purchase of a number of shares
of Common Stock not less than the applicable Fixed Purchase Maximum Amount (as defined in the ELOC Purchase Agreement), the Company may
also direct the ELOC Purchaser to purchase on the immediately following business day an additional number of shares of Common Stock in
an amount up to the Maximum VWAP Purchase Amount (as defined in the ELOC Purchase Agreement) (a “VWAP Purchase”) at a purchase
price equal to the lesser of 95% of (i) the volume weighted average price for the Common Stock on the applicable purchase date for the
VWAP Purchase and (ii) the lowest intraday sales price of a share of the Common Stock on the applicable purchase date for the VWAP Purchase.
At any time after the Commencement Date, and so long as such date is also a purchase date for a VWAP Purchase of a number of shares of
Common Stock, then the Company may also direct the ELOC Purchaser to purchase on the immediately following business day an additional
number of shares of Common Stock in an amount up to the Maximum Additional VWAP Purchase Amount (as defined in the ELOC Purchase Agreement)
(an “Additional VWAP Purchase”) at a purchase price equal to the lesser of 95% of (i) the volume weighted average price for
the Common Stock on the applicable purchase date for such Additional VWAP Purchase and (ii) the lowest intraday sales price of a share
of the Common Stock on the applicable purchase date for such Additional VWAP Purchase.
Under the applicable Nasdaq rules, in no event
may the Company issue to the ELOC Purchaser under the ELOC Purchase Agreement more than the Exchange Cap, equal to 3,067,438 shares of
Common Stock (representing 19.99% of the total number of our shares of Common Stock issued and outstanding immediately prior to the execution
of the ELOC Purchase Agreement), unless the Company obtains stockholder approval to issue shares of Common Stock in excess of the Exchange
Cap or unless sales of Common Stock are made at a price equal to or greater than $2.23 per share, such that the Exchange Cap limitation
would not apply under applicable Nasdaq rules. In any event, the ELOC Purchase Agreement provides that the Company may not issue or sell
any shares of Common Stock under the ELOC Purchase Agreement if such issuance or sale would breach any applicable Nasdaq rules. The ELOC
Purchase Agreement prohibits the Company from directing the ELOC Purchaser to purchase any shares of our Common Stock if those shares,
when aggregated with all other shares of our Common Stock then beneficially owned by the ELOC Purchaser (as calculated pursuant to Section
13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder), would result in the ELOC Purchaser beneficially
owning more than 4.99% of the outstanding Common Stock.
As consideration for the ELOC Purchaser’s
irrevocable commitment to purchase shares of Common Stock upon the terms of and subject to satisfaction of the conditions set forth in
the ELOC Purchase Agreement, concurrently with the execution and delivery of the ELOC Purchase Agreement, we issued a Convertible Promissory
Note to the ELOC Purchaser in the amount of $300,000 due and payable on May 17, 2024 and convertible into shares of Common Stock (such
shares of Common Stock, the “Note Shares”).
In addition, in connection with the ELOC Purchase
Agreement, the Company and the ELOC Purchaser entered into a Registration Rights Agreement whereby, among other things, the Company shall
file a registration statement registering the resale of the Note Shares within 10 business days following the date of the Registration
Rights Agreement.
Amendment to Forward Purchase Agreement
On November 17, 2023, the Company entered into
a Forward Purchase Agreement Confirmation Amendment (the “FPA Amendment”) with (i) Meteora Special Opportunity Fund I, LP
(“MSOF”), (ii) Meteora Capital Partners, LP (“MCP”), (iii) Meteora Select Trading Opportunities Master, LP (“MSTO”),
(iv) Meteora Strategic Capital, LLC (“MSC”) (with MSOF, MCP, MSTO and MSC collectively as “Seller”) and (v) Spectaire
Inc. (“Spectaire Sub”) for purposes of amending the previously disclosed OTC Equity Prepaid Forward Transaction, dated as
of January 14, 2023 (amended on October 16, 2023 and as amended from time to time, the “Confirmation”) by and among Seller,
the Company and Spectaire Sub. Pursuant to the FPA Amendment, the parties agreed to reduce the Reset Price (as defined in the Confirmation)
to $1.75 and the Company agreed to release 125,000 Recycled Shares (as defined in the Confirmation) to the Seller as additional Share
Consideration Shares (as defined in the Confirmation).
This Current Report shall
not constitute an offer to sell or the solicitation of an offer to buy, nor shall such securities be offered or sold in the United States
absent registration or an applicable exemption from the registration requirements and certificates evidencing such shares contain a legend
stating the same.
The foregoing
description of the ELOC Purchase Agreement, the Convertible Promissory Note, the Registration Rights Agreement and the FPA Amendment does
not purport to be complete and is qualified in its entirety by reference to the full text of each of the ELOC Purchase Agreement, the
Convertible Promissory Note, the Registration Rights Agreement and the FPA Amendment, copies of which are filed as Exhibit 10.1, Exhibit
10.2, Exhibit 10.3 and Exhibit 10.4 to this Current Report on Form 8-K, respectively, and are incorporated by reference herein.
Item 3.02 Unregistered Sales of Equity Securities
The information set
forth in “Item 1.01 Entry into a Material Definitive Agreement” relating to the issuance of Common Stock is incorporated
by reference herein in its entirety. The Company issued the Common Stock in reliance upon the exemption from registration provided by
Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D promulgated thereunder. This Current Report on Form 8-K shall
not constitute an offer to sell or the solicitation of an offer to buy, nor shall such securities be offered or sold in the United States
absent registration or an applicable exemption from the registration requirements and certificates evidencing such shares contain a legend
stating the same.
Item 9.01. Financial Statements and Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Spectaire Holdings
Inc. |
|
|
|
Date: November 20, 2023 |
By: |
/s/ Brian Semkiw |
|
Name: |
Brian Semkiw |
|
Title: |
Chief Executive Officer |
3
Exhibit 10.1
Execution Version
COMMON STOCK PURCHASE AGREEMENT
DATED AS OF NOVEMBER 17, 2023
BY AND
BETWEEN
SPECTAIRE HOLDINGS, INC.
AND
KEYSTONE CAPITAL PARTNERS,
LLC
TABLE OF CONTENTS
ARTICLE I PURCHASE AND SALE OF COMMON STOCK |
1 |
Section 1.1 |
Purchase and Sale of Stock |
1 |
Section 1.2 |
Commencement Date; Settlement Dates |
2 |
Section 1.3 |
Current Report; |
2 |
Section 1.4 |
Registration Statement |
2 |
|
|
|
ARTICLE II PURCHASE TERMS |
3 |
Section 2.1 |
Fixed Purchases |
3 |
Section 2.2 |
VWAP Purchases |
4 |
Section 2.3 |
Additional VWAP Purchases |
5 |
Section 2.4 |
Settlement |
6 |
Section 2.5 |
Compliance with Rules of Trading Market. |
7 |
Section 2.6 |
Beneficial Ownership Limitation |
8 |
Section 2.7 |
Note Shares |
8 |
|
|
|
ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE INVESTOR |
8 |
Section 3.1 |
Organization and Standing of the Investor |
8 |
Section 3.2 |
Authorization and Power |
8 |
Section 3.3 |
No Conflicts |
9 |
Section 3.4 |
Information |
9 |
Section 3.5 |
No Governmental Review |
9 |
Section 3.6 |
Not an Affiliate |
9 |
Section 3.7 |
Certain Trading Activities |
10 |
Section 3.8 |
Statutory Underwriter Status |
10 |
Section 3.9 |
Resales of Securities |
10 |
|
|
|
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE COMPANY |
10 |
Section 4.1 |
Organization, Good Standing and Power. |
10 |
Section 4.2 |
Authorization, Enforcement |
11 |
Section 4.3 |
Capitalization |
11 |
Section 4.4 |
Issuance of Securities |
11 |
Section 4.5 |
No Conflicts |
12 |
Section 4.6 |
Commission Documents, Financial Statements; Disclosure Controls and Procedures; Internal Controls Over Financial Reporting; Accountants. |
12 |
Section 4.7 |
Subsidiaries |
14 |
Section 4.8 |
No Material Adverse Effect |
15 |
Section 4.9 |
No Undisclosed Liabilities |
15 |
Section 4.10 |
No Undisclosed Events or Circumstances |
15 |
Section 4.11 |
Indebtedness |
15 |
Section 4.12 |
Title To Assets |
16 |
Section 4.13 |
Actions Pending |
16 |
Section 4.14 |
Compliance With Law |
16 |
Section 4.15 |
Certain Fees |
16 |
Section 4.16 |
Operation of Business |
17 |
Section 4.17 |
Environmental Compliance |
18 |
Section 4.18 |
Material Agreements |
18 |
Section 4.19 |
Transactions With Affiliates |
18 |
Section 4.20 |
Securities Act |
19 |
Section 4.21 |
Employees; Labor Laws |
20 |
Section 4.22 |
Use of Proceeds |
20 |
Section 4.23 |
Investment Company Act Status |
20 |
Section 4.24 |
ERISA |
20 |
Section 4.25 |
Taxes |
21 |
Section 4.26 |
Insurance |
21 |
Section 4.27 |
U.S. Real Property Holding Corporation |
21 |
Section 4.28 |
Listing and Maintenance Requirements; DTC Eligibility |
22 |
Section 4.29 |
No Unlawful Payments |
22 |
Section 4.30 |
Money Laundering Laws |
22 |
Section 4.31 |
OFAC |
23 |
Section 4.32 |
Disclosure |
23 |
Section 4.33 |
Bank Holding Company Act |
23 |
Section 4.34 |
IT Systems |
24 |
Section 4.35 |
Compliance With Data Privacy Laws |
24 |
Section 4.36 |
Stock Option Plans |
25 |
Section 4.37 |
Dilutive Effect |
25 |
Section 4.38 |
Manipulation of Price |
25 |
Section 4.39 |
Application of Takeover Protections |
25 |
Section 4.40 |
Potential Products; FDA; EMEA |
|
Section 4.41 |
Acknowledgement Regarding Investor’s Acquisition of Securities |
26 |
|
|
|
ARTICLE V COVENANTS |
26 |
Section 5.1 |
Securities Compliance |
26 |
Section 5.2 |
Registration and Listing |
27 |
Section 5.3 |
Compliance with Laws |
27 |
Section 5.5 |
Reservation of Common Stock; No Frustration; No Dilutive Issuances; No Similar Transactions |
28 |
Section 5.6 |
Stop Orders |
30 |
Section 5.7 |
Amendments to the Registration Statement; Prospectus Supplements; Free Writing Prospectuses |
30 |
Section 5.8 |
Prospectus Delivery |
31 |
Section 5.9 |
Selling Restrictions |
32 |
Section 5.10 |
Effective Registration Statement |
32 |
Section 5.11 |
Non-Public Information |
33 |
Section 5.12 |
Broker/Dealer |
33 |
Section 5.13 |
Earnings Statement |
33 |
Section 5.14 |
Corporate Existence |
34 |
Section 5.15 |
Fundamental Transaction |
34 |
ARTICLE VI CONDITIONS TO COMMENCEMENT; CONDITIONS TO THE SALE AND PURCHASE OF THE SHARES. |
34 |
Section 6.1 |
Conditions to Commencement |
34 |
Section 6.2 |
Conditions Precedent to the Obligations of the Company |
34 |
Section 6.3 |
Conditions Precedent to the Obligations of the Investor |
36 |
|
|
|
ARTICLE VII TERMINATION |
39 |
Section 7.1 |
Automatic Termination; Termination by Mutual Consent; Termination by the Company |
39 |
Section 7.2 |
Other Termination |
39 |
Section 7.3 |
Effect of Termination |
40 |
|
|
|
ARTICLE VIII INDEMNIFICATION |
41 |
Section 8.1 |
General Indemnity |
41 |
Section 8.2 |
Indemnification Procedures |
42 |
|
|
|
ARTICLE IX MISCELLANEOUS |
43 |
Section 9.1 |
Fees and Expenses |
43 |
Section 9.2 |
Specific Enforcement, Consent to Jurisdiction, Waiver of Jury Trial |
43 |
Section 9.3 |
Entire Agreement; Amendment |
44 |
Section 9.4 |
Notices |
44 |
Section 9.5 |
Waivers |
45 |
Section 9.6 |
Headings; Construction |
45 |
Section 9.7 |
Successors and Assigns |
46 |
Section 9.8 |
Governing Law |
46 |
Section 9.9 |
Survival |
46 |
Section 9.10 |
Counterparts |
46 |
Section 9.11 |
Publicity |
47 |
Section 9.12 |
Severability |
47 |
Section 9.13 |
No Third Party Beneficiaries |
47 |
Section 9.14 |
Further Assurances |
47 |
|
|
|
Annex I. |
Definitions |
|
COMMON STOCK PURCHASE AGREEMENT
This COMMON
STOCK PURCHASE AGREEMENT is made and entered into as of November 17, 2023 (this “Agreement”), by and between Keystone
Capital Partners, LLC, a Delaware limited liability company (the “Investor”), and Spectaire Holdings, Inc., a Delaware
corporation (the “Company”). Capitalized terms used but not defined herein shall have the meanings ascribed to such
terms in Annex I hereto.
RECITALS
WHEREAS,
, the parties desire that, upon the terms and subject to the conditions and limitations set forth herein, the Company may issue and sell
to the Investor, from time to time as provided herein, and the Investor shall purchase from the Company, up to that certain amount as
the Company may register by filing one or more registration statements in compliance with the Securities Act and pursuant to Rule 415
under the Securities Act, of newly issued shares of the Company’s common stock, par value $0.0001 per share (“Common
Stock”);
WHEREAS,
such sales of Common Stock by the Company to the Investor will be made in reliance upon the provisions of Section 4(a)(2) of the Securities
Act (“Section 4(a)(2)”) and Rule 506(b) of Regulation D promulgated by the Commission under the Securities Act
(“Regulation D”), and upon such other exemption from the registration requirements of the Securities Act as
may be available with respect to any or all of the sales of Common Stock to the Investor to be made hereunder;
WHEREAS,
the parties hereto are concurrently entering into a Registration Rights Agreement in the form attached as Exhibit A hereto (the
“Registration Rights Agreement”), pursuant to which the Company shall register the resale of the Registrable
Securities (as defined in the Registration Rights Agreement), upon the terms and subject to the conditions set forth therein; and
WHEREAS,
in consideration for the Investor’s execution and delivery of this Agreement, the Company is concurrently issuing to the Investor
the Commitment Note pursuant to and in accordance with Section 2.7;
NOW, THEREFORE,
the parties hereto, intending to be legally bound, hereby agree as follows:
ARTICLE I
PURCHASE AND SALE OF COMMON
STOCK
Section
1.1 Purchase and Sale of Stock. Upon the terms and subject to the conditions of this Agreement, during the Investment Period,
the Company, in its sole discretion, shall have the right, but not the obligation, to issue and sell to the Investor, and the Investor
shall purchase from the Company, up to the lesser of (i) $20,000,000 (the “Total Commitment”) in aggregate gross purchase
price of duly authorized, validly issued, fully paid and non-assessable shares of Common Stock and (ii) the Exchange Cap, to the extent
applicable under Section 2.5 (such lesser amount of shares of Common Stock, the “Aggregate Limit”), by the delivery
to the Investor of Fixed Purchase Notices, VWAP Purchase Notices and Additional VWAP Purchase Notices as provided in Article II.
Section
1.2 Closing Date; Commencement Date; Settlement Dates. This Agreement shall become effective and binding upon (a) the payment
of the Investor Expense Reimbursement to the Investor on or prior to the Closing Date pursuant to Section 9.1, (b) the delivery of the
Commitment Note to the Investor, (c) the delivery of counterpart signature pages of this Agreement executed by each of the parties hereto,
and (d) the delivery of all other documents, instruments and writings required to be delivered on the Closing Date, in each case as provided
in Section 6.1, to the offices _____, at 5:00 p.m., New York time, or at such other time as the parties may agree, on the Closing
Date. Upon the initial satisfaction or (to the extent permitted by applicable law) waiver of the conditions set forth in Section 6.1 (such
event, the “Commencement” and the date of initial satisfaction of all of such conditions, the “Commencement
Date”) and during the Investment Period the Company shall issue and sell to the Investor, and the Investor shall purchase from
the Company, the Shares in respect of each Fixed Purchase, each VWAP Purchase and each Additional VWAP Purchase. The payment for, against
delivery of, Shares in respect of each Fixed Purchase, each VWAP Purchase and each Additional VWAP Purchase shall occur in accordance
with Section 2.4.
Section
1.3 Current Report. The Company shall, within the time period required under applicable securities laws, file with the Commission
a Current Report on Form 8-K disclosing the execution and describing the material terms of this Agreement, including, without limitation,
the issuance of the Commitment Note to the Investor in accordance with Sections 2.7 and 6.1, and attaching as an exhibit thereto a copy
of this Agreement and, if applicable, a copy of any press release issued by the Company disclosing the foregoing (including all exhibits
thereto, the “Current Report”). The Company shall provide the Investor a reasonable opportunity to comment on a draft
of the Current Report.
Section
1.4 Registration Statement. The Company shall file the Registration Statement in accordance with the Registration Rights Agreement.
Prior to the date of such filing, the Company shall provide the Investor a reasonable opportunity to comment on a draft of the Registration
Statement and give due consideration to all such comments (provided, however, that the failure of the Investor to
make any objection to the form and content thereof shall not relieve the Company of any obligation or liability under this Agreement or
affect the Investor’s right to rely on the representations and warranties made by the Company in this Agreement). If required under
the Securities Act (or any written interpretive guidance of the Staff of the Commission relating thereto) with respect to any Fixed Purchase,
any VWAP Purchase or any Additional VWAP Purchase to be effected pursuant to this Agreement (individually or collectively with any one
or more other Fixed Purchases, VWAP Purchases or Additional VWAP Purchases under this Agreement), as mutually determined by the Company
and the Investor, then, as soon as reasonably practicable, but in no event later than (i) 8:30 a.m., New York time, on the Trading Day
immediately following the applicable Fixed Purchase Date, with respect to any such Fixed Purchase, and (ii) 8:30 a.m., New York time,
on the applicable VWAP Purchase Date or Additional VWAP Purchase Date, as applicable, with respect to any such VWAP Purchase or any such
Additional VWAP Purchase, as applicable, the Company shall file with the Commission a Prospectus Supplement pursuant to Rule 424(b) under
the Securities Act (or alternatively shall file with the Commission a current report on Form 8-K pursuant to the Exchange Act that is
incorporated by reference into the Registration Statement and the Prospectus upon the filing of such current report with the Commission),
disclosing the information with respect to such purchase(s) required to be disclosed in the Registration Statement and the Prospectus
under the Securities Act (or any written interpretive guidance of the Staff of the Commission relating thereto). To the extent not previously
disclosed in a Prospectus Supplement filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act (or in
any current report on Form 8-K filed by the Company with the Commission pursuant to the Exchange Act that is incorporated by reference
into the Registration Statement and the Prospectus), the Company shall disclose, in each Quarterly Report on Form 10-Q and each Annual
Report on Form 10-K filed by the Company with the Commission after the Commencement Date, the total number of Shares that have been issued
and sold to the Investor pursuant to all Fixed Purchase(s), all VWAP Purchase(s) and all Additional VWAP Purchase(s) (if any and as applicable)
effected pursuant to this Agreement during the relevant fiscal quarter, the applicable per Share and total aggregate Fixed Purchase Price,
VWAP Purchase Price or Additional VWAP Purchase Price (as applicable) paid by the Investor for such Shares, and the net proceeds received
by the Company from the sale of such Shares to the Investor in such Fixed Purchase(s), VWAP Purchase(s) and Additional VWAP Purchase(s)
(if any and as applicable).
ARTICLE
II PURCHASE TERMS
Subject to
the satisfaction or (to the extent permitted by applicable law) waiver of the conditions set forth in this Agreement, the parties agree
(unless otherwise mutually agreed upon by the parties in writing) as follows:
Section
2.1 Fixed Purchases. Upon the initial satisfaction or (to the extent permitted by applicable law) waiver of the
conditions set forth in Section 6.1 and from time to time thereafter, subject to the satisfaction or (to the extent permitted by
applicable law) waiver of the conditions set forth in Section 6.2 and Section 6.3, the Company shall have the right, but not the
obligation, to direct the Investor, by its timely delivery to the Investor of a Fixed Purchase Notice, substantially in the form of Exhibit
A, on a Fixed Purchase Date, to purchase a specified Fixed Purchase Share Amount, which shall not exceed $50,000 (the
“Fixed Purchase Maximum Amount”), at the Fixed Purchase Price therefor on such Fixed Purchase Date, pursuant to
and in accordance with this Agreement (each such purchase, a “Fixed Purchase”); provided, further,
that the Company and the Investor may mutually agree to increase the Fixed Purchase Maximum Amount to any Fixed Purchase pursuant to
this Agreement. The Company may timely deliver to the Investor a Fixed Purchase Notice for a Fixed Purchase on any Trading Day
selected by the Company as the Fixed Purchase Date for such Fixed Purchase, provided that: (i) the Company may not deliver to the
Investor more than one Fixed Purchase Notice on any single Trading Day; (ii) the Company may not deliver to the Investor a Fixed
Purchase Notice (A) during the consecutive Trading Day period beginning on (and including) any Fixed Purchase Share Delivery Date
for any Fixed Purchase pursuant to this Agreement, and ending on and including the second (2nd) Trading Day after the
later of (1) the Fixed Purchase Settlement Date for such Fixed Purchase and (2) such later Trading Day after such Fixed Purchase
Settlement Date on which such Fixed Purchase is fully settled in accordance with this Agreement, (B) during the consecutive Trading
Day period beginning on (and including) any VWAP Purchase Date for any VWAP Purchase pursuant to this Agreement, and ending on (and
including) the first (1st) Trading Day after the later of (1) the VWAP Purchase Settlement Date for such VWAP Purchase
and (2) such later Trading Day after such VWAP Purchase Settlement Date on which such VWAP Purchase is fully settled in accordance
with this Agreement, (C) during the consecutive Trading Day period beginning on (and including) the Additional VWAP Purchase Date
for any Additional VWAP Purchase pursuant to this Agreement, and ending on (and including) the first (1st) Trading Day
after the later of (1) the Additional VWAP Purchase Settlement Date for such Additional VWAP Purchase and (2) such later Trading Day
after such Additional VWAP Purchase Settlement Date on which such Additional VWAP Purchase is fully settled in accordance with this
Agreement, or (D) during the MPA Period; (iii) all Shares subject to all prior Fixed Purchases, all prior VWAP Purchases and all
prior Additional VWAP Purchases (as applicable) effected by the Company pursuant to this Agreement have been received by the
Investor as DWAC Shares in accordance with this Agreement prior to the Company’s delivery to the Investor of such Fixed
Purchase Notice for such Fixed Purchase on such Fixed Purchase Date; and (iv) the Closing Sale Price of the Common Stock on such
Fixed Purchase Date is not less than the Threshold Price; provided, however, that the Investor may waive any of the
requirements or restrictions referred to in clauses (ii) and (iii) of this sentence with respect to any Fixed Purchase pursuant to
this Agreement prior to the delivery by the Company to the Investor of the applicable Fixed Purchase Notice therefor. The Investor
is obligated to accept each Fixed Purchase Notice properly prepared and timely delivered by the Company in accordance with the terms
of and subject to the satisfaction of the conditions contained in this Agreement. If the Company delivers any Fixed Purchase Notice
directing the Investor to purchase a Fixed Purchase Share Amount in excess of the applicable Fixed Purchase Maximum Amount that the
Company is then permitted to include in such Fixed Purchase Notice, such Fixed Purchase Notice shall be void ab initio to the
extent of the amount by which the Fixed Purchase Share Amount set forth in such Fixed Purchase Notice exceeds such applicable Fixed
Purchase Maximum Amount, and the Investor shall have no obligation to purchase, and shall not purchase, such excess Shares pursuant
to such Fixed Purchase Notice; provided, however, that the Investor shall remain obligated to purchase the applicable
Fixed Purchase Maximum Amount pursuant to such Fixed Purchase Notice for such Fixed Purchase.
Section
2.2 VWAP Purchases. Upon the initial satisfaction or (to the extent permitted by applicable law) waiver of the conditions set
forth in Section 6.1 on the Commencement Date and from time to time thereafter, subject to the satisfaction or (to the extent permitted
by applicable law) waiver of the conditions set forth in Section 6.2 and Section 6.3, in addition to Fixed Purchases as described in Section
2.1, the Company shall also have the right, but not the obligation, to direct the Investor, by its timely delivery to the Investor of
a VWAP Purchase Notice, substantially in the form of Exhibit B, on a VWAP Purchase Exercise Date, to purchase a specified VWAP
Purchase Share Amount, which shall not exceed the VWAP Purchase Maximum Amount, at the VWAP Purchase Price therefor (as confirmed in the
applicable VWAP Purchase Confirmation) on the applicable VWAP Purchase Date for such VWAP Purchase, pursuant to and in accordance with
this Agreement (each such purchase, a “VWAP Purchase”); provided, however, that the Investor’s
committed obligation under any single VWAP Purchase shall not exceed $1,000,000; provided, further, however, that
the Company and the Investor may mutually agree to increase the VWAP Purchase Maximum Amount and/or such dollar limit applicable to any
VWAP Purchase pursuant to this Agreement. The Company may timely deliver to the Investor a VWAP Purchase Notice for a VWAP Purchase on
any Trading Day selected by the Company as the VWAP Purchase Exercise Date for such VWAP Purchase, provided that: (i) the Company has
also timely delivered to the Investor, simultaneously with the delivery to the Investor of such VWAP Purchase Notice on such Trading Day,
a valid Fixed Purchase Notice for a Fixed Purchase directing the Investor to purchase a specified Fixed Purchase Share Amount equal to
the Fixed Purchase Maximum Amount (such Trading Day constituting both the Fixed Purchase Date for such Fixed Purchase and the VWAP Purchase
Exercise Date for such VWAP Purchase); (ii) the Company may not deliver to the Investor more than one VWAP Purchase Notice on any single
Trading Day (such VWAP Purchase Notice to be delivered in the manner set forth in clause (i) hereof and otherwise in accordance with this
Agreement); (iii) the Company may not deliver to the Investor a VWAP Purchase Notice (A) on any Fixed Purchase Date on which the Company
has delivered to the Investor a Fixed Purchase Notice for a Fixed Purchase directing the Investor to purchase a specified Fixed Purchase
Share Amount less than the Fixed Purchase Maximum Amount, or during the consecutive Trading Day period beginning on (and including) the
Fixed Purchase Share Delivery Date for such Fixed Purchase pursuant to this Agreement and ending on and including the second (2nd)
Trading Day after the later of (1) the Fixed Purchase Settlement Date for such Fixed Purchase and (2) such later Trading Day after such
Fixed Purchase Settlement Date on which such Fixed Purchase is fully settled in accordance with this Agreement, (B) during the consecutive
Trading Day period beginning on (and including) any VWAP Purchase Date for any VWAP Purchase pursuant to this Agreement, and ending on
(and including) the first (1st) Trading Day after the later of (1) the VWAP Purchase Settlement Date for such VWAP Purchase
and (2) such later Trading Day after such VWAP Purchase Settlement Date on which such VWAP Purchase is fully settled in accordance with
this Agreement, (C) during the consecutive Trading Day period beginning on (and including) the Additional VWAP Purchase Date for any Additional
VWAP Purchase pursuant to this Agreement, and ending on (and including) the first (1st) Trading Day after the later of (1)
the Additional VWAP Purchase Settlement Date for such Additional VWAP Purchase and (2) such later Trading Day after such Additional VWAP
Purchase Settlement Date on which such Additional VWAP Purchase is fully settled in accordance with this Agreement, or (D) during the
MPA Period; (iv) all Shares subject to all prior Fixed Purchases, all prior VWAP Purchases and all prior Additional VWAP Purchases (as
applicable) effected by the Company pursuant to this Agreement have been received by the Investor as DWAC Shares in accordance with this
Agreement prior to the Company’s delivery to the Investor of such VWAP Purchase Notice for such VWAP Purchase on such VWAP Purchase
Exercise Date; and (v) the Closing Sale Price of the Common Stock on such VWAP Purchase Exercise Date is not less than the Threshold Price;
provided, however, that the Investor may waive any of the requirements or restrictions referred to in clauses (i) through
(iv) of this sentence with respect to any VWAP Purchase pursuant to this Agreement prior to the delivery by the Company to the Investor
of the applicable VWAP Purchase Notice therefor. The Investor is obligated to accept each VWAP Purchase Notice properly prepared and timely
delivered by the Company to the Investor in accordance with the terms of and subject to the satisfaction of the conditions contained in
this Agreement. If the Company delivers any VWAP Purchase Notice directing the Investor to purchase a VWAP Purchase Share Amount in excess
of the applicable VWAP Purchase Maximum Amount that the Company is then permitted to include in such VWAP Purchase Notice, such VWAP Purchase
Notice shall be void ab initio to the extent of the amount by which the VWAP Purchase Share Amount set forth in such VWAP Purchase
Notice exceeds such applicable VWAP Purchase Maximum Amount, and the Investor shall have no obligation to purchase, and shall not purchase,
such excess Shares pursuant to such VWAP Purchase Notice; provided, however, that the Investor shall remain obligated to
purchase the applicable VWAP Purchase Maximum Amount pursuant to such VWAP Purchase Notice for such VWAP Purchase. At or prior to 5:30
p.m., New York time, on the VWAP Purchase Date for each VWAP Purchase, the Investor shall provide to the Company a written confirmation
for such VWAP Purchase substantially in the form of Exhibit C (each, a “VWAP Purchase Confirmation”), setting
forth the applicable VWAP Purchase Price per Share to be paid by the Investor for the Shares purchased by the Investor in such VWAP Purchase,
and the total aggregate VWAP Purchase Price to be paid by the Investor for the total VWAP Purchase Share Amount purchased by the Investor
in such VWAP Purchase.
Section
2.3 Additional VWAP Purchases. Upon the initial satisfaction or (to the extent permitted by applicable law) waiver of the conditions
set forth in Section 6.1 on the Commencement Date and from time to time thereafter, subject to the satisfaction or (to the extent permitted
by applicable law) waiver of the conditions set forth in Section 6.2 and Section 6.3, in addition to Fixed Purchases as described in Section
2.1 and in addition to VWAP Purchases as described in Section 2.2, the Company shall also have the right, but not the obligation, to direct
the Investor, by its timely delivery to the Investor of an Additional VWAP Purchase Notice, substantially in the form of Exhibit D,
on the same Trading Day constituting a VWAP Purchase Date with respect to which the Company timely delivered to the Investor a valid VWAP
Purchase Notice on the applicable VWAP Purchase Exercise Date in accordance with Section 2.2 (in which case such Trading Day shall constitute
both the VWAP Purchase Date for such VWAP Purchase and the Additional VWAP Purchase Date for such Additional VWAP Purchase), to purchase
a specified Additional VWAP Purchase Share Amount, which shall not exceed the applicable Additional VWAP Purchase Maximum Amount, at the
applicable Additional VWAP Purchase Price therefor on such Additional VWAP Purchase Date in accordance with this Agreement (each such
purchase, an “Additional VWAP Purchase”); provided, however, that the Investor’s committed obligation
under all Additional VWAP Purchases properly effected in accordance with this Section 2.3 on the same Additional VWAP Purchase Date, together
with the VWAP Purchase properly effected under Section 2.2 on the same Trading Day as such Additional VWAP Purchase Date for such Additional
VWAP Purchase(s), shall not exceed $1,000,000 in the aggregate for such VWAP Purchase and all such Additional VWAP Purchases effected
on the same Trading Day; provided, further, however, that the Company and the Investor may mutually agree to increase
the Additional VWAP Purchase Maximum Amount applicable to any Additional VWAP Purchase pursuant to this Agreement, and/or may mutually
agree to increase such aggregate dollar limit applicable to any such VWAP Purchase and all such Additional VWAP Purchases effected on
the same Trading Day pursuant to this Agreement. The Company may timely deliver to the Investor an Additional VWAP Purchase Notice for
an Additional VWAP Purchase on any Trading Day selected by the Company as the Additional VWAP Purchase Date for such Additional VWAP Purchase,
provided that: (i) such Trading Day is also the VWAP Purchase Date for a VWAP Purchase with respect to which the Company timely delivered
to the Investor, on the applicable VWAP Purchase Exercise Date, a valid VWAP Purchase Notice simultaneously with the timely delivery by
the Company to the Investor of a valid Fixed Purchase Notice directing the Investor to purchase a specified Fixed Purchase Share Amount
equal to the Fixed Purchase Maximum Amount in a Fixed Purchase on the applicable Fixed Purchase Date (such Fixed Purchase Date also constituting
the VWAP Purchase Exercise Date for such VWAP Purchase); (ii) the Company may not deliver to the Investor an Additional VWAP Purchase
Notice (A) on any Trading Day other than as referenced in clause (i) above, (B) during the consecutive Trading Day period beginning on
(and including) any VWAP Purchase Share Delivery Date for any VWAP Purchase pursuant to this Agreement, and ending on (and including)
the first (1st) Trading Day after the later of (x) the VWAP Purchase Settlement Date for such VWAP Purchase and (y) such later
Trading Day after such VWAP Purchase Settlement Date on which such VWAP Purchase is fully settled in accordance with this Agreement, (C)
during the consecutive Trading Day period beginning on (and including) any Additional VWAP Purchase Share Delivery Date for any Additional
VWAP Purchase pursuant to this Agreement, and ending on (and including) the first (1st) Trading Day after the later of (x)
the Additional VWAP Purchase Settlement Date for such Additional VWAP Purchase and (y) such later Trading Day after such Additional VWAP
Purchase Settlement Date on which such Additional VWAP Purchase is fully settled in accordance with this Agreement, or (D) during the
MPA Period; (iii) all Shares subject to all prior Fixed Purchases, all prior VWAP Purchases and all prior Additional VWAP Purchases (as
applicable) effected by the Company pursuant to this Agreement have been received by the Investor as DWAC Shares in accordance with this
Agreement prior to the Company’s delivery to the Investor of such Additional VWAP Purchase Notice for such Additional VWAP Purchase
on such Additional VWAP Purchase Date; and (iv) the Closing Sale Price of the Common Stock on the Trading Day immediately prior to such
Additional VWAP Purchase Date is not less than the Threshold Price; provided, however, that the Investor may waive any of
the requirements or restrictions referred to in clauses (ii) and (iii) of this sentence with respect to any Additional VWAP Purchase pursuant
to this Agreement prior to the delivery by the Company to the Investor of the applicable Additional VWAP Purchase Notice therefor. The
Investor is obligated to accept each Additional VWAP Purchase Notice properly prepared and timely delivered by the Company to the Investor
in accordance with the terms of and subject to the satisfaction of the conditions contained in this Agreement. If the Company delivers
any Additional VWAP Purchase Notice directing the Investor to purchase an Additional VWAP Purchase Share Amount in excess of the applicable
Additional VWAP Purchase Maximum Amount that the Company is then permitted to include in such Additional VWAP Purchase Notice, such Additional
VWAP Purchase Notice shall be void ab initio to the extent of the amount by which the Additional VWAP Purchase Share Amount set
forth in such Additional VWAP Purchase Notice exceeds such applicable Additional VWAP Purchase Maximum Amount, and the Investor shall
have no obligation to purchase, and shall not purchase, such excess Shares pursuant to such Additional VWAP Purchase Notice; provided,
however, that the Investor shall remain obligated to purchase the applicable Additional VWAP Purchase Maximum Amount pursuant to
such Additional VWAP Purchase Notice for such Additional VWAP Purchase. At or prior to 5:30 p.m., New York time, on the Additional VWAP
Purchase Date for each Additional VWAP Purchase, the Investor shall provide to the Company a written confirmation for such Additional
VWAP Purchase substantially in the form of Exhibit E (each, an “Additional VWAP Purchase Confirmation”), setting
forth the applicable Additional VWAP Purchase Price per Share to be paid by the Investor for the Shares purchased by the Investor in such
Additional VWAP Purchase, and the total aggregate Additional VWAP Purchase Price to be paid by the Investor for the total Additional VWAP
Purchase Share Amount purchased by the Investor in such Additional VWAP Purchase.
Section
2.4 Settlement. The Shares constituting the applicable Fixed Purchase Share Amount purchased by the Investor in each Fixed
Purchase, the Shares constituting the applicable VWAP Purchase Share Amount purchased by the Investor in each VWAP Purchase, and the Shares
constituting the applicable Additional VWAP Purchase Share Amount purchased by the Investor in each Additional VWAP Purchase shall be
delivered to the Investor as DWAC Shares (i) with respect to such Fixed Purchase, not later than 10:00 a.m., New York time, on the
Trading Day immediately following the Fixed Purchase Date for such Fixed Purchase (each, a “Fixed Purchase Share Delivery Date”),
(ii) with respect to such VWAP Purchase, not later than 10:00 a.m., New York time, on the Trading Day immediately following the VWAP Purchase
Date for such VWAP Purchase (each, a “VWAP Purchase Share Delivery Date”), and (iii) with respect to such Additional
VWAP Purchase, not later than 10:00 a.m., New York time, on the Trading Day immediately following the Additional VWAP Purchase Date for
such Additional VWAP Purchase (each, an “Additional VWAP Purchase Share Delivery Date”), respectively. Subject to the
timely receipt of the Shares constituting the applicable Fixed Purchase Share Amount purchased by the Investor in each Fixed Purchase
as DWAC Shares on the applicable Fixed Purchase Share Delivery Date, the payment for, against delivery of, Shares in respect of such Fixed
Purchase shall be settled not later than the third (3rd) Trading Day immediately following the applicable Fixed Purchase Share
Delivery Date for such Fixed Purchase (each, a “Fixed Purchase Settlement Date”). Subject to the timely receipt of
the Shares constituting the applicable VWAP Purchase Share Amount purchased by the Investor in each VWAP Purchase as DWAC Shares on the
applicable VWAP Purchase Share Delivery Date, the payment for, against delivery of, Shares in respect of such VWAP Purchase shall be settled
not later than the third (3rd) Trading Day immediately following the applicable VWAP Purchase Share Delivery Date for such
VWAP Purchase (each, a “VWAP Purchase Settlement Date”). Subject to the timely receipt of the Shares constituting the
applicable Additional VWAP Purchase Share Amount purchased by the Investor in each Additional VWAP Purchase as DWAC Shares on the applicable
Additional VWAP Purchase Share Delivery Date, the payment for, against delivery of, Shares in respect of such Additional VWAP Purchase
shall be settled not later than the third (3rd) Trading Day immediately following the applicable Additional VWAP Purchase Share
Delivery Date for such Additional VWAP Purchase (each, an “Additional VWAP Purchase Settlement Date”). For each Fixed
Purchase, each VWAP Purchase and each Additional VWAP Purchase, the Investor shall pay to the Company an amount in cash equal to, (i)
in the case of a Fixed Purchase, the product of (A) the total number of Shares purchased by the Investor in such Fixed Purchase and (B)
the applicable Fixed Purchase Price for such Shares, (ii) in the case of a VWAP Purchase, the product of (A) the total number of Shares
purchased by the Investor in such VWAP Purchase and (B) the applicable VWAP Purchase Price for such Shares, and (iii) in the case of an
Additional VWAP Purchase, the product of (A) the total number of Shares purchased by the Investor in such Additional VWAP Purchase and
(B) the applicable Additional VWAP Purchase Price for such Shares, in each case as full payment for such Shares, via wire transfer of
immediately available funds on the applicable Fixed Purchase Settlement Date, the applicable VWAP Purchase Settlement Date and the applicable
Additional VWAP Purchase Settlement Date, respectively, if all of such Shares are timely received by the Investor on the applicable Fixed
Purchase Share Delivery Date for such Fixed Purchase, on the applicable VWAP Purchase Share Delivery Date for such VWAP Purchase, and
on the applicable Additional VWAP Purchase Share Delivery Date for such Additional VWAP Purchase in accordance with this Section 2.4,
or, if such Shares are not so timely received by the Investor in accordance with this Section 2.4, then payment therefor shall be made
on the Trading Day immediately following the Trading Day on which the Investor has received all of such Shares as DWAC Shares. If the
Company or the Transfer Agent shall fail for any reason, other than a failure of the Investor or its Broker-Dealer to set up a DWAC and
required instructions, to electronically transfer any Shares as DWAC Shares in respect of a Fixed Purchase, a VWAP Purchase or an Additional
VWAP Purchase within three (3) Trading Days following the receipt by the Company of the applicable purchase price therefor in compliance
with this Section 2.4, and if on or after such Trading Day the Investor purchases (in an open market transaction or otherwise) shares
of Common Stock to deliver in satisfaction of a sale by the Investor of such Shares that the Investor anticipated receiving from the Company
in respect of such Fixed Purchase, VWAP Purchase or Additional VWAP Purchase (as applicable), then the Company shall, within three (e)
Trading Days after the Investor’s request, either (1) pay cash to the Investor in an amount equal to the Investor’s total
purchase price (including brokerage commissions, broker review fees, and legal fees, if any) for the shares of Common Stock so purchased
(the “Cover Price”), at which point the Company’s obligation to deliver such Shares as DWAC Shares shall terminate,
or (ii) promptly honor its obligation to deliver to the Investor such Shares as DWAC Shares and pay cash to the Investor in an amount
equal to the excess (if any) of the Cover Price over the total purchase price paid by the Investor pursuant to this Agreement for all
of the Shares to be purchased by the Investor in connection with such Fixed Purchase, VWAP Purchase or Additional VWAP Purchase (as applicable).
The Company shall not issue any fraction of a share of Common Stock upon any Fixed Purchase, VWAP Purchase or Additional VWAP Purchase.
If the issuance would result in the issuance of a fraction of a share of Common Stock, the Company shall round such fraction of a share
of Common Stock up or down to the nearest whole share. All payments made under this Agreement shall be made in lawful money of the United
States of America or wire transfer of immediately available funds to such account as the Company may from time to time designate by written
notice in accordance with the provisions of this Agreement. Whenever any amount expressed to be due by the terms of this Agreement is
due on any day that is not a Trading Day, the same shall instead be due on the next succeeding day that is a Trading Day.
Section
2.5 Compliance with Rules of Trading Market.
(a) Exchange
Cap. Subject to Section 2.5(b), the Company shall not issue or sell any shares of Common Stock pursuant to this Agreement, and
the Investor shall not purchase or acquire any shares of Common Stock pursuant to this Agreement, to the extent that after giving effect
thereto, the aggregate number of shares of Common Stock that would be issued pursuant to this Agreement and the transactions contemplated
hereby would exceed 3,067,438 (such number of shares equal to 19.99% of the number of shares of Common Stock issued and outstanding immediately
prior to the execution of this Agreement), which number of shares shall be reduced, on a share-for-share basis, by the number of shares
of Common Stock issued or issuable pursuant to any transaction or series of transactions that may be aggregated with the transactions
contemplated by this Agreement under applicable rules of the Trading Market (such maximum number of shares, the “Exchange Cap”),
unless the Company’s stockholders have approved the issuance of Common Stock pursuant to this Agreement in excess of the Exchange
Cap in accordance with the applicable rules of the Trading Market. For the avoidance of doubt, the Company may, but shall be under no
obligation to, request its stockholders to approve the issuance of Common Stock pursuant to this Agreement; provided, that if such
stockholder approval is not obtained, the Exchange Cap shall be applicable for all purposes of this Agreement and the transactions contemplated
hereby at all times during the term of this Agreement (except as set forth in Section 2.5(b)).
(b) At-Market
Transaction. Notwithstanding Section 2.5(a) above, the Exchange Cap shall not be applicable for any purposes of this Agreement
and the transactions contemplated hereby, solely to the extent that (and only for so long as) the Average Price shall equal or exceed
the Base Price (it being hereby acknowledged and agreed that the Exchange Cap shall be applicable for all purposes of this Agreement and
the transactions contemplated hereby at all other times during the term of this Agreement, unless the stockholder approval referred to
in Section 2.5(a) is obtained). The parties acknowledge and agree that the Base Price hereunder represents the lower of (i) the Nasdaq
official closing price of the Common Stock on the Trading Market (as reflected on Nasdaq.com) on the date of this Agreement and (ii) the
average Nasdaq official closing price of the Common Stock on the Trading Market (as reflected on Nasdaq.com) for the five (5) consecutive
Trading Days ending on the date of this Agreement.
(c) General.
The Company shall not issue or sell any shares of Common Stock pursuant to this Agreement if such issuance or sale would reasonably be
expected to result in (i) a violation of the Securities Act or (ii) a breach of the rules of the Trading Market. The provisions of this
Section 2.5 shall be implemented in a manner otherwise than in strict conformity with the terms of this Section 2.5 only if necessary
to ensure compliance with the Securities Act and the applicable rules of the Trading Market. The limitations contained in this Section
2.3 may not be waived by the Company or the Investor.
Section
2.6 Beneficial Ownership Limitation. Notwithstanding any other provision of this Agreement, the Investor shall not purchase
or acquire, or be obligated or have the right to purchase or acquire, any shares of Common Stock pursuant to this Agreement which, when
aggregated with all other shares of Common Stock then beneficially owned (as calculated pursuant to Section 13(d) of the Exchange Act
and Rule 13d-3 promulgated thereunder) by the Investor and its Affiliates, would result in the beneficial ownership by the Investor of
more than 4.99% of the then issued and outstanding shares of Common Stock (the “Beneficial Ownership Limitation”).
If the Company issues a VWAP Purchase Notice with respect to any VWAP Purchase that would cause the aggregate number of shares of Common
Stock then beneficially owned (as calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder) by the
Investor and its Affiliates to exceed the Beneficial Ownership Limitation, such VWAP Purchase Notice shall be void ab initio to
the extent of the amount by which the number of shares of Common Stock otherwise issuable pursuant to such VWAP Purchase Notice, together
with all shares of Common Stock then beneficially owned (as calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated
thereunder) by the Investor and its Affiliates, would exceed the Beneficial Ownership Limitation. Upon the written or oral request of
the Investor, the Company shall promptly (but not later than the next Trading Day) confirm orally or in writing to the Investor the number
of shares of Common Stock then outstanding. The Investor and the Company shall each cooperate in good faith in the determinations required
hereby and the application hereof. The Investor’s written certification to the Company of the applicability of the Beneficial Ownership
Limitation, and the resulting effect thereof hereunder at any time, shall be conclusive with respect to the applicability thereof and
such result absent manifest error. Upon delivery of a written notice to the Company, the Investor may from time to time increase or decrease
the Beneficial Ownership Limitation to any other amount of Common Stock not in excess of 4.99% of the then issued and outstanding shares
of Common Stock as specified in such notice; provided that any such increase in the Beneficial Ownership Limitation will not be effective
until the sixty-first (61st) day after such written notice is delivered to the Company. The provisions of this Section 2.6
shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2.6 to the extent necessary
to correct this Section 2.6 (or any portion of this Section 2.6) which may be defective or inconsistent with the intended Beneficial Ownership
Limitation contained in this Section 2.6 or to make changes or supplements necessary or desirable to properly give effect to such limitation.
The limitations contained in this Section 2.6 may not be waived by the Company or the Investor.
Section
2.7 Commitment Note. In consideration for the Investor’s execution and delivery of this Agreement and the Registration
Rights Agreement (the “Closing”), the Company shall deliver to the Investor, concurrently with the execution of this
Agreement, a convertible promissory note, in substantially the form attached as Exhibit F (the “Commitment Note”),
which note shall be convertible into shares of Common Stock (such shares of Common Stock, the “Note Shares”) on the
terms and subject to the conditions set forth therein. For the avoidance of doubt, the Commitment Note and all of the Note Shares shall
be fully earned as of the Closing Date, regardless of whether any Fixed Purchases, VWAP Purchases, or Additional VWAP Purchases are effected
hereunder and regardless of any subsequent termination of this Agreement.
ARTICLE III
REPRESENTATIONS AND WARRANTIES OF
THE INVESTOR
The Investor hereby makes the following
representations and warranties to the Company:
Section
3.1 Organization and Standing of the Investor. The Investor is a limited liability company duly organized and validly existing
under the laws of the State of Delaware.
Section
3.2 Authorization and Power. The Investor has the requisite limited liability company power and authority to enter into and
perform its obligations under this Agreement and to purchase the Shares in accordance with the terms hereof. The execution, delivery and
performance of this Agreement by the Investor and the consummation by it of the transactions contemplated hereby have been duly authorized
by all necessary corporate action, and no further consent or authorization of the Investor, its Board of Directors or members is required.
This Agreement has been duly executed and delivered by the Investor. This Agreement constitutes a valid and binding obligation of the
Investor enforceable against it in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation, conservatorship, receivership, or similar laws relating to, or affecting generally the enforcement
of, creditor’s rights and remedies or by other equitable principles of general application.
Section
3.3 No Conflicts. The execution, delivery and performance by the Investor of this Agreement and the consummation by the Investor
of the transactions contemplated herein do not and shall not (i) result in a violation of such Investor’s charter documents, bylaws
or other applicable organizational instruments, (ii) conflict with, constitute a default (or an event which, with notice or lapse of time
or both, would become a default) under, or give rise to any rights of termination, amendment, acceleration or cancellation of, any material
agreement, mortgage, deed of trust, indenture, note, bond, license, lease agreement, instrument or obligation to which the Investor is
a party or is bound, (iii) create or impose any lien, charge or encumbrance on any property of the Investor under any agreement or any
commitment to which the Investor is party or under which the Investor is bound or under which any of its properties or assets are bound,
or (iv) result in a violation of any federal, state, local or foreign statute, rule, or regulation, or any order, judgment or decree
of any court or Governmental Entity applicable to the Investor or by which any of its properties or assets are bound or affected, except,
in the case of clauses (ii), (iii) and (iv), for such conflicts, defaults, terminations, amendments, acceleration, cancellations and violations
as would not, individually or in the aggregate, prohibit or otherwise interfere with the ability of the Investor to enter into and perform
its obligations under this Agreement in any material respect. The Investor is not required under federal, state, local or foreign law,
rule or regulation to obtain any consent, authorization or order of, or make any filing or registration with, any court or Governmental
Entity in order for it to execute, deliver or perform any of its obligations under this Agreement or to purchase the Shares in accordance
with the terms hereof.
Section
3.4 Information. All materials relating to the business, financial condition, management and operations of the Company and
materials relating to the offer and sale of the Securities which have been requested by the Investor have been furnished or otherwise
made available to the Investor or its advisors (subject to Section 5.12 of this Agreement). The Investor and its advisors have been afforded
the opportunity to ask questions of representatives of the Company. The Investor has sought such accounting, legal and tax advice as it
has considered necessary to make an informed investment decision with respect to its acquisition of the Securities. The Investor understands
that it (and not the Company) shall be responsible for its own tax liabilities that may arise as a result of this investment or the transactions
contemplated by this Agreement. The Investor is aware of all of its obligations under U.S. federal and applicable state securities laws
and all rules and regulations promulgated thereunder in connection with this Agreement and the transactions contemplated hereby and the
purchase and sale of the Securities.
Section
3.5 No Governmental Review. The Investor understands that no United States federal or state agency or any other Governmental
Entity has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the
Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.
Section
3.6 Not an Affiliate. The Investor is not an officer, director or an Affiliate of the Company. As of the date of this Agreement,
the Investor does not beneficially own any shares of Common Stock or securities exercisable for or convertible into shares of Common Stock,
and during the Restricted Period, Investor will not acquire beneficial ownership of any shares of the Company’s capital stock (including
shares of Common Stock or securities exercisable for or convertible into shares of Common Stock) other than pursuant to this Agreement;
provided, however, that nothing in this Agreement shall prohibit or be deemed to prohibit the Investor from purchasing,
in an open market transaction or otherwise, shares of Common Stock necessary to make delivery by the Investor in satisfaction of a sale
by the Investor of Shares that the Investor anticipated receiving from the Company in connection with the settlement of a Fixed Purchase,
a VWAP Purchase and/or an Additional VWAP Purchase, if the Company or its Transfer Agent shall have failed for any reason (other than
a failure of Investor or its Broker-Dealer to set up a DWAC and required instructions) to electronically transfer all of the Shares subject
to such Fixed Purchase, VWAP Purchase and/or Additional VWAP Purchase (as applicable) to the Investor on the applicable settlement date
therefor by crediting the Investor’s or its designated Broker-Dealer’s account at DTC through its DWAC delivery system in
compliance with Section 2.4 of this Agreement.
Section
3.7 Certain Trading Activities. Other than with respect to the Commencement of the transactions contemplated hereunder, during
the period commencing at the time that the Investor was first contacted by the Company, or any other Person representing the Company,
regarding the transactions contemplated hereby and ending immediately prior to the execution of this Agreement, none of the Investor,
any of its Affiliates or any entity managed or controlled by the Investor has, directly or indirectly, executed any purchases or sales,
including Short Sales, of any securities of the Company (including, without limitation, the Common Stock), or any stock pledge, forward
sales contract, option, put, call, swap or similar hedging arrangement (including on a total return basis) with respect to any securities
of the Company (including, without limitation, the Common Stock).
Section
3.8 Statutory Underwriter Status. The Investor acknowledges that it will be disclosed as an “underwriter” in the
Registration Statement and any additional Prospectus Supplements filed pursuant to Section 1.3. to the extent required by applicable law
and to the extent such Prospectus Supplement is related to the offer and sale of Securities issued and issuable pursuant to this Agreement.
Section
3.9 Resales of Securities. The Investor represents, warrants and covenants that it will resell Securities purchased or acquired
by the Investor from the Company pursuant to this Agreement only in a manner described under the caption “Plan of Distribution”
in the Registration Statement, and in a manner in compliance with all applicable U.S. federal and state securities laws, rules and regulations.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF
THE COMPANY
Except as set forth in the Commission
Documents, the Company hereby makes the following representations, warranties and covenants to the Investor:
Section
4.1 Organization, Good Standing and Power. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise
organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite
power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company
nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws
or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in
good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property
owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would
not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect and no proceeding has been
instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or
qualification.
Section
4.2 Authorization, Enforcement. The Company has the requisite corporate power and authority to enter into and perform its obligations
under this Agreement and to issue the Securities in accordance with the terms hereof. Except for approvals of the Company’s Board
of Directors or a committee thereof as may be required in connection with any issuance and sale of Shares to the Investor hereunder (which
approvals shall be obtained prior to the delivery of any Fixed Purchase Notice, any VWAP Purchase Notice and any Additional VWAP Purchase
Notice), the execution, delivery and performance by the Company of this Agreement and the consummation by it of the transactions contemplated
hereby have been duly and validly authorized by all necessary corporate action, and no further consent or authorization of the Company,
its Board of Directors or its stockholders is required. This Agreement has been duly executed and delivered by the Company and constitutes
a valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability
may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship, receivership or similar
laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other equitable principles of
general application (including any limitation of equitable remedies).
Section
4.3 Capitalization. All the outstanding shares of capital stock of the Company and each of its Subsidiaries have been duly
and validly authorized and issued and are fully paid and non-assessable, and, except as otherwise set forth in the Commission Documents,
all outstanding shares of capital stock or membership interests of the Subsidiaries are owned by the Company either directly or through
wholly owned Subsidiaries and are free and clear of any perfected security interest or any other security interests, claims, liens or
encumbrances. Except as set forth in the Commission Documents and this Agreement, there are no agreements or arrangements under which
the Company is obligated to register the sale of any securities under the Securities Act. Except as set forth in the Commission Documents,
no shares of capital stock of the Company are entitled to preemptive rights and there are no outstanding debt securities and no contracts,
commitments, understandings, or arrangements by which the Company is or may become bound to issue additional shares of the capital stock
of the Company or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities
or rights convertible into or exchangeable for, any shares of capital stock of the Company other than those issued or granted in the ordinary
course of business pursuant to the Company’s equity incentive and/or compensatory plans or arrangements. Except for customary transfer
restrictions contained in agreements entered into by the Company to sell restricted securities or as set forth in the Commission Documents,
the Company is not a party to, and it has no Knowledge of, any agreement restricting the voting or transfer of any shares of the capital
stock of the Company. Except as set forth in the Commission Documents, there are no securities or instruments containing anti-dilution
or similar provisions that will be triggered by this Agreement or any of the other Transaction Documents or the consummation of the transactions
described herein or therein. The Company has made available via the Commission’s Electronic Data Gathering, Analysis and Retrieval
System (“EDGAR”) true and correct copies of the Company’s Certificate of Incorporation as in effect on the Closing
Date (the “Charter”), and the Company’s Bylaws as in effect on the Closing Date (the “Bylaws”).
Section
4.4 Issuance of Securities. The Note Shares and the Shares to be purchased by the Investor pursuant to a particular Fixed Purchase
Notice, a particular VWAP Purchase Notice or a particular Additional VWAP Purchase Notice, will be, prior to the delivery to the Investor
hereunder of such Note Shares or such Fixed Purchase Notice, VWAP Purchase Notice and Additional VWAP Purchase Notice, as applicable,
duly authorized by all necessary corporate action on the part of the Company. The Note Shares, when issued to the Investor in accordance
with the Commitment Note, and the Shares, when issued and sold against payment therefor in accordance with this Agreement, shall be validly
issued and outstanding, fully paid and non-assessable and free from all liens, charges, taxes, security interests, encumbrances, rights
of first refusal, preemptive or similar rights and other encumbrances with respect to the issue thereof, and the Investor shall be entitled
to all rights accorded to a holder of Common Stock.
Section
4.5 No Conflicts. The execution, delivery and performance by the Company of this Agreement and the consummation by the Company
of the transactions contemplated hereby do not and shall not (i) result in a violation of any provision of the Company’s Charter
or Bylaws, (ii) other than any conflicts, defaults or rights that have been waived, conflict with, constitute a default (or an event which,
with notice or lapse of time or both, would become a default) under, or give rise to any rights of termination, amendment, acceleration
or cancellation of, any material agreement, mortgage, deed of trust, indenture, note, bond, license, lease agreement, instrument or obligation
to which the Company or any of its Subsidiaries is a party or is bound, (iii) create or impose a lien, charge or encumbrance on any property
or assets of the Company or any of its Subsidiaries under any agreement or any commitment to which the Company or any of its Subsidiaries
is a party or by which the Company or any of its Subsidiaries is bound or to which any of their respective properties or assets is subject,
or (iv) result in a violation of any federal, state, local or foreign statute, rule, regulation, order, judgment or decree applicable
to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries are bound or affected
(including federal and state securities laws and regulations and the rules and regulations of the Trading Market), except, in the case
of clauses (ii), (iii) and (iv), for such conflicts, defaults, terminations, amendments, acceleration, cancellations, liens, charges,
encumbrances and violations as would not, individually or in the aggregate, have a Material Adverse Effect. Except as specifically contemplated
by this Agreement and as required under the Securities Act and any applicable state securities laws, the Company is not required under
any federal, state, local or foreign law, rule or regulation to obtain any consent, authorization or order of, or make any filing or registration
with, any court or Governmental Entity (including, without limitation, the Trading Market) in order for it to execute, deliver or perform
any of its obligations under this Agreement, or to issue the Securities to the Investor in accordance with the terms hereof (other than
(i) such consents, authorizations, orders, filings or registrations as have been obtained or made prior to the Closing Date and (ii) any
filings which may be required to be made by the Company with the Commission subsequent to the Closing Date).
Section
4.6 Commission Documents, Financial Statements; Disclosure Controls and Procedures; Internal Controls Over Financial Reporting; Accountants.
(a) Since
October 19, 2023, the Company has filed (giving effect to permissible extensions in accordance with Rule 12b-25 under the Exchange Act)
all Commission Documents required to be filed with or furnished to the Commission by the Company under the Securities Act or the Exchange
Act, including those required to be filed with or furnished to the Commission under Section 13(a) or Section 15(d) of the Exchange Act.
As of the date of this Agreement, no Subsidiary of the Company is required to file or furnish any report, schedule, registration, form,
statement, information or other document with the Commission. As of its filing date (or, if amended or superseded by a filing prior
to the Commencement Date, on the date of such amended or superseded filing), each Commission Document filed with or furnished to the Commission
complied in all material respects with the requirements of the Securities Act or the Exchange Act, as applicable, and such Commission
Document did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under which they were made, not misleading. Each Commission Document
to be filed with or furnished to the Commission after the Commencement Date and incorporated by reference in the Registration Statement,
the Prospectus and any Prospectus Supplement required to be filed pursuant to Section 1.3 during the Investment Period (including, without
limitation, the Current Report), when such document becomes effective or is filed with or furnished to the Commission and, if applicable,
when such document becomes effective, as the case may be, shall comply in all material respects with the requirements of the Securities
Act or the Exchange Act, as applicable, and shall not contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were
made, not misleading. There are no outstanding or unresolved comments or undertakings in such comment letters received by the Company
from the Commission. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement
filed by the Company under the Securities Act or the Exchange Act.
(b) The
consolidated financial statements of the Company included or incorporated by reference in the Commission Documents filed with or furnished
to the Commission present fairly, in all material respects, the consolidated financial position of the Company and the consolidated Subsidiaries
as of the dates indicated and the consolidated results of operations, cash flows and changes in stockholders’ equity of the Company
and the consolidated Subsidiaries for the periods specified (subject, in the case of unaudited statements, to normal year-end audit adjustments
which will not be material, either individually or in the aggregate) and have been prepared in compliance with the published requirements
of the Securities Act and Exchange Act, as applicable, and in conformity with generally accepted accounting principles in the United States
(“GAAP”) applied on a consistent basis (except (i) for such adjustments to accounting standards and practices as are
noted therein and (ii) in the case of unaudited interim statements, to the extent they may exclude footnotes or may be condensed or summary
statements) during the periods involved. Any pro forma financial statements or data included or incorporated by reference in the Commission
Documents filed with or furnished to the Commission comply with the requirements of Regulation S-X of the Securities Act, including, without
limitation, Article 11 thereof, and the assumptions used in the preparation of such pro forma financial statements and data are reasonable,
the pro forma adjustments used therein are appropriate to give effect to the circumstances referred to therein and the pro forma adjustments
have been properly applied to the historical amounts in the compilation of those statements and data. The other financial and statistical
data with respect to the Company and the Subsidiaries contained or incorporated by reference in the Commission Documents filed with or
furnished to the Commission are accurately and fairly presented and prepared on a basis consistent with the financial statements and books
and records of the Company. There are no financial statements (historical or pro forma) that are required to be included or incorporated
by reference in the Commission Documents filed with or furnished to the Commission that are not included or incorporated by reference
as required. The Company and the Subsidiaries do not have any material liabilities or obligations, direct or contingent (including
any off-balance sheet obligations or any “variable interest entities” as that term is used in Accounting Standards Codification
Paragraph 810-10-25-20), not described in the Commission Documents that are required to be described or incorporated by reference in the
Commission Documents. All disclosures contained or incorporated by reference in the Commission Documents, if any, regarding “non-GAAP
financial measures” (as such term is defined by the rules and regulations of the Commission) comply in all material respects with
Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Securities Act, to the extent applicable. The reserves, if any,
established by the Company or the lack of reserves, if applicable, are reasonable based upon facts and circumstances known by the Company
on the date hereof and there are no loss contingencies that are required to be accrued by the Statement of Financial Accounting Standard
No. 5 of the Financial Accounting Standards Board which are not provided for by the Company in its financial statements or otherwise.
The Company is not currently contemplating to amend or restate any of the financial statements (including, without limitation, any notes
or any letter of the independent accountants of the Company with respect thereto) included or incorporated by reference in the Commission
Documents, nor is the Company currently aware of facts or circumstances which would require the Company to amend or restate any such financial
statements, in each case, in order for any of such financials statements to be in compliance with GAAP and the rules and regulations of
the Commission. The Company has not been informed by its independent accountants that they recommend that the Company amend or restate
any of the financial statements included or incorporated by reference in the Commission Documents or that there is any need for the Company
to amend or restate any of such financial statements.
(c) Except
as set forth in the Commission Documents, the Company maintains a system of internal accounting controls sufficient to provide reasonable
assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability;
(iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to
any differences. The Company is not aware of any material weaknesses in its internal control over financial reporting (other than as set
forth or incorporated by reference in the Commission Documents). Except as set forth or incorporated by reference in the Commission Documents,
since the date of the latest audited financial statements of the Company included in the 2022 Form 10-K, there has been no change in the
Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect,
the Company’s internal control over financial reporting. Except as set forth or incorporated by reference in the Commission Documents,
the Company has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15) that comply with the
requirements of the Exchange Act. The Company’s certifying officers have evaluated the effectiveness of the Company’s controls
and procedures as of a date within 90 days prior to the filing date of the 2022 Form 10-K (such date, the “Evaluation Date”).
The Company presented in its 2022 Form 10-K the conclusions of the certifying officers about the effectiveness of the disclosure controls
and procedures based on their evaluations as of the most recent Evaluation Date and, except as set forth in the Commission Documents,
the “disclosure controls and procedures” are effective.
(d) The
Company has filed with the Commission and made available via EDGAR all certifications and statements required by (x) Rule 13a-14 or Rule
15d-14 under the Exchange Act or (y) 18 U.S.C. Section 1350 (Section 906 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley
Act”)) with respect to all relevant Commission Documents. The Company is in compliance in all material respects with the provisions
of the Sarbanes-Oxley Act applicable to it as of the date hereof. The Company maintains disclosure controls and procedures required by
Rule 13a-15 or Rule 15d-15 under the Exchange Act; such controls and procedures are effective to ensure that all material information
concerning the Company and its Subsidiaries is made known on a timely basis to the individuals responsible for the timely and accurate
preparation of the Company’s Commission filings and other public disclosure documents. As used in this Section 4.6(c), the term
“file” shall be broadly construed to include any manner in which a document or information is furnished, supplied or otherwise
made available to the Commission.
(e) UHY
LLP (the “Auditor”) are independent public accountants within the meaning of the Securities Act and the Public Company
Accounting Oversight Board (United States). To the Company’s Knowledge, the Accountant is not in violation of the auditor independence
requirements of the Sarbanes-Oxley Act with respect to the Company.
(f) There
is and has been no failure on the part of the Company or, to the Knowledge of the Company, any of the Company’s directors or officers,
in their capacities as such, to comply in all material respects with any applicable provisions of the Sarbanes-Oxley Act and the rules
and regulations promulgated thereunder. Each of the principal executive officer and the principal financial officer of the Company (or
each former principal executive officer of the Company and each former principal financial officer of the Company as applicable) has made
all certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act with respect to all reports, schedules, forms, statements
and other documents required to be filed by it or furnished by it to the Commission during the past 12 months. For purposes of the preceding
sentence, “principal executive officer” and “principal financial officer” shall have the meanings given to such
terms in the Exchange Act Rules 13a-15 and 15d-15.
Section
4.7 Subsidiaries. No Subsidiary of the Company is currently prohibited, directly or indirectly, from paying any dividends to
the Company, from making any other distribution on such Subsidiary’s capital stock, from repaying to the Company any loans or advances
to such Subsidiary from the Company or from transferring any of such Subsidiary’s property or assets to the Company or any other
Subsidiary of the Company, except as described or incorporated by reference in, or contemplated by, the Commission Documents or as would
not reasonably be expected to have a Material Adverse Effect.
Section
4.8 No Material Adverse Effect. Except as otherwise disclosed in any Commission Document, since the end of the Company’s
most recent audited fiscal year: (i) the Company has not experienced or suffered any Material Adverse Effect, and there exists no current
state of facts, condition or event which would have a Material Adverse Effect; (ii) there has not occurred any material adverse change,
or any development that would reasonably be expected to result in a prospective material adverse change, in the condition, financial or
otherwise, or in the earnings, business or operations of the Company from that set forth in the Commission Documents, including, without
limitation, as a result of the recent outbreak of COVID-19, or as a result of any measures intended to contain the outbreak of COVID-19
imposed by any federal, state, local or foreign government or government agency in any country or region in which the Company, or any
of its agents, consultants, advisors or vendors, has assets or properties or conducts business, including, without limitation, any limitations,
curtailments, suspensions or closures of businesses, business offices or establishments, schools, properties and other public areas due
to quarantines, curfews, travel restrictions, workplace controls, “stay-at-home” orders, social distancing requirements or
guidelines or other public gathering restrictions or limitations; (iii) neither the Company nor any of its Subsidiaries has incurred any
material liability or obligation, direct or contingent, nor entered into any material transaction; (iv) the Company has not purchased
any of its outstanding capital stock, nor declared, paid or otherwise made any dividend or distribution of any kind on its capital stock
other than ordinary and customary dividends; and (v) there has not been any material change in the capital stock, short-term debt or
long-term debt of the Company.
Section
4.9 No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or
losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to
be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed
in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses
since September 30, 2023 and which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
Section
4.10 No Undisclosed Events or Circumstances. No event, liability, development or circumstance has occurred or exists, or is
reasonably expected to exist or occur with respect to the Company, any of its Subsidiaries or any of their respective businesses, properties,
liabilities, prospects, operations (including results thereof) or condition (financial or otherwise), that (i) would be required to be
disclosed by the Company under applicable securities laws in the Commission Documents, which has not been disclosed or incorporated by
reference in the Commission Documents, or (ii) would reasonably be expected to have a Material Adverse Effect.
Section
4.11 Indebtedness. The Commission Documents sets forth, as of September 30, 2023, all outstanding secured and unsecured Indebtedness
of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments through such date. For the purposes of this
Agreement, “Indebtedness” shall mean (a) any liabilities for borrowed money or amounts owed in excess of $100,000 (other
than trade accounts payable incurred in the ordinary course of business), (b) all guaranties, endorsements, indemnities and other contingent
obligations in respect of Indebtedness of others in excess of $100,000, whether or not the same are or should be reflected in the Company’s
balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar
transactions in the ordinary course of business; and (c) the present value of any lease payments in excess of $100,000 due under leases
required to be capitalized in accordance with GAAP. There is no existing or continuing default or event of default in respect of any Indebtedness
of the Company or any of its Subsidiaries. The Company has not taken any steps, and does not currently expect to take any steps, to seek
protection pursuant to Title 11 of the United States Code or any similar federal or state bankruptcy law or law for the relief of debtors,
nor does the Company have any Knowledge that its creditors intend to initiate involuntary bankruptcy, insolvency, reorganization or liquidation
proceedings or other proceedings for relief under Title 11 of the United States Code or any other federal or state bankruptcy law or any
law for the relief of debtors. The Company is financially solvent and is generally able to pay its debts as they become due.
Section
4.12 Title To Assets. The Company and each of its Subsidiaries have good and marketable title in fee simple to all real property
and good and marketable title to all personal property owned by them which is material to the business of the Company, in each case free
and clear of all liens, encumbrances and defects except such as are described or incorporated by reference in the Commission Documents
or such as do not materially affect the value of such property and do not interfere with the use made and proposed to be made of such
property by the Company and its Subsidiaries; and any real property and buildings held under lease by the Company and its Subsidiaries
are held by it under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere in any material
respect with the use made and proposed to be made of such property and buildings by the Company and its Subsidiaries, in each case except
as described or incorporated by reference in the Commission Documents.
Section
4.13 Actions Pending. There are no legal or governmental proceedings pending or, to the Knowledge of the Company,
threatened to which the Company or any Subsidiary is a party or to which any of the properties of the Company or any Subsidiary is
subject (i) other than proceedings accurately described or incorporated by reference in the Commission Documents and proceedings
that would not have a Material Adverse Effect on the Company and its Subsidiaries, taken as a whole, or on the power or ability of
the Company to perform its obligations under this Agreement or to consummate the transactions contemplated by this Agreement or (ii)
that are required to be described in the Commission Documents and are not so described or incorporated by reference therein.
Section
4.14 Compliance With Law. The business of the Company and the Subsidiaries has been and is presently being conducted in compliance
with all applicable federal, state, local and foreign governmental laws, rules, regulations and ordinances, except as set forth or incorporated
by reference in the Commission Documents and except for such non-compliance which, individually or in the aggregate, would not have a
Material Adverse Effect. Neither the Company nor any of its Subsidiaries is in violation of any judgment, decree or order or any statute,
ordinance, rule or regulation of any Governmental Entity applicable to the Company or any of its Subsidiaries, except in all cases for
any such violations which would not, individually or in the aggregate, have or reasonably be expected to have a Material Adverse Effect.
Section
4.15 Certain Fees. No brokers, finders or financial advisory fees or commissions is or shall be payable by the Company or any
Subsidiary (or any of their respective affiliates) with respect to the transactions contemplated by this Agreement. Except as set forth
in the Commission Documents, there are no contracts, agreements or understandings between the Company and any person that would give rise
to a valid claim against the Company, the Investor or the Broker-Dealer for a brokerage commission, finder’s fee or other like payment
in connection with the transactions contemplated by this Agreement or, to the Company’s Knowledge, any arrangements, agreements,
understandings, payments or issuance with respect to the Company or any of its officers, directors, stockholders, partners, employees,
Subsidiaries or Affiliates that may affect the FINRA’s determination of the amount of compensation to be received by any FINRA member
or person associated with any FINRA member in connection with the transactions contemplated by this Agreement. Except as set forth in
this Section 4.15 or as disclosed in the Commission Documents, no “items of value” (within the meaning of FINRA Rule 5110)
have been received, and no arrangements have been entered into for the future receipt of any items of value, from the Company or any of
its officers, directors, stockholders, partners, employees, Subsidiaries or Affiliates by any FINRA member or person associated with any
FINRA member, during the period commencing 180 days immediately preceding the Closing Date and ending on the date this Agreement is terminated
in accordance with Article VII, that may affect the FINRA’s determination of the amount of compensation to be received by any FINRA
member or person associated with any FINRA member in connection with the transactions contemplated by this Agreement.
Section
4.16 Operation of Business.
(a) The
Company and the Subsidiaries possess or have obtained, all licenses, certificates, consents, orders, approvals, permits and other authorizations
issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign Governmental Entity that
are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as currently conducted,
as described or incorporated by reference in the Commission Documents (the “Permits”), except where the failure to
possess, obtain or make the same would not, individually or in the aggregate, have a Material Adverse Effect. Neither the Company nor
any Subsidiary has received written notice of any proceeding relating to revocation or modification of any such Permit or has any reason
to believe that such Permit will not be renewed in the ordinary course, except where the failure to obtain any such renewal would not,
individually or in the aggregate, have a Material Adverse Effect. This Section 4.16(a) does not relate to environmental matters, such
items being the subject of Section 4.17.
(b) Except
as described or incorporated by reference in the Commission Documents, the Company and its Subsidiaries own or possess adequate enforceable
rights to use all patents, patent applications, trademarks (both registered and unregistered), trade names, trademark registrations, service
marks, service mark registrations, Internet domain name registrations, copyrights, copyright registrations, licenses and know-how (including
trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures) (collectively,
the “Intellectual Property”), necessary for the conduct of their respective businesses as conducted as of the date
hereof, except to the extent that the failure to own or possess adequate rights to use such Intellectual Property would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company and its Subsidiaries have not received any
written notice of any claim of infringement or conflict which asserted Intellectual Property rights of others, which infringement or conflict,
if the subject of an unfavorable decision, would result in a Material Adverse Effect. There are no pending, or to the Company’s
Knowledge, threatened judicial proceedings or interference proceedings challenging the Company’s or any of its Subsidiaries’
rights in or to or the validity of the scope of any of the Company’s or its Subsidiaries’ Intellectual Property. No other
Person has any right or claim in any of the Company’s or any of its Subsidiaries’ Intellectual Property by virtue of any contract,
license or other agreement entered into between such Person and the Company or any of its Subsidiaries or by any non-contractual obligation,
other than by written licenses granted by the Company or any of its Subsidiaries. Neither the Company nor any of its Subsidiaries has
received any written notice of any claim challenging the rights of the Company or any of its Subsidiaries in or to any Intellectual Property
owned, licensed or optioned by the Company or any of its Subsidiaries, which claim, if the subject of an unfavorable decision, would result
in a Material Adverse Effect.
Section
4.17 Environmental Compliance. Other than as set forth or incorporated by reference in the Commission Documents, to the Knowledge
of the Company, the Company and its Subsidiaries are not in violation of any statute, any rule, regulation, decision or order of any governmental
agency or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous or toxic substances (collectively,
“Environmental Laws”), owns or operates any real property contaminated with any substance that is subject to any Environmental
Laws, is liable for any off-site disposal or contamination pursuant to any Environmental Laws, or subject to any claim relating to any
Environmental Laws, which violation, contamination, liability or claim would, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect; and the Company is not aware of any pending investigation which might lead to such a claim. Other than
as set forth or incorporated by reference in the Commission Documents, there is no judgment, decree, injunction, rule, writ or order of
any Governmental Entity under any Environmental Laws outstanding against the Company and its Subsidiaries which would, individually or
in the aggregate, reasonably be expected to have a Material Adverse Effect.
Section
4.18 Material Agreements. Except as set forth or incorporated by reference in the Commission Documents, neither the Company
nor any Subsidiary of the Company is a party to any written or oral contract, instrument, agreement commitment, obligation, plan or arrangement,
a copy of which would be required to be filed with the Commission as an exhibit to an annual report on Form 10-K (collectively, “Material
Agreements”). Each of the Material Agreements described in the Commission Documents, as of the applicable date or time this
representation is being made under Article VI hereof conform in all material respects to the descriptions thereof contained or incorporated
by reference therein. Except as set forth or incorporated by reference in the Commission Documents, the Company and each of its Subsidiaries
have performed in all material respects all the obligations then required to be performed by them under the Material Agreements, have
received no notice of default or an event of default by the Company or any of its Subsidiaries thereunder and are not aware of any basis
for the assertion thereof, and neither the Company or any of its Subsidiaries nor, to the Knowledge of the Company, any other contracting
party thereto are in default under any Material Agreement now in effect, the result of which would have a Material Adverse Effect. Except
as set forth or incorporated by reference in the Commission Documents, each of the Material Agreements is in full force and effect, and
constitutes a legal, valid and binding obligation enforceable in accordance with its terms against the Company and/or any of its Subsidiaries
and, to the Knowledge of the Company, each other contracting party thereto, except as such enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting
generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application.
Section
4.19 Transactions With Affiliates. Except as set forth or incorporated by reference in the Commission Documents, none of the
officers or directors of the Company and, to the Knowledge of the Company, none of the Company’s stockholders, the officers or directors
of any stockholder of the Company, or any family member or Affiliate of any of the foregoing, has either directly or indirectly any interest
in, or is a party to, any transaction that is required to be disclosed as a related party transaction pursuant to Item 404 of Regulation
S-K promulgated under the Securities Act.
Section
4.20 Securities Act. The Company will comply with all applicable federal and state securities laws in connection with the offer,
issuance and sale of the Securities contemplated by this Agreement.
(a) The
Registration Statement, as of the Commencement Date, will meet the requirements set forth in Rule 415(a)(1)(x) under the Securities Act.
The Base Prospectus will comply in all material respects on its date and on the Commencement Date, and will comply in all material respects
on each applicable Purchase Condition Satisfaction Time and, when taken together with the applicable Prospectus Supplement and any applicable
Permitted Free Writing Prospectus, on each applicable Purchase Condition Satisfaction Time with the requirements of the Securities Act
and did not on its date and on the Commencement Date and shall not on each applicable VWAP Purchase Exercise Date and, when taken together
with the applicable Prospectus Supplement and any applicable Permitted Free Writing Prospectus, on each applicable VWAP Purchase Settlement
Date contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make
the statements therein, in the light of the circumstances under which they were made, not misleading; provided that this representation
and warranty will not apply to statements in or omissions from the Base Prospectus made in reliance upon and in conformity with information
relating to the Investor furnished to the Company in writing by or on behalf of the Investor expressly for use therein.
(b) Each
Prospectus Supplement required to be filed pursuant to Section 1.3 hereof, when taken together with the Base Prospectus and any applicable
Permitted Free Writing Prospectus, on its date and on the applicable VWAP Purchase Settlement Date, shall comply in all material respects
with the provisions of the Securities Act and shall not on its date and on the applicable VWAP Purchase Settlement Date contain an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein,
in the light of the circumstances under which they are made, not misleading, except that this representation and warranty does not apply
to statements in or omissions from any Prospectus Supplement made in reliance upon and in conformity with information relating to the
Investor furnished to the Company in writing by or on behalf of the Investor expressly for use therein.
(c) As
of the date hereof, the Company is not an “ineligible issuer” (as defined in Rule 405 under the Securities Act). Each Permitted
Free Writing Prospectus (a) shall conform in all material respects to the requirements of the Securities Act on the date of its first
use, (b) when considered together with the Prospectus on each applicable VWAP Purchase Exercise Date and on each applicable VWAP Purchase
Settlement Date, shall not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein, in the light of the circumstances under which they are made, not misleading, and (c) shall
not include any information that conflicts with the information contained in the Registration Statement, including any document incorporated
by reference therein and any Prospectus Supplement deemed to be a part thereof that has not been superseded or modified. The immediately
preceding sentence does not apply to statements in or omissions from any Permitted Free Writing Prospectus made in reliance upon and in
conformity with information relating to the Investor furnished to the Company in writing by or on behalf of the Investor expressly
for use therein.
(d) Prior
to the Commencement Date, the Company has not distributed any offering material in connection with the offering and sale of the Securities.
From and after the Commencement Date and prior to the completion of the distribution of the Securities, the Company shall not distribute
any offering material in connection with the offering and sale of the Securities, other than the Registration Statement, the Base Prospectus
as supplemented by any Prospectus Supplement or a Permitted Free Writing Prospectus.
Section
4.21 Employees; Labor Laws. No material labor dispute with the employees of the Company exists, except as set forth or incorporated
by reference in the Commission Documents, or, to the Knowledge of the Company, is imminent; and the Company is not aware of any existing,
threatened or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors that would reasonably
be expected to have a Material Adverse Effect. Neither the Company nor any Subsidiary is in violation of or has received notice of any
violation with respect to any federal or state law relating to discrimination in the hiring, promotion or pay of employees, nor any applicable
federal or state wage and hour laws, nor any state law precluding the denial of credit due to the neighborhood in which a property is
situated, the violation of any of which would, individually or in the aggregate, have or reasonably be expected to have a Material Adverse
Effect.
Section
4.22 Use of Proceeds. The proceeds from the sale of the Shares shall be used by the Company and its Subsidiaries as set forth
in the Registration Statement and any Prospectus Supplement filed pursuant to Section 1.3 or other Commission Document incorporated by
reference in the Registration Statement and any other Prospectus Supplement.
Section
4.23 Investment Company Act Status. The Company is not, and as a result of the consummation of the transactions contemplated
by this Agreement and the application of the proceeds from the sale of the Shares as set forth in the Registration Statement and any other
Prospectus Supplement filed pursuant to Section 1.3 or other Commission Document incorporated by reference in the Registration Statement
and any other Prospectus Supplement, shall not be, an “investment company” or a company “controlled” by an “investment
company,” within the meaning of the Investment Company Act of 1940, as amended.
Section
4.24 ERISA. Except as set forth or incorporated by reference in the Commission Documents, the Company is not a party to an
“employee benefit plan,” as defined in Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”),
which: (i) is subject to Title IV of ERISA and (ii) is or was at any time maintained, administered or contributed to by the Company or
any of its ERISA Affiliates (as defined hereafter). These plans are referred to collectively herein as the “Employee Plans.”
An “ERISA Affiliate” of any person or entity means any other person or entity which, together with that person or entity,
could be treated as a single employer under Section 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended (the “Code”).
Each Employee Plan has been maintained in material compliance with its terms and the requirements of applicable law. Except as set forth
or incorporated by reference in the Commission Documents, there is no liability in respect of post-retirement health and medical benefits
for retired employees of the Company or any of its ERISA Affiliates, other than medical benefits required to be continued under applicable
law. No “prohibited transaction” (as defined in either Section 406 of ERISA or Section 4975 of the Code) has occurred with
respect to any Employee Plan; and each Employee Plan that is intended to be qualified under Section 401(a) of the Code is so qualified,
and nothing has occurred, whether by action or by failure to act, which could cause the loss of such qualification.
Section
4.25 Taxes. The Company and each of its Subsidiaries (i) has timely made or filed all foreign, federal and state income and
all other tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has timely paid all taxes and
other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations,
except those being contested in good faith and (iii) has set aside on its books provision reasonably adequate for the payment of all taxes
for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company and its Subsidiaries know of no
basis for any such claim. The Company is not operated in such a manner as to qualify as a passive foreign investment company, as defined
in Section 1297 of the Code. The net operating loss carryforwards (“NOLs”) for United States federal income tax purposes
of the consolidated group of which the Company is the common parent, if any, shall not be adversely effected by the transactions contemplated
hereby. The transactions contemplated hereby do not constitute an “ownership change” within the meaning of Section 382 of
the Code, thereby preserving the Company’s ability to utilize such NOLs.
Section
4.26 Insurance. (i) The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility
against such losses and risks in such amounts and subject to such self-insurance retentions as are prudent and customary in the businesses
in which they are engaged; (ii) all policies of insurance and fidelity or surety bonds insuring the Company or any of the Subsidiaries
or their respective businesses, assets, employees, officers and directors are in full force and effect; (iii) the Company and each of
its Subsidiaries are in compliance with the terms of such policies and instruments in all material respects; and there are no claims by
the Company or any of its Subsidiaries under any such policy or instrument as to which any insurance company is denying liability or defending
under a reservation of rights clause; and (iv) the Company and its Subsidiaries have no reason to believe that they will not be able to
renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be
necessary to continue its business at a cost that would not reasonably be expected to have a Material Adverse Effect, whether or not arising
from transactions in the ordinary course of business, except as set forth or incorporated by reference in the Commission Documents.
Section
4.27 U.S. Real Property Holding Corporation. Neither the Company nor any of its Subsidiaries is, or has ever been, and so long
as any of the Securities are held by the Investor, shall become a U.S. real property holding corporation within the meaning of Section
897 of the Code.
Section
4.28 Listing and Maintenance Requirements; DTC Eligibility. The Common Stock is registered pursuant to Section 12(b) of the
Exchange Act, and the Company has taken no action designed to, or which to its Knowledge is likely to have the effect of, terminating
the registration of the Common Stock under the Exchange Act, nor has the Company received any notification that the Commission is contemplating
terminating such registration. Except as set forth in the Commission Documents and as of the Commencement Date, the Company has not received
notice from the Trading Market or any Eligible Market on which the Common Stock is or has been listed or quoted to the effect that the
Company is not in compliance with the listing or maintenance requirements of such Trading Market or Eligible Market, as applicable. Except
as set forth in the Commission Documents and as of the Commencement Date, the Company is in compliance with all such listing and maintenance
requirements. The Common Stock may be issued and transferred electronically to third parties via DTC through its Deposit/Withdrawal at
Custodian (“DWAC”) delivery system. The Company has not received notice from DTC to the effect that a suspension of,
or restriction on, accepting additional deposits of the Common Stock, electronic trading or book-entry services by DTC with respect to
the Common Stock is being imposed or is contemplated.
Section
4.29 No Unlawful Payments. Neither the Company nor any of its Subsidiaries nor, to the Knowledge of the Company, any
director, officer, agent, employee or Affiliate of the Company or any of its Subsidiaries is aware of or has taken any action,
directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977 or the U.K.
Bribery Act of 2010, each as may be amended, and the rules and regulations thereunder (the “FCPA” and
“UKBA”, respectively), or other applicable anti-bribery laws and regulations, including, without limitation,
making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment,
promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the
giving of anything of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political
party or official thereof or any candidate for foreign political office, in contravention of the FCPA, the UKBA or other applicable
anti-bribery laws and regulations; and the Company, its Subsidiaries and, to the Knowledge of the Company, its Affiliates have
conducted their businesses in compliance with the FCPA, the UKBA or other applicable anti-bribery laws and regulations, and have
instituted and maintain and enforce policies and procedures designed to ensure, and which are reasonably expected to continue to
ensure, continued compliance therewith.
Section
4.30 Money Laundering Laws. The operations of the Company and its Subsidiaries are and have been conducted at all times in
compliance with applicable financial recordkeeping and reporting requirements and the money laundering statutes and the rules and regulations
thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively,
the “Money Laundering Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority
or body or any arbitrator involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to
the Knowledge of the Company, threatened.
Section
4.31 OFAC. Neither the Company nor any of its Subsidiaries nor, to the Knowledge of the Company, any director, officer,
agent, employee or Affiliate of the Company or any of its Subsidiaries (i) is currently subject to any sanctions administered by the
U.S. government, including the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”) or the
U.S. Department of State, the United Nations Security Council, the European Union, or the United Kingdom (including sanctions
administered or controlled by Her Majesty’s Treasury) (collectively, “Sanctions” and such persons,
“Sanctioned Persons”) or other relevant sanctions authority, and (ii) will use the proceeds of this offering,
directly or indirectly, to fund or facilitate the activities of any Sanctioned Persons or entity or any country, region or territory
that is, at the time of such funding or facilitation, subject to Sanctions or any person or entity located in a country, region or
territory subject to Sanctions (including any administered or enforced by OFAC or the U.S. Department of State), the United Nations
Security Council, the European Union, or the United Kingdom (including sanctions administered or controlled by Her Majesty’s
Treasury). Neither the Company nor any of its subsidiaries nor, to the Knowledge of the Company, any director, officer, agent,
employee or Affiliate of the Company or any of its subsidiaries, is a person that is, or is 50% or more owned or otherwise
controlled by a person that is: (i) the subject of any Sanctions; or (ii) located, organized or resident in a country, region or
territory that is, or whose government is, the subject of Sanctions that broadly prohibit dealings with that country, region or
territory (including at the time of this agreement, Cuba, Iran, North Korea, Syria and Crimea) (collectively, “Sanctioned
Countries” and each, a “Sanctioned Country”). The Company and its Subsidiaries have not engaged in any
dealings or transactions with or for the benefit of Sanctioned Persons, or with or in a Sanctioned Country, in the preceding three
years, nor does the Company or any of its subsidiaries have any plans to deal or transact with Sanctioned Persons, or with or in
Sanctioned Countries.
Section
4.32 Disclosure. The Company confirms that neither it nor any other Person acting on its behalf has provided the Investor or
any of its agents, advisors or counsel with any information that constitutes or would reasonably be expected to constitute material, nonpublic
information concerning the Company or any of its Subsidiaries, other than the existence of the transactions contemplated by this Agreement.
The Company understands and confirms that the Investor will rely on the foregoing representations in effecting resales of Securities under
the Registration Statement and the Prospectus. All disclosure provided to Investor regarding the Company and its Subsidiaries, their businesses
and the transactions contemplated by this Agreement (including, without limitation, the representations and warranties of the Company
contained in this Article IV ) furnished in writing by or on behalf of the Company or any of its Subsidiaries for purposes of or in connection
with the transactions contemplated by this Agreement (other than forward-looking information and projections and information of a general
economic nature and general information about the Company’s industry), taken together, is true and correct in all material respects
on the date on which such information is dated or certified, and does not contain any untrue statement of a material fact or omit to state
any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made,
not misleading at such time.
Section
4.33 Bank Holding Company Act. Neither the Company nor any of its Subsidiaries or affiliates is subject to the Bank Holding
Company Act of 1956, as amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve System
(the “Federal Reserve”). Neither the Company nor any of its Subsidiaries or affiliates owns or controls, directly or
indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the
total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any
of its Subsidiaries or affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject
to the BHCA and to regulation by the Federal Reserve.
Section
4.34 IT Systems. The Company and its Subsidiaries’ information technology assets and equipment, computers, systems, networks,
hardware, software, websites, applications, and databases (collectively, “IT Systems”) are adequate for, and operate
and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries
as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants
that would reasonably be expected to have a Material Adverse Effect. The Company and its Subsidiaries have implemented and maintained
commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect
their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data, including
“Personal Data,” used in connection with their businesses. “Personal Data” means (i) a natural person’s
name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver’s
license number, passport number, credit card number, bank information, or customer or account number; (ii) any information which would
qualify as “personally identifying information” under the Federal Trade Commission Act, as amended; (iii) “personal
data” as defined by the European Union General Data Protection Regulation (“GDPR”) (EU 2016/679); (iv) any information
which would qualify as “protected health information” under the Health Insurance Portability and Accountability Act of 1996,
as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, “HIPAA”); and (v)
any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection
or analysis of any data related to an identified person’s health or sexual orientation. There have been no breaches, violations,
outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the
duty to notify any other person or such, nor any incidents under internal review or investigations relating to the same except in each
case, where such would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. The
Company and its Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations
of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy
and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access,
misappropriation or modification except in each case, where such would not, either individually or in the aggregate, reasonably be expected
to result in a Material Adverse Effect.
Section
4.35 Compliance With Data Privacy Laws The Company and its Subsidiaries are, and at all prior times were, in compliance with
all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company and
its Subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May 25, 2018, have been and currently
are in compliance with, the GDPR (EU 2016/679) (collectively, the “Privacy Laws”) except in each case, where such would
not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. To ensure compliance with
the Privacy Laws, the Company and its Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure
compliance in all material respects with their policies and procedures relating to data privacy and security and the collection, storage,
use, disclosure, handling, and analysis of Personal Data (the “Policies”). The Company and its Subsidiaries have at
all times made all disclosures to users or customers required by applicable laws and regulatory rules or requirements, and none of such
disclosures made or contained in any Policy have, to the knowledge
of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. The
Company further certifies that neither it nor any Subsidiary: (i) has received notice of any actual or potential liability under or relating
to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably
be expected to result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation,
or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any obligation
or liability under any Privacy Law
Section
4.36 Stock Option Plans. Each stock option granted by the Company was granted (i) in accordance with the terms of the
applicable stock option plan of the Company and (ii) with an
exercise price at least equal to the fair market value of the Common Stock on the date such stock option would be considered granted
under GAAP and applicable law. No stock option granted under the Company’s stock option plan has been backdated. The Company
has not knowingly granted, and there is no and has been no policy or practice of the Company to knowingly grant, stock options prior
to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material
information regarding the Company or its Subsidiaries or their financial results or prospects.
Section
4.37 Dilutive Effect. The Company is aware and acknowledges that issuance of the Securities could cause dilution to existing
stockholders and could significantly increase the number of outstanding shares of Common Stock. The Company further acknowledges that
its obligation to issue the Commitment Note and to issue the Shares pursuant to each Fixed Purchase Notice, each VWAP Purchase Notice
and each Additional VWAP Purchase Notice delivered by the Company to the Investor pursuant to this Agreement is, in each case, absolute
and unconditional regardless of the dilutive effect that such issuance may have on the ownership interests of other stockholders of the
Company.
Section
4.38 Manipulation of Price. Neither the Company nor any of its officers, directors or Affiliates has, and, to the Knowledge
of the Company, no Person acting on their behalf has, (i) taken, directly or indirectly, any action designed or intended to cause or to
result in the stabilization or manipulation of the price of any security of the Company, or which caused or resulted in, or which would
in the future reasonably be expected to cause or result in, the stabilization or manipulation of the price of any security of the Company,
in each case to facilitate the sale or resale of any of the Securities or (ii) sold, bid for, purchased, or paid any compensation for
soliciting purchases of, any of the Securities, paid or agreed to pay to any Person any compensation for soliciting another to purchase
any other securities of the Company. Neither the Company nor any of its officers, directors or Affiliates will during the term of this
Agreement, and, to the Knowledge of the Company, no Person acting on their behalf will during the term of this Agreement, take any of
the actions referred to in the immediately preceding sentence.
Section
4.39 Application of Takeover Protections. The Company and its Board of Directors have taken all necessary action, if any, in
order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights
agreement) or other similar anti-takeover provision under the Company’s Charter or the laws of its state of incorporation that is
or could become applicable to the Investor as a result of the Investor and the Company fulfilling their respective obligations or exercising
their respective rights under the Transaction Documents (as applicable),
including, without limitation, as a result of the Company’s issuance of the Securities and the Investor’s ownership of the
Securities.
Section
4.40 Acknowledgement Regarding Investor’s Acquisition of Securities. The Company acknowledges and agrees that the Investor
is acting solely in the capacity of an arm’s length purchaser with respect to this Agreement and the transactions contemplated hereby.
The Company further acknowledges that the Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to this Agreement or the transactions contemplated hereby, and any advice given by the Investor or any of its representatives
or agents in connection with this Agreement or the transactions contemplated hereby is merely incidental to the Investor’s acquisition
of the Securities. The Company further represents to the Investor that the Company’s decision to enter into this Agreement has been
based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives. The Company
acknowledges and agrees that the Investor has not made and does not make any representations or warranties with respect to the transactions
contemplated by this Agreement other than those specifically set forth in Article III of this Agreement.
ARTICLE
V
COVENANTS
The Company
covenants with the Investor, and the Investor covenants with the Company, as follows, which covenants of one party are for the benefit
of the other party, during the Investment Period:
Section
5.1 Securities Compliance. The Company shall notify the Trading Market, as required, in accordance with its rules and regulations,
of the transactions contemplated by this Agreement, and shall take all necessary action, undertake all proceedings and obtain all registrations,
permits, consents and approvals for the legal and valid issuance of the Securities to the Investor in accordance with the terms of this
Agreement. Without limiting the generality of the foregoing, the Company shall take all reasonably necessary action, undertake all proceedings
and obtain all registrations, permits, consents and approvals in order to (i) qualify the Securities for offering and sale to the Investor,
or to obtain an exemption for the Securities to be offered and sold to the Investor and (ii) qualify the Securities for offer and resale
by the Investor, or to obtain an exemption for the Securities to be offered and resold by the Investor, in each case under the applicable
securities laws of such states and other jurisdictions (domestic or foreign) as the Investor may reasonably designate, and to maintain
such qualifications and exemptions in effect for so long as required for the distribution of the Securities (but in no event for less
than one year from the date of this Agreement); provided, however, that the Company shall not be obligated to file any general
consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not
so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.
In each jurisdiction in which the Securities have been so qualified or exempt, the Company will file such statements and reports as may
be required by the laws of such jurisdiction to continue such qualification or exemption, as the case may be, in effect for so long as
required for the distribution of the Securities (but in no event for less than one year from the date of this Agreement).
Section
5.2 Registration and Listing. The Company shall take all action necessary to cause the Common Stock to continue to be registered
as a class of securities under Section 12(b) or 12(g) of the Exchange Act, shall comply in all material respects with its reporting and
filing obligations under the Exchange Act, and shall not take any action or file any document (whether or not permitted by the Securities
Act or the Exchange Act) to terminate or suspend such registration or to terminate or suspend its reporting and filing obligations under
the Exchange Act or Securities Act, except as permitted herein. Without limiting the generality of the foregoing, the Company shall file
all reports, schedules, registrations, forms, statements, information and other documents required to be filed by the Company with the
Commission pursuant to the Exchange Act, including all material required to be filed pursuant to Sections 13(a), 13(c), 14 or 15(d) of
the Exchange Act, in each case within the time periods required by the Exchange Act (giving effect to permissible extensions in accordance
with Rule 12b-25 under the Exchange Act). The Company shall use its reasonable best efforts to continue the listing and trading of its
Common Stock and the listing of the Note Shares acquired and the Shares purchased by the Investor hereunder on the Trading Market, and
shall comply with the Company’s reporting, filing and other obligations under the bylaws, listed securities maintenance standards
and other rules and regulations of FINRA and the Trading Market. The Company shall not take any action which would or would reasonably
be expected to result in the delisting or suspension of the Common Stock on the Trading Market.
Section 5.3 Compliance with
Laws.
(a)
The Company shall comply, and cause each Subsidiary to comply, (a) with all laws, rules, regulations, permits and orders applicable
to the business and operations of the Company and its Subsidiaries, except as would not have a Material Adverse Effect and (b) with all
applicable provisions of the Securities Act and the Exchange Act. Without limiting the foregoing: (A) neither the Company nor any of its
officers or directors (1) will take, directly or indirectly, any action designed or intended to cause or to result in, or which would
in the future reasonably be expected to cause or result in, the stabilization or manipulation of the price of any security of the Company,
in each case to facilitate the sale or resale of any of the Securities, or (2) sell, bid for, purchase, or pay any compensation for soliciting
purchases of, any of the Securities; and (B) neither the Company, nor any of its Subsidiaries, nor to the Knowledge of the Company, any
of their respective directors, officers, agents, employees or any other Persons acting on their behalf shall, in connection with the operation
of the Company’s and its Subsidiaries’ respective businesses, (a) use any corporate funds for unlawful contributions, payments,
gifts or entertainment or to make any unlawful expenditures relating to political activity to government officials, candidates or members
of political parties or organizations, (b) pay, accept or receive any unlawful contributions, payments, expenditures or gifts, or (c)
violate or operate in noncompliance with any applicable export restrictions, anti-boycott regulations, embargo regulations or other applicable
domestic or foreign laws and regulations, including, without limitation, the FCPA, the UKBA, the Money Laundering Laws and OFAC. The Company
shall conduct its business in such a manner as will ensure that the Company will not be deemed to constitute a passive foreign investment
company within the meaning of Section 1297 of the Code.
(b) The
Investor shall comply with all laws, rules, regulations and orders applicable to the performance by it of its obligations under this
Agreement and its investment in the Securities, except as would not, individually or in the aggregate, prohibit or otherwise
interfere with the ability of the Investor to enter into and perform its obligations under this Agreement in any material respect.
Without limiting the foregoing, the Investor shall comply with all applicable provisions of the Securities Act and the Exchange Act,
including Regulation M thereunder, and any applicable securities laws of any non-U.S. jurisdictions. Neither the Investor nor any of
its officers or directors will take, directly or indirectly, any action designed or intended to cause or to result in, or which
would in the future reasonably be expected to cause or result in, the stabilization or manipulation of the price of any security of
the Company, in each case to facilitate the sale or resale of any of the Securities.
Section
5.4 Due Diligence. Subject to the requirements of Section 5.11 of this Agreement, from time to time during the Investment Period,
with 24 hours advance notice, the Company shall make available for inspection and review by the Investor, customary documentation allowing
the Investor and/or its appointed counsel or advisors to conduct due diligence. The Company shall not be required to reimburse the Investor
or its counsel or advisors in connection with any such due diligence from and after the date of this Agreement.
Section
5.5 Reservation of Common Stock; No Frustration; No Dilutive Issuances; No Similar Transactions.
(a) Reservation
of Common Stock. The Company has available and the Company shall reserve and keep available at all times, free of preemptive
and other similar rights of stockholders, the requisite aggregate number of authorized but unissued shares of Common Stock to enable
the Company to timely effect (i) the issuance and delivery of all Note Shares to be issued and delivered to the Investor under
Section 2.7 and Section 6.1 within the time period specified in such Sections, (ii) the issuance, sale and delivery of all Shares to
be issued, sold and delivered in respect of each Fixed Purchase effected under this Agreement, in the case of this clause (ii), at
least prior to the delivery by the Company to the Investor of the applicable Fixed Purchase Notice in connection with such Fixed
Purchase, (iii) the issuance, sale and delivery of all Shares to be issued, sold and delivered in respect of each VWAP Purchase
effected under this Agreement, in the case of this clause (iii), at least prior to the delivery by the Company to the Investor of
the applicable VWAP Purchase Notice in connection with such VWAP Purchase, and (iv) the issuance, sale and delivery of all Shares to
be issued, sold and delivered in respect of each Additional VWAP Purchase effected under this Agreement, in the case of this clause
(iv), at least prior to the delivery by the Company to the Investor of the applicable Additional VWAP Purchase Notice in connection
with such Additional VWAP Purchase.
(b) No
Frustration. The Company shall not enter into, announce or recommend to its stockholders any agreement, plan, arrangement or
transaction in or of which the terms thereof would restrict, materially delay, conflict with or impair the ability or right of the
Company to perform its obligations under this Agreement, including, without limitation, the obligation of the Company to deliver (i)
the Commitment Note on the Closing Date, and (ii) the Shares to the Investor in respect of a Fixed Purchase on the applicable Fixed
Purchase Share Delivery Date for such Fixed Purchase, (iii) the Shares to the Investor in respect of a VWAP Purchase on the
applicable VWAP Purchase Share Delivery Date for such VWAP Purchase, and (iv) the Shares to the Investor in respect of an Additional
VWAP Purchase on the applicable Additional VWAP Purchase Share Delivery Date for such Additional VWAP Purchase. For the avoidance of doubt, nothing in this Section 5.5(b) shall in
any way limit the Company’s right to terminate this Agreement in accordance with Section 7.1 (subject in all cases to Section 7.3).
(c) No
Dilutive Issuances Before Settlement of a Pending Purchase. None of the Company or any Subsidiary shall issue, sell or grant
any right, option or warrant to purchase, or issue, sell or grant any right to reprice (or reset the purchase price therefor), or otherwise
dispose of for cash (or enter into any agreement, plan or arrangement contemplating any of the foregoing, or seek to utilize any existing
agreement, plan or arrangement to effect any of the foregoing), or announce any offer, issuance, sale or grant of any option or warrant
to purchase or other disposition for cash (or any agreement, plan or arrangement therefor), at any time during (i) the period beginning
on the Trading Day immediately preceding each Fixed Purchase Date for a Fixed Purchase and ending on and including the third (3rd)
Trading Day after the later of (1) the Fixed Purchase Settlement Date for such Fixed Purchase and (2) such later Trading Day after such
Fixed Purchase Settlement Date on which such Fixed Purchase is fully settled in accordance with this Agreement, (ii) the period beginning
on the Trading Day immediately preceding each VWAP Purchase Exercise Date for a VWAP Purchase and ending on and including the third (3rd)
Trading Day after the later of (1) the VWAP Purchase Settlement Date for such VWAP Purchase and (2) such later Trading Day after such
VWAP Purchase Settlement Date on which such VWAP Purchase is fully settled in accordance with this Agreement, and (iii) the period beginning
on the Trading Day immediately preceding each Additional VWAP Purchase Exercise Date for an Additional VWAP Purchase and ending on and
including the third (3rd) Trading Day after the later of (1) the Additional VWAP Purchase Settlement Date for such Additional
VWAP Purchase and (2) such later Trading Day after such Additional VWAP Purchase Settlement Date on which such Additional VWAP Purchase
is fully settled in accordance with this Agreement (each such period for each Fixed Purchase, each VWAP Purchase and each Additional
VWAP Purchase, a “Reference Period”), any Common Stock or Common Stock Equivalents, at an effective price per share
of Common Stock less than the applicable Fixed Purchase Price per Share for such Fixed Purchase, the applicable VWAP Purchase Price per
Share for such VWAP Purchase, or the applicable Additional VWAP Purchase Price per Share for such Additional VWAP Purchase (as applicable)
(such price, the “Reference Price”) to be to be paid by the Investor in such Fixed Purchase, VWAP Purchase and Additional
VWAP Purchase (as applicable) effected during such Reference Period (each such issuance, a “Dilutive Issuance”), other
than an Exempt Issuance (it being understood and agreed that if the holder of the Common Stock or Common Stock Equivalents so issued
shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices
or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to receive
shares of Common Stock at an effective price per share of Common Stock that is less than the applicable Reference Price, such issuance
shall be deemed to have occurred for less than the applicable Reference Price on such date of the Dilutive Issuance at such effective
price). If the Company enters into a Variable Rate Transaction involving the issuance of Common Stock Equivalents having a conversion
price, exercise price, exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the
Common Stock at any time after the initial issuance of such Common Stock Equivalents, the Company shall be deemed to have issued, as
of the date the Common Stock Equivalents were issued (whether or not such Common Stock Equivalents are then immediately exercisable or
convertible), the Common Stock underlying such Common Stock Equivalents at the lowest possible conversion or exercise price at which
such Common Stock Equivalents may be converted or exercised for Common Stock (and if such Common Stock Equivalents include a “floor
price” representing the lowest conversion or exercise price at which such Common Stock Equivalents may be converted or exercised,
the Company shall be deemed to have issued the Common Stock underlying such Common Stock Equivalents at a price equal to such floor price).
The Investor shall be entitled to seek injunctive relief against the Company, and any Subsidiary (as applicable) to preclude any such
Dilutive Issuance that does not constitute an Exempt Issuance, which remedy shall be in addition to any right to collect damages, without
the necessity of showing economic loss and without any bond or other security being required.
(d) No
Other Similar Transactions. From and after the date of this Agreement until the earliest of (i) the date of automatic
termination of this Agreement pursuant to Section 7.1, (ii) the
effective date of termination of this Agreement by the mutual written consent of the parties hereto pursuant to Section 7.1, and
(iii) the effective date of termination of this Agreement by the Investor pursuant to Section 7.2, neither the Company nor any
Subsidiary shall issue, sell or grant any, or otherwise dispose of or issue (or enter into any agreement, plan or arrangement
contemplating any of the foregoing, or seek to utilize any existing agreement, plan or arrangement to effect any of the foregoing),
or announce any offer, issuance, sale or grant or other disposition or issuance (or any agreement, plan or arrangement therefor) any
Common Stock or Common Stock Equivalents (or a combination of units thereof) in any “equity line of credit” in which the
Company may offer, issue or sell Common Stock or Common Stock Equivalents (or any combination of units thereof) at a future
determined price, other than (A) any Securities issued to the Investor pursuant to this Agreement, (B) any equity or debt securities
of the Company issued to the Investor, Keystone Capital Partners, LLC or any of their respective Affiliates pursuant to any contract
or arrangement other than this Agreement or the transactions contemplated hereby, by and between the Company, on the one hand, and
the Investor and/or any of its Affiliates, on the other hand, or by and between the Company, on the one hand, and Keystone Capital
Partners, LLC and/or any of its Affiliates, on the other hand, or (C) any securities issued upon the exercise or exchange of or
conversion of any shares of Common Stock or Common Stock Equivalents held by the Investor, Keystone Capital Partners, LLC or any of
their respective Affiliates at any time. From and after the date of this Agreement until the effective date of termination of this
Agreement pursuant to Section pursuant to and in accordance with Section 7.1 or Section 7.2 (subject in all cases to Section 7.3),
neither the Company nor any Subsidiary shall issue, sell or grant any, or otherwise dispose of or issue (or enter into any
agreement, plan or arrangement contemplating any of the foregoing, or seek to utilize any existing agreement, plan or arrangement to
effect any of the foregoing), or announce any offer, issuance, sale or grant or other disposition or issuance (or any agreement,
plan or arrangement therefor) any Common Stock or Common Stock Equivalents (or a combination of units thereof) in any “at the
market offering” or “equity distribution program” to or through one or more registered broker-dealers acting as
agent or principal under one or more written agreements between the Company and such registered broker-dealer(s).
Section
5.6 Stop Orders. The Company shall advise the Investor promptly (but in no event later than 24 hours) and shall confirm such
advice in writing: (i) of the Company’s receipt of notice of any request by the Commission for amendment of or a supplement to the
Registration Statement, the Prospectus, any Permitted Free Writing Prospectus or for any additional information; (ii) of the Company’s
receipt of notice of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or prohibiting
or suspending the use of the Prospectus or any Prospectus Supplement, or of the suspension of qualification of the Securities
for offering or sale in any jurisdiction, or the initiation or contemplated initiation of any proceeding for such purpose; and (iii) of
the Company becoming aware of the happening of any event, which makes any statement of a material fact made in the Registration Statement,
the Prospectus or any Permitted Free Writing Prospectus untrue or which requires the making of any additions to or changes to the statements
then made in the Registration Statement, the Prospectus or any Permitted Free Writing Prospectus in order to state a material fact required
by the Securities Act to be stated therein or necessary in order to make the statements then made therein (in the case of the Prospectus,
in light of the circumstances under which they were made) not misleading, or of the necessity to amend the Registration Statement or supplement
the Prospectus or any Permitted Free Writing Prospectus to comply with the Securities Act or any other law. The Company shall not be required
to disclose to the Investor the substance or specific reasons of any of the events set forth in clauses (i) through (iii) of the immediately
preceding sentence, but rather, shall only be required to disclose that the event has occurred. The Company shall not issue any Fixed
Purchase Notice, any VWAP Purchase Notice or any Additional VWAP Purchase Notice during the continuation of any of the foregoing events.
If at any time the Commission shall issue any stop order suspending the effectiveness of the Registration Statement or prohibiting or
suspending the use of the Prospectus or any Prospectus Supplement, the Company shall use reasonable best efforts to obtain the withdrawal
of such order at the earliest possible time.
Section
5.7 Amendments to the Registration Statement; Prospectus Supplements; Free Writing Prospectuses.
(a)
Except as provided in this Agreement and other than periodic and current reports required to be filed pursuant to the Exchange
Act, the Company shall not file with the Commission any amendment to the Registration Statement that relates to the Investor, this Agreement
or the transactions contemplated hereby or file with the Commission any Prospectus Supplement that relates to the Investor, this Agreement
or the transactions contemplated hereby with respect to which (i) the Investor shall not previously have been advised, (ii) the Company
shall not have given the Investor and its counsel a reasonable opportunity to comment on a draft thereof prior to filing with the Commission,
(iii) the Company shall not have given due consideration to any comments thereon received from the Investor or its counsel prior to filing
with the Commission, or (iv) the Investor shall reasonably object after being so advised or after having completed its review (provided,
however, that the failure of the Investor to make such objection shall not relieve the Company of any obligation or liability
under this Agreement or affect the Investor’s right to rely on the representations and warranties made by the Company in this Agreement),
unless the Company reasonably has determined that it is necessary to amend the Registration Statement or make any supplement to the Prospectus
to comply with the Securities Act or any other applicable law or regulation, in which case the Company shall promptly (but in no event
later than 24 hours) so inform the Investor, the Investor shall be provided with a reasonable opportunity to review and comment upon any
disclosure relating to the Investor and the Company shall expeditiously furnish to the Investor an electronic copy thereof (it being acknowledged
and agreed that the provisions of Section 1.3, and not this Section 5.7, shall apply with respect to the Registration Statement). In addition,
for so long as, in the reasonable opinion of counsel for the Investor, the Prospectus (or in lieu thereof, the notice referred to in Rule
173(a) under the Securities Act) is required to be delivered in connection with any acquisition or sale of Securities by the Investor,
the Company shall not file any (1) Prospectus Supplement with respect to the Securities, without delivering
or making available a copy of such Prospectus Supplement (in the form filed with the Commission), together with the Base Prospectus, to
the Investor promptly after the filing thereof with the Commission, or (2) any amendment to the Registration Statement, without promptly
delivering or making available a copy of such amendment to the Registration Statement (in the form filed with the Commission) to the Investor
promptly after the filing thereof with the Commission, in each case via e-mail in “.pdf” format to an e-mail account designated
by the Investor.
(b)
The Company has not made, and agrees that unless it obtains the prior written consent of the Investor it will not make, an offer
relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a Free Writing Prospectus
required to be filed by the Company or the Investor with the Commission or retained by the Company or the Investor under Rule 433 under
the Securities Act. The Investor has not made, and agrees that unless it obtains the prior written consent of the Company it will not
make, an offer relating to the Securities that would constitute a Free Writing Prospectus required to be filed by the Company with the
Commission or retained by the Company under Rule 433 under the Securities Act. Any such Issuer Free Writing Prospectus or other Free Writing
Prospectus consented to by the Investor or the Company is referred to in this Agreement as a “Permitted Free Writing Prospectus.”
The Company agrees that (x) it has treated and will treat, as the case may be, each Permitted Free Writing Prospectus as an Issuer Free
Writing Prospectus and (y) it has complied and will comply, as the case may be, with the requirements of Rules 164 and 433 under the Securities
Act applicable to any Permitted Free Writing Prospectus, including in respect of filing with the Commission, legending and record keeping.
Section
5.8 Prospectus Delivery. For so long as, in the reasonable opinion of counsel for the Investor, the Prospectus (or in lieu
thereof, the notice referred to in Rule 173(a) under the Securities Act) is required to be delivered in connection with any acquisition
or sale of Securities by the Investor, the Company will furnish to the Investor and its counsel (at the expense of the Company) copies
of the Base Prospectus and all Prospectus Supplements that are filed with the Commission, in each case, in the form filed with the Commission,
as soon as reasonably practicable via e-mail in “.pdf” format to an e-mail account designated by the Investor and, at the
Investor’s request, will also furnish copies of the Base Prospectus and all Prospectus Supplements, in each case, in the form filed
with the Commission, to each exchange or market on which sales of the Securities may be made and to each Broker-Dealer or other Person
designated by the Investor. The Company consents to the use of the Prospectus (and of any Prospectus Supplement thereto) in accordance
with the provisions of the Securities Act and with the securities or “Blue Sky” laws of the jurisdictions in which the Securities
may be sold by the Investor, in connection with the offering and sale of the Securities and for such period of time thereafter as the
Prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Securities Act) is required by the Securities Act to be
delivered in connection with sales of the Securities. If during such period of time any event shall occur that in the judgment of the
Company and its counsel is required to be set forth in the Registration Statement or the Prospectus or any Permitted Free Writing Prospectus
or should be set forth therein in order to make the statements made therein (in the case of the Prospectus, in light of the circumstances
under which they were made) not misleading, or if it is necessary to amend the Registration Statement or supplement or amend the Prospectus
or any Permitted Free Writing Prospectus to comply with the Securities Act or any other applicable law or regulation, the Company shall
forthwith prepare and, subject to Section 5.7(a)
above, file with the Commission an appropriate amendment to the Registration Statement or Prospectus Supplement to the Prospectus (or
supplement to the Permitted Free Writing Prospectus) and shall expeditiously furnish or make available to the Investor a copy thereof
in accordance with this Section 5.8. The Investor shall comply with any Prospectus delivery requirements under the Securities Act applicable
to it. The Investor acknowledges and agrees that it is not authorized to give any information or to make any representation not contained
in the Prospectus or the documents incorporated by reference or specifically referred to therein in connection with the offer and sale
of the Securities.
Section
5.9 Selling Restrictions. Except as expressly set forth below, the Investor covenants that commencing upon the execution
of this Agreement on the Closing Date and ending on the date of any termination of this Agreement pursuant to Section 7.1 or Section
7.2 (the “Restricted Period”), neither the Investor nor any of its Affiliates nor any entity managed or
controlled by the Investor (collectively, the “Restricted Persons” and each of the foregoing is referred to
herein as a “Restricted Person”) shall, directly or indirectly, (i) engage in any Short Sales of the Common Stock
or (ii) hedging transaction, which establishes a net short position with respect to the Common Stock, with respect to each of
clauses (i) and (ii) hereof, either for its own account or for the account of any other Restricted Person. Notwithstanding the
foregoing, it is expressly understood and agreed that nothing contained herein shall (without implication that the contrary would
otherwise be true) prohibit any Restricted Person during the Restricted Period from: (1) selling “long” (as defined
under Rule 200 promulgated under Regulation SHO) the Securities; or (2) selling a number of shares of Common Stock equal to the
number of Shares that the Investor is unconditionally obligated to purchase under a pending Fixed Purchase Notice, a pending VWAP
Purchase Notice and/or under any one or more pending Additional VWAP Purchase Notices, but has not yet received from the Company or
its transfer agent pursuant to this Agreement, so long as (X) the Investor (or its Broker-Dealer, as applicable) delivers the Shares
purchased pursuant to such pending Fixed Purchase Notice, such pending VWAP Purchase Notice and such pending Additional VWAP
Purchase Notices (as applicable) to the purchaser thereof promptly upon the Investor’s receipt of such Shares from the Company
in accordance with Section 2.4 of this Agreement and (Y) neither the Company or its transfer agent shall have failed for any reason
to deliver such Shares to the Investor or its Broker-Dealer so that such Shares are timely received by the Investor as DWAC Shares
on the applicable Fixed Purchase Share Delivery Date for such Fixed Purchase, the applicable VWAP Purchase Share Delivery Date for
such VWAP Purchase and the applicable Additional VWAP Purchase Share Delivery Date for such Additional VWAP Purchase(s) (as
applicable) in accordance with Section 2.4 of this Agreement. In addition to the foregoing, in connection with any sale of
Securities, the Investor shall comply in all respects with all applicable laws, rules, regulations and orders, including, without
limitation, the requirements of the Securities Act and the Exchange Act.
Section
5.10 Effective Registration Statement. The Company shall use its reasonable best efforts to keep the Registration Statement
effective pursuant to Rule 415 promulgated under the Securities Act, and to keep the Registration Statement and the Prospectus current
and available for issuances and sales of Securities by the Company to the Investor, and for the resale of Securities by the Investor,
at all times during the term of this Agreement and, to the extent the Investor owns any Securities upon the termination of this Agreement
shall maintain the effectiveness of the Registration Statement with respect to the registration of those Securities, until the 180th day
next following the termination of this Agreement (the “Registration Period”). Without limiting the generality
of the foregoing, during the Registration Period, the Company shall prepare and, subject to Section 5.7(a) above, file with the Commission,
at the Company’s expense, such amendments (including, without limitation, post-effective amendments) to the Registration Statement
and such Prospectus Supplements pursuant to Rule 424(b) under the Securities Act, in each case, as may be necessary to keep the Registration
Statement effective pursuant to Rule 415 promulgated under the Securities Act, and to keep the Registration Statement and the Prospectus
current and available for issuances and sales of Securities by the Company to the Investor, and for the resale of Securities by the Investor,
at all times during the Registration Period.
Section
5.11 Non-Public Information. Neither the Company or any of its Subsidiaries, nor any of their respective directors, officers,
employees or agents shall disclose any material non-public information about the Company to the Investor, unless a simultaneous public
announcement thereof is made by the Company in the manner contemplated by Regulation FD. In the event of a breach of the foregoing covenant
by the Company or any of its Subsidiaries, or any of their respective directors, officers, employees and agents, on the Cleansing Date
(defined below) and in compliance with the conditions set forth below, the Investor may publicly disclose such information without the
prior approval by the Company, any of its Subsidiaries, or any of their respective directors, officers, employees or agents, to the extent
the Investor (in its reasonable good faith judgment) deems such information to be material non-public information, in the form of a press
release, public advertisement or otherwise; provided, however, prior to exercising this right, the Investor shall provide
the Company with written notice of the Company's alleged failure to disclose such information, which notice shall (i) include a description
of the disclosure that the Investor intends to make and (ii) provide the Company with at least one (1) business day to cure such failure
(the first business day following such one-business day cure period, the “Cleansing Date”). The Investor shall not
have any liability to the Company, any of its Subsidiaries, or any of their respective directors, officers, employees, stockholders or
agents, for any such disclosure.
Section
5.12 Broker/Dealer. The Investor shall use one or more broker-dealers to effectuate all sales, if any, of the Securities that
it may acquire or purchase from the Company pursuant to this Agreement which (or whom) shall be unaffiliated with the Investor and not
then currently engaged or used by the Company (collectively, the “Broker-Dealer”). The Investor shall provide the Company
with all information regarding the Broker-Dealer reasonably requested by the Company. The Investor shall be solely responsible for all
fees and commissions of the Broker- Dealer, which shall not exceed customary brokerage fees and commissions, and shall be responsible
for designating only a DTC participant eligible to receive DWAC Shares.
Section
5.13 Earnings Statement. The Company will make generally available to its security holders as soon as practicable, but in any
event not later than 15 months after the end of the Company’s current fiscal quarter, an earnings statement covering a 12-month
period that satisfies the provisions of Section 11(a) of and Rule 158 under the Securities Act. The terms “earnings statement”
and “make generally available to its security holders” shall have the meanings set forth in Rule 158 under the Securities
Act.
Section
5.14 Corporate Existence. The Company shall take all steps necessary to preserve and continue the corporate existence of
the Company; provided, however, that, except as provided in Section 5.15, nothing in this Agreement shall be deemed to
prohibit the Company from engaging in any Fundamental Transaction with another Person. For the avoidance of doubt, nothing in this
Section 5.14 shall in any way limit the Company’s right to terminate this Agreement in accordance with Section 7.1 (subject in
all cases to Section 7.3).
Section
5.15 Fundamental Transaction. If a Fixed Purchase Notice, a VWAP Purchase Notice or an Additional VWAP Purchase Notice has
been delivered to the Investor and the transactions contemplated therein have not yet been fully settled in accordance with the terms
and conditions of this Agreement, the Company shall not effect any Fundamental Transaction until the expiration of five (5) Trading Days
following the date of full settlement thereof and the issuance to the Investor of all of the Shares issuable pursuant to the Fixed Purchase,
the VWAP Purchase or the Additional VWAP Purchase to which such Fixed Purchase Notice, VWAP Purchase Notice or Additional VWAP Purchase
Notice, respectively, relates.
ARTICLE VI
CONDITIONS TO COMMENCEMENT;
CONDITIONS TO THE SALE AND PURCHASE OF THE SHARES
Section
6.1 Conditions to Commencement. On the Closing Date, simultaneously with the execution of this Agreement, the Company shall
issue the Commitment Note to the Investor or its designee(s). For the avoidance of doubt, the Commitment Note and all of the Note Shares
shall be fully earned as of the Closing Date, regardless of whether any Fixed Purchases, any VWAP Purchases or any Additional VWAP Purchases
are made or settled hereunder or any subsequent termination of this Agreement. On or prior to the Closing Date, the Company shall have
paid by wire transfer of immediately available funds to an account designated by the Investor, the Investor Expense Reimbursement in accordance
with Section 9.1, all of which Investor Expense Reimbursement shall be fully earned and non-refundable as of the Closing Date, regardless
of whether any Fixed Purchases, any VWAP Purchases or any Additional VWAP Purchases are made or settled hereunder or any subsequent termination
of this Agreement. On the Commencement Date, the Company shall deliver to the Investor (a) the opinions and negative assurances of outside
counsel to the Company, dated the Commencement Date, in the forms mutually agreed to by the parties hereto, (b) a certificate from the
Company, dated the Commencement Date, in the form of Exhibit G hereto.
Section
6.2 Conditions Precedent to the Obligations of the Company. The obligation hereunder of the Company to issue and sell the Shares
to the Investor under any Fixed Purchase Notice, any VWAP Purchase Notice and any Additional VWAP Purchase Notice delivered to the Investor
by the Company under this Agreement on or after the Commencement Date (as applicable) is subject to the satisfaction at the applicable
Purchase Condition Satisfaction Time, or (to the extent permitted by applicable law) the waiver, of each of the conditions set forth in
this Section 6.2. These conditions are for the Company’s sole benefit and (to the extent permitted by applicable law) may be waived
by the Company at any time in its sole discretion, except as expressly provided below.
(a) Accuracy
of the Investor’s Representations and Warranties. The representations and warranties of the Investor contained in this
Agreement (i) that are not qualified by “materiality” shall have been true and correct in all material respects when
made and shall be true and correct in all material respects at the applicable Purchase Condition Satisfaction Time with the same
force and effect as if made at such time, except to the extent such representations and warranties are as of another date or time,
in which case, such representations and warranties shall be true and correct in all material respects as of such other date or time
and (ii) that are qualified by “materiality” shall have been true and correct when made and shall be true and correct at
the applicable Purchase Condition Satisfaction Time with the same force and effect as if made at such time, except to the extent
such representations and warranties are as of another date or time, in which case, such representations and warranties shall be true
and correct as of such other date or time.
(b)
Registration Statement. The Registration Statement shall be effective and neither the Company nor the Investor shall have received notice that the Commission
has issued or intends to issue a stop order with respect to the Registration Statement. The Company shall have a maximum dollar amount
certain of Common Stock registered under the Registration Statement which (i) as of the Commencement Date, is sufficient to issue to the
Investor not less than (A) the Total Commitment worth of Common Stock plus (B) the Note Shares and (ii) as of the applicable Fixed Purchase
Date, VWAP Purchase Exercise Date and Additional VWAP Purchase Date (as applicable), is sufficient to issue to the Investor not less than
the maximum dollar amount worth of Shares issuable pursuant to the applicable Fixed Purchase Notice, VWAP Purchase Notice and Additional
VWAP Purchase Notice, respectively.
(c)
Other Commission Filings. The Current Report shall have been filed with the Commission as required pursuant to Section
1.3, and all Prospectus Supplements required to have been filed with the Commission pursuant to Section 1.3 shall have been filed with
the Commission in accordance with Section 1.3. All reports, schedules, registrations, forms, statements, information and other documents
required to have been filed by the Company with the Commission pursuant to the reporting requirements of the Exchange Act, including all
material required to have been filed pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, shall have been filed with the
Commission and such filings shall have been made within the applicable time period prescribed for such filing under the Exchange Act.
All other material required to be filed by the Company or any other offering participant pursuant to Rule 433(d) under the Securities
Act shall have been filed with the Commission within the applicable time periods prescribed for such filings by Rule 433 under the Securities
Act.
(d)
Performance by the Investor. The Investor shall have performed, satisfied and complied in all material respects with
all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Investor at or
prior to the applicable Purchase Condition Satisfaction Time.
(e)
No Injunction. No statute, rule, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered,
promulgated, threatened or endorsed by any court or Governmental Entity of competent jurisdiction which prohibits the consummation of
or which would materially modify or delay any of the transactions contemplated by this Agreement.
(f) No
Suspension of Trading in or Notice of Delisting of Common Stock. Trading in the Common Stock shall not have been suspended
by the Commission, the Trading Market or FINRA (except for any suspension of trading of limited duration agreed to by the Company, which suspension shall
be terminated prior to the applicable Purchase Condition Satisfaction Time), the Company shall not have received any final and non-appealable
notice that the listing or quotation of the Common Stock on the Trading Market shall be terminated on a date certain (unless, prior to
such date certain, the Common Stock is listed or quoted on any other Eligible Market). At any time since the most recent prior Purchase
Condition Satisfaction Time (as applicable), none of the events described in clauses (i), (ii) and (iii) of Section 5.6 shall have occurred
(but an event described in clause (iii) of Section 5.6 shall only apply if it has not been cured through the filing of a report with the
Commission on EDGAR).
(g)
No Proceedings or Litigation. No action, suit or proceeding before any arbitrator or any court or Governmental Entity
shall have been commenced, and no inquiry or investigation by any Governmental Entity shall have been commenced, against the Company or
any Subsidiary, or any of the officers, directors or affiliates of the Company or any Subsidiary, seeking to restrain, prevent or change
the transactions contemplated by this Agreement, or seeking material damages in connection with such transactions.
(h)
Certain Limitations. The issuance and sale of the Shares issuable pursuant to the applicable Fixed Purchase Notice,
VWAP Purchase Notice or Additional VWAP Purchase Notice (as applicable) shall not (i) exceed the applicable Fixed Purchase Maximum Amount,
the applicable VWAP Purchase Maximum Amount or the applicable Additional VWAP Purchase Maximum Amount, respectively, (ii) cause the Aggregate
Limit or the Beneficial Ownership Limitation to be exceeded, or (iii) cause the Exchange Cap (to the extent applicable under Section 2.5)
to be exceeded, unless in the case of this clause (iii), the Company’s stockholders have theretofore approved the issuance of Common
Stock under this Agreement in excess of the Exchange Cap in accordance with the applicable rules of the Trading Market.
Section
6.3 Conditions Precedent to the Obligations of the Investor. The obligation hereunder of the Investor to accept a Fixed Purchase
Notice, a VWAP Purchase Notice and an Additional VWAP Purchase Notice (as applicable) timely delivered to the Investor by the Company
under this Agreement on or after the Commencement Date and to acquire and pay for the Shares subject to such Fixed Purchase Notice, VWAP
Purchase Notice and Additional VWAP Purchase Notice, respectively, is subject to the satisfaction at the applicable Purchase Condition
Satisfaction Time, or (to the extent permitted by applicable law) the waiver, of each of the conditions set forth in this Section 6.3.
These conditions are for the Investor’s sole benefit and (to the extent permitted by applicable law) may be waived by the Investor
at any time in its sole discretion, except as expressly provided below.
(a)
Accuracy of the Company’s Representations and Warranties. The representations and warranties of the Company
contained in this Agreement (i) that are not qualified by “materiality” or “Material Adverse Effect” shall have
been true and correct in all material respects when made and shall be true and correct in all material respects at the applicable Purchase
Condition Satisfaction Time with the same force and effect as if made at such time, except to the extent such representations and warranties
are as of another date or time, in which case, such representations and warranties shall be true and correct in all material respects
as of such other date or time and (ii) that are qualified by “materiality” or “Material Adverse Effect” shall
have been true and correct when made and shall be true and correct at the applicable Purchase Condition Satisfaction Time with the same
force and effect as if made at such time, except to the extent such representations and warranties are as of
another date or time, in which case, such representations and warranties shall be true and correct as of such other date or time.
(b)
Registration Statement. The Registration Statement shall be effective and neither the Company nor the Investor shall
have received notice that the Commission has issued or intends to issue a stop order with respect to the Registration Statement. The Company
shall have a maximum dollar amount certain of Common Stock registered under the Registration Statement which (i) as of the Commencement
Date, is sufficient to issue to the Investor not less than (A) the Total Commitment worth of Common Stock plus (B) the Note Shares and
(ii) as of the applicable Fixed Purchase Date, VWAP Purchase Exercise Date and Additional VWAP Purchase Date (as applicable), is sufficient
to issue to the Investor not less than the maximum dollar amount worth of Shares issuable pursuant to the applicable Fixed Purchase Notice,
VWAP Purchase Notice and Additional VWAP Purchase Notice, respectively. As of the Commencement Date and the applicable Fixed Purchase
Date, the applicable VWAP Purchase Exercise Date or the applicable Additional Fixed Purchase Date (as applicable), the Investor shall
be permitted to utilize the Prospectus to resell all of the Securities it then owns or has the right to acquire pursuant to all Fixed
Purchase Notices, VWAP Purchase Notices and Additional VWAP Purchase Notices, respectively, delivered by the Company to the Investor pursuant
to this Agreement.
(c)
Other Commission Filings. The Current Report shall have been filed with the Commission as required pursuant to Section
1.3, and all Prospectus Supplements required to have been filed with the Commission pursuant to Section 1.3 shall have been filed with
the Commission in accordance with Section 1.3. All reports, schedules, registrations, forms, statements, information and other documents
required to have been filed by the Company with the Commission pursuant to the reporting requirements of the Exchange Act, including all
material required to have been filed pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, shall have been filed with the
Commission and such filings shall have been made within the applicable time period prescribed for such filing under the Exchange Act.
All other material required to be filed by the Company or any other offering participant pursuant to Rule 433(d) under the Securities
Act shall have been filed with the Commission within the applicable time periods prescribed for such filings by Rule 433 under the Securities
Act.
(d)
No Suspension of Trading in or Notice of Delisting of Common Stock. Trading in the Common Stock shall not have been
suspended by the Commission, the Trading Market or FINRA (except for any suspension of trading of limited duration agreed to by the Company,
which suspension shall be terminated prior to the applicable Purchase Condition Satisfaction Time), the Company shall not have received
any final and non-appealable notice that the listing or quotation of the Common Stock on the Trading Market shall be terminated on a date
certain (unless, prior to such date certain, the Common Stock is listed or quoted on any other Eligible Market), nor shall there have
been imposed any suspension of, or restriction on, accepting additional deposits of the Common Stock, electronic trading or book-entry
services by DTC with respect to the Common Stock that is continuing, the Company shall not have received any notice from DTC to the effect
that a suspension of, or restriction on, accepting additional deposits of the Common Stock, electronic trading or book-entry services
by DTC with respect to the Common Stock is being imposed or is contemplated (unless, prior to such suspension or restriction, DTC shall
have notified the Company in writing that DTC has determined not to impose any such suspension or restriction). At any time since the
most recent prior Purchase Condition Satisfaction Time (as applicable), none of the
events described in clauses (i), (ii) and (iii) of Section 5.6 shall have occurred (but an event described in clause (iii) of Section
5.6 shall only apply if it has not been cured through the filing of a report with the Commission on EDGAR).
(e)
Performance of the Company. The Company shall have performed, satisfied and complied in all material respects with
all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior
to the applicable Purchase Condition Satisfaction Time. The Company shall have delivered to the Investor at or prior to the applicable
Purchase Condition Satisfaction Time the Compliance Certificate substantially in the form attached hereto as Exhibit H.
(f)
No Injunction. No statute, rule, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered,
promulgated, threatened or endorsed by any court or Governmental Entity of competent jurisdiction which prohibits the consummation of
or which would materially modify or delay any of the transactions contemplated by this Agreement.
(g)
No Proceedings or Litigation. No action, suit or proceeding before any arbitrator or any court or Governmental Entity
shall have been commenced, and no inquiry or investigation by any Governmental Entity shall have been commenced, against the Company or
any Subsidiary, or any of the officers, directors or affiliates of the Company or any Subsidiary, seeking to restrain, prevent or change
the transactions contemplated by this Agreement, or seeking material damages in connection with such transactions.
(h)
Certain Limitations. The issuance and sale of the Shares issuable pursuant to the applicable Fixed Purchase Notice,
VWAP Purchase Notice or Additional VWAP Purchase Notice (as applicable) shall not (i) exceed the applicable Fixed Purchase Maximum Amount,
the applicable VWAP Purchase Maximum Amount or the applicable Additional VWAP Purchase Maximum Amount, respectively, (ii) cause the Aggregate
Limit or the Beneficial Ownership Limitation to be exceeded, or (iii) cause the Exchange Cap (to the extent applicable under Section 2.5)
to be exceeded, unless in the case of this clause (iii), the Company’s stockholders have theretofore approved the issuance of Common
Stock under this Agreement in excess of the Exchange Cap in accordance with the applicable rules of the Trading Market.
(i)
Shares and Note Shares Authorized and Delivered. The Shares issuable pursuant to such Fixed Purchase Notice, VWAP Purchase
Notice and/or Additional VWAP Purchase Notice (as applicable) shall have been duly authorized by all necessary corporate action of the
Company. The Company shall have delivered all Shares relating to all prior Fixed Purchase Notices, all prior VWAP Purchase Notices and
all prior Additional VWAP Purchase Notices to the Investor or its designee(s) as DWAC Shares. The Company shall have timely delivered
the Commitment Note to the Investor or its designee(s) as DWAC Shares in accordance with Section 2.7 and Section 6.1.
(j)
Listing of Securities. All of the Securities that may be issued pursuant to this Agreement shall have been approved
for listing or quotation on the Trading Market (or on an Eligible Market) as of the Commencement Date, subject only to notice of issuance.
(k)
No Termination Event. There shall not have occurred any event that would permit the Investor to terminate this Agreement
pursuant to Section 7.2.
(l)
Bring Down Opinions of Counsel. Each time the Company (i) files a Registration Statement or (ii) amends the Registration
Statement relating to the Securities by means of a post-effective amendment (each date of filing of one or more of the documents referred
to in clauses (i) and (ii) shall be a “Representation Date”), the Company shall furnish the Investor, within three
(3) Trading Days after each filing date thereof, the opinions and negative assurance “bring down” from outside counsel to
the Company, in forms mutually agreed to by the parties (such agreement not to be unreasonably withheld, delayed or conditioned).
ARTICLE
VII
TERMINATION
Section
7.1 Automatic Termination; Termination by Mutual Consent; Termination by the Company. Unless earlier terminated as provided
hereunder, this Agreement shall terminate automatically, without any further action or notice by any Person, on the earliest to occur
of (i) the first day of the month next following the 24-month anniversary of the Commencement Date, (ii) the date on which the Investor
shall have purchased the Total Commitment worth of Shares pursuant to this Agreement, (iii) the date on which the Common Stock shall have
failed to be listed or quoted on the Trading Market or any Eligible Market, (iv) the thirtieth (30th) Trading Day next following
the date on which, pursuant to or within the meaning of any Bankruptcy Law, the Company commences a voluntary case or any Person commences
a proceeding against the Company, in each case that is not discharged or dismissed prior to such thirtieth (30th) Trading Day,
and (v) the date on which, pursuant to or within the meaning of any Bankruptcy Law, a Custodian is appointed for the Company or for all
or substantially all of its property, or the Company makes a general assignment for the benefit of its creditors. Subject to Section 7.3,
this Agreement may be terminated at any time by the mutual written consent of the parties, effective as of the date of such mutual written
consent unless otherwise provided in such written consent. Subject to Section 7.3, the Company may terminate this Agreement, at any time
and in its sole discretion, effective upon three (3) Trading Days’ prior written notice to the Investor delivered in accordance
with Section 9.4; provided, however, that (i) the Company shall have issued and delivered the Commitment Note to the Investor
in accordance with Section 2.7 and shall have paid all Investor Expense Reimbursement fees and amounts to the Investor required to be
paid pursuant to Section 9.1 of this Agreement prior to such termination, and (ii) prior to issuing any press release, or making any public
statement or announcement, with respect to such termination, the Company shall consult with the Investor and shall obtain the Investor’s
consent to the form and substance of such press release or other disclosure, which consent shall not be unreasonably delayed or withheld.
Section
7.2 Other Termination. Subject to Section 7.3, the Investor shall have the right to terminate this Agreement effective upon
three (3) Trading Days’ prior written notice to the Company in accordance with Section 9.4, if: (a) any condition, occurrence, state
of facts or event constituting a Material Adverse Effect has occurred and is continuing; (b) a Fundamental Transaction shall have occurred;
(c) the effectiveness of the Registration Statement, or any post-effective amendment thereto, lapses for any reason (including, without
limitation, the issuance of a stop order by the Commission) or the Registration Statement or any post-effective amendment thereto, or any Prospectus
Supplement otherwise becomes unavailable to the Investor for the sale of all of the Securities included therein, and such lapse or unavailability
continues for a period of continues for a period of twenty (20) consecutive Trading Days or for more than an aggregate of sixty (60) Trading
Days in any 365-day period, other than due to acts of the Investor; (d)
trading in the Common Stock on the Trading Market (or if the Common Stock is then listed on an Eligible Market, trading in the
Common Stock on such Eligible Market) shall have been suspended and such suspension continues for a period of three (3) consecutive Trading
Days; or (e)
the Company is in material breach or default of this Agreement, and, if such breach or default is capable of being cured, such
breach or default is not cured within ten (10) Trading Days after notice of such breach or default is delivered to the Company pursuant
to Section 10.4. Unless notification thereof is required elsewhere in this Agreement (in which case such notification shall be provided
in accordance with such other provision), the Company shall promptly (but in no event later than 24 hours) notify the Investor (and, if
required under applicable law, including, without limitation, Regulation FD promulgated by the Commission, or under the applicable rules
and regulations of the Trading Market, the Company shall publicly disclose such information in accordance with Regulation FD and the applicable
rules and regulations of the Trading Market) upon becoming aware of any of the events set forth in the immediately preceding sentence.
Section
7.3 Effect of Termination. In the event of termination by the Company or the Investor pursuant to Section 7.1 or 7.2, as
applicable, written notice thereof shall forthwith be given to the other party as provided in Section 9.4 and the transactions
contemplated by this Agreement shall be terminated without further action by either party. If this Agreement is terminated as
provided in Section 7.1 or 7.2 herein, this Agreement shall become void and of no further force and effect, except that (a) the
provisions of Article VIII (Indemnification), Section 9.1 (Fees and Expenses), Section 9.2 (Specific Enforcement, Consent to
Jurisdiction, Waiver of Jury Trial), Section 9.4 (Notices), Section 9.8 (Governing Law), Section 9.9 (Survival), Section 9.11
(Publicity), Section 9.12 (Severability) and this Article VII (Termination) shall remain in full force and effect notwithstanding
such termination, (b) if the Investor owns any Securities at the time of such termination, the covenants and agreements of the
Company and the Investor, as applicable, contained in Section 5.1(a) (Securities Compliance), Section 5.3 (Compliance with Laws),
Section 5.6 (Stop Orders), Section 5.7 (Amendments to the Registration Statement; Prospectus Supplements; Free Writing
Prospectuses), Section 5.8 (Prospectus Delivery), Section 5.10 (Effective Registration Statement), Section 5.11 (Non-Public
Information) and Section 5.12 (Broker/Dealer) shall remain in full force and effect notwithstanding such termination for a period of
six (6) months following such termination, and (c) if the Investor or its designee(s) own any Securities at the time of such
termination, the covenants and agreements of the Company contained in Section 5.2 (Registration and Listing) shall remain in full
force and effect notwithstanding such termination for a period of thirty (30) days following such termination. Notwithstanding
anything in this Agreement to the contrary, no termination of this Agreement by any party shall (i) become effective prior to the
fifth (5th) Trading Day immediately following the applicable Fixed Purchase Settlement Date, VWAP Purchase Settlement
Date or Additional VWAP Purchase Settlement Date (as applicable) related to any pending Fixed Purchase Notice, VWAP Purchase Notice
or Additional VWAP Purchase Notice, respectively, that has not been fully settled in accordance with the terms and conditions of
this Agreement (it being hereby acknowledged and agreed that no termination of this Agreement shall limit, alter, modify, change or
otherwise affect any of the Company’s or the Investor’s rights or obligations under this Agreement with respect to any
pending Fixed Purchase, VWAP Purchase or Additional VWAP Purchase (as applicable), and that the parties shall fully perform their
respective obligations with respect to any such pending Fixed Purchase, VWAP Purchase or Additional VWAP Purchase, respectively,
under this Agreement), (ii) affect the Investor Expense Reimbursement payable to the Investor, all of which Investor Expense
Reimbursement shall be non-refundable when paid on the Closing Date pursuant to Section 9.1, regardless of whether any Fixed
Purchases, VWAP Purchases or Additional VWAP Purchases are made or settled hereunder or any subsequent termination of this
Agreement, or (iii) affect any Note Shares previously issued or delivered, or any rights of any holder thereof, it being hereby
acknowledged and agreed that the Commitment Note shall be fully earned as of the Closing Date, regardless of whether any Fixed
Purchases, VWAP Purchases or Additional VWAP Purchases are made or settled hereunder or any subsequent termination of this
Agreement. Nothing in this Section 7.3 shall be deemed to release the Company or the Investor from any liability for any breach or
default under this Agreement, or to impair the rights of the Company and the Investor to compel specific performance by the other
party of its obligations under this Agreement.
ARTICLE
VIII
INDEMNIFICATION
Section 8.1 General Indemnity.
(a) Indemnification
by the Company. The Company shall indemnify and hold harmless the Investor, each of its directors, officers, partners,
employees, investment managers, investment advisors and Affiliates, and each Person, if any, who controls the Investor within the
meaning of Section 15 of the Securities Act or Section 20(a) of the Exchange Act from and against all losses, claims, damages,
liabilities and expenses (including reasonable costs of defense and investigation and all reasonable attorneys’ fees) to which
the Investor and each such other Person may become subject, under the Securities Act or otherwise, insofar as such losses, claims,
damages, liabilities and expenses arise out of or are based upon (i) any violation of United States federal or state securities laws
or the rules and regulations of the Trading Market in connection with the transactions contemplated by this Agreement by the Company
or any of its Subsidiaries, affiliates, officers, directors or employees, (ii) any untrue statement or alleged untrue statement of a
material fact contained, or incorporated by reference, in the Registration Statement or any amendment thereto or any omission or
alleged omission to state therein, or in any document incorporated by reference therein, a material fact required to be stated
therein or necessary to make the statements therein not misleading, or (iii) any untrue statement or alleged untrue statement of a
material fact contained, or incorporated by reference, in the Prospectus, any Issuer Free Writing Prospectus, or in any amendment
thereof or supplement thereto, or in any “issuer information” (as defined in Rule 433 under the Securities Act) of the
Company, which “issuer information” is required to be, or is, filed with the Commission or otherwise contained in any
Free Writing Prospectus, or any amendment or supplement thereto, or any omission or alleged omission to state therein, or in any
document incorporated by reference therein, a material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not misleading; provided, however, that (A) the Company
shall not be liable under this Section 8.1(a) to the extent that a court of competent jurisdiction shall have determined by a final
judgment (from which no further appeals are available) that such loss, claim, damage, liability or expense resulted directly and
solely from any such acts or failures to act, undertaken or omitted to be taken by the Investor or such Person through its bad faith
or willful misconduct, (B) the foregoing indemnity shall not apply to any loss, claim, damage, liability or expense to the extent,
but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged
omission made in reliance upon and in conformity with written information furnished to the Company by or on behalf of the Investor
expressly for use in the Current Report or any Prospectus Supplement or Permitted Free Writing Prospectus, or any amendment thereof
or supplement thereto, and (C) with respect to the Prospectus, the foregoing indemnity shall not inure to the benefit of the
Investor or any such Person from whom the Person asserting any loss, claim, damage, liability or expense purchased Common Stock, if
copies of all Prospectus Supplements required to be filed pursuant to Section 1.3, together with the Base Prospectus, were timely
delivered or made available to the Investor pursuant hereto and a copy of the Base Prospectus, together with a Prospectus Supplement
(as applicable), was not sent or given by or on behalf of the Investor or any such Person to such Person, if required by law to have
been delivered, at or prior to the written confirmation of the sale of the Common Stock to such Person, and if delivery of the Base
Prospectus, together with a Prospectus Supplement (as applicable), would have cured the defect giving rise to such loss, claim,
damage, liability or expense.
The Company
shall reimburse the Investor and each such controlling Person promptly upon demand (with accompanying presentation of documentary evidence)
for all legal and other costs and expenses reasonably incurred by the Investor or such indemnified Persons in investigating, defending
against, or preparing to defend against any such claim, action, suit or proceeding with respect to which it is entitled to indemnification.
(b)
Indemnification by the Investor. The Investor shall indemnify and hold harmless the Company, each of its directors,
officers, employees and Affiliates, and each Person, if any, who controls the Company within the meaning of Section 15 of the Securities
Act or Section 20(a) of the Exchange Act from and against all losses, claims, damages, liabilities and expenses (including reasonable
costs of defense and investigation and all reasonable attorneys’ fees) to which the Company and each such other Person may become
subject, under the Securities Act or otherwise, insofar as such losses, claims, damages, liabilities and expenses arise out of or are
based upon any untrue statement or alleged untrue statement of a material fact contained in the Current Report, the Registration Statement
or any Prospectus Supplement or Permitted Free Writing Prospectus, or in any amendment thereof or supplement thereto, or any omission
or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein, in light
of the circumstances under which they were made, not misleading, in each case, to the extent, but only to the extent, the untrue statement,
alleged untrue statement, omission or alleged omission was made in reliance upon, and in conformity with, written information furnished
by the Investor to the Company expressly for inclusion in the Current Report, the Registration Statement or such Prospectus Supplement
or Permitted Free Writing Prospectus, or any amendment thereof or supplement thereto.
The Investor
shall reimburse the Company and each such director, officer or controlling Person promptly upon demand for all legal and other costs and
expenses reasonably incurred by the Company or such indemnified Persons in investigating, defending against, or preparing to defend against
any such claim, action, suit or proceeding with respect to which it is entitled to indemnification.
Section
8.2 Indemnification Procedures. Promptly after a Person receives notice of a claim or the commencement of an action for which
the Person intends to seek indemnification under Section 8.1, the Person will notify the indemnifying party in writing of the claim or
commencement of the action, suit or proceeding; provided, however, that failure to notify the indemnifying party will not
relieve the indemnifying party from liability under Section 8.1, except to the extent it has been materially prejudiced by the failure
to give notice. The indemnifying party will be entitled to participate in the defense of any claim, action, suit or proceeding as to which
indemnification is being sought, and if the indemnifying party acknowledges in writing the obligation to indemnify the party against whom
the claim or action is brought, the indemnifying party may (but will not be required to) assume the defense against the claim, action,
suit or proceeding with counsel satisfactory to it. After an indemnifying party notifies an indemnified party that the indemnifying party
wishes to assume the defense of a claim, action, suit or proceeding, the indemnifying party will not be liable for any legal or other
expenses incurred by the indemnified party in connection with the defense against the claim, action, suit or proceeding except that if,
in the opinion of counsel to the indemnifying party, one or more of the indemnified parties should be separately represented in connection
with a claim, action, suit or proceeding, the indemnifying party will pay the reasonable fees and expenses of one separate counsel for
the indemnified parties. Each indemnified party, as a condition to receiving indemnification as provided in Section 8.1, will cooperate
in all reasonable respects with the indemnifying party in the defense of any action or claim as to which indemnification is sought. No
indemnifying party will be liable for any settlement of any action effected without its prior written consent. Notwithstanding the foregoing
sentence, if at any time an indemnified party shall have requested (by written notice provided in accordance with Section 9.4) an indemnifying
party to reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for
any settlement of the nature contemplated hereby effected without its written consent if (a) such settlement is entered into more than
45 days after receipt by such indemnifying party of the aforesaid request, (b) such indemnifying party shall have received written notice
of the terms of such settlement at least 30 days prior to such settlement being entered into and (c) such indemnifying party shall not
have reimbursed such indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party will,
without the prior written consent of the indemnified party, effect any settlement of a pending or threatened action with respect to which
an indemnified party is, or is informed that it may be, made a party and for which it would be entitled to indemnification, unless the
settlement includes an unconditional release of the indemnified party from all liability and claims which are the subject matter of the
pending or threatened action.
If for any
reason the indemnification provided for in this Agreement is not available to, or is not sufficient to hold harmless, an indemnified party
in respect of any loss or liability referred to in Section 8.1 as to which such indemnified party is entitled to indemnification thereunder,
each indemnifying party shall, in lieu of indemnifying the indemnified party, contribute to the amount paid or payable by the indemnified
party as a result of such loss or liability, (i) in the proportion which is appropriate to reflect the relative benefits received by the
indemnifying party, on the one hand, and by the indemnified party, on the other hand, from the sale of Securities which is the subject
of the claim, action, suit or proceeding which resulted in the loss or liability or (ii) if the allocation provided by clause (i) is not
permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)
above, but also the relative fault of the indemnifying party, on the one hand, and the indemnified party, on the other hand, with respect to the statements
or omissions which are the subject of the claim, action, suit or proceeding that resulted in the loss or liability, as well as any other
relevant equitable considerations.
The remedies
provided for in Section 8.1 and this Section 8.2 are not exclusive and shall not limit any rights or remedies which may otherwise be available
to any indemnified Person at law or in equity.
ARTICLE
IX
MISCELLANEOUS
Section
9.1 Fees and Expenses. Each party shall bear its own fees and expenses related to the transactions contemplated by this Agreement;
provided, however, that the Company shall pay, on or prior to the Closing Date, by wire transfer of immediately available
funds to an account designated by the Investor on or prior to the date of this Agreement, an aggregate amount up to $25,000 (the “Investor
Expense Reimbursement”) as reimbursement for the Investor’s reasonable out-of-pocket expenses (including the Investor’s
legal fees and expenses), in connection with the preparation, negotiation, execution and delivery of this Agreement, legal due diligence
of the Company and review of the Registration Statement, the Registration Statement, the Current Report, any Permitted Free Writing Prospectus
and all other related transaction documentation. The Company shall pay all U.S. federal, state and local stamp and other similar transfer
and other taxes and duties levied in connection with issuance of the Securities pursuant hereto. For the avoidance of doubt, all of the
fees payable to the Investor or its counsel pursuant to this Section 9.1 shall be non-refundable, regardless of whether any Fixed Purchases,
any VWAP Purchases or any Additional VWAP Purchases are made or settled hereunder or any subsequent termination of this Agreement.
Section 9.2 Specific Enforcement,
Consent to Jurisdiction, Waiver of Jury Trial.
(a)
The Company and the Investor acknowledge and agree that irreparable damage would occur in the event that any of the provisions
of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that
either party shall be entitled to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement by the
other party and to enforce specifically the terms and provisions hereof (without the necessity of showing economic loss and without any
bond or other security being required), this being in addition to any other remedy to which either party may be entitled by law or equity.
(b)
Each of the Company and the Investor (i) hereby irrevocably submits to the jurisdiction of the U.S. District Court and other courts
of the United States sitting in the State of New York for the purposes of any suit, action or proceeding arising out of or relating to
this Agreement, and (ii) hereby waives, and agrees not to assert in any such suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of such court, that the suit, action or proceeding is brought in an inconvenient forum or that the venue of
the suit, action or proceeding is improper. Each of the Company and the Investor consents to process being served in any such suit, action
or proceeding by mailing a copy thereof to such party at the address in effect for notices to it under this Agreement and agrees that
such service shall constitute good and sufficient service of process and notice thereof. Nothing in this Section 9.2
shall affect or limit any right to serve process in any other manner permitted by law.
(c)
EACH OF THE COMPANY AND THE INVESTOR HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO
A TRIAL BY JURY IN RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE
TRANSACTIONS CONTEMPLATED HEREBY OR DISPUTES RELATING HERETO. EACH OF THE COMPANY AND THE INVESTOR (A) CERTIFIES THAT NO REPRESENTATIVE,
AGENT OR ATTORNEY OF THE OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION,
SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTY HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT
BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 9.2.
Section
9.3 Entire Agreement; Amendment. This Agreement, together with the exhibits referred to herein, represents the entire agreement
of the parties with respect to the subject matter hereof, and there are no promises, undertakings, representations or warranties by either
party relative to subject matter hereof not expressly set forth herein. No provision of this Agreement may be amended other than by a
written instrument signed by both parties hereto. All exhibits to this Agreement are hereby incorporated by reference in, and made a part
of, this Agreement as if set forth in full herein.
Section
9.4 Notices. Any notice, demand, request, waiver or other communication required or permitted to be given hereunder shall be
in writing and shall be effective (a) upon hand delivery or electronic mail delivery at the address or number designated below (if delivered
on a business day during normal business hours where such notice is to be received), or the first business day following such delivery
(if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business
day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such
mailing, whichever shall first occur. The address for such communications shall be:
If to the Company:
Spectaire Holdings, Inc.
155 Arlington St
Watertown, MA 02472
Telephone Number: (847) 644-1430
Email: lfernandes@spectaire.com
Attention: Leonardo Fernandes
With a copy (which shall not constitute notice) to:
Latham & Watkins
200
Clarendon Street
Boston, MA 02116
Telephone Number: (617) 948-6083
Email: Stephen.Ranere@lw.com
Attention: Stephen Ranere
If to the Investor:
Keystone Capital Partners, LLC
139 Fulton St
New York, NY 10038
Telephone Number: (646) 349-0916
Email: fz@keystone-cp.com
Attention: Fredric G. Zaino
With a copy (which shall not constitute notice) to:
McMurdo Law Group LLC
1185 Avenue of the Americas, 3rd Floor
New York, NY 10036
Telephone Number: (917) 318-2865
Email: matt@nannaronelaw.com
Attention: Matthew McMurdo
Either party hereto may from time to time change its address
for notices by giving at least five (5) days’ advance written notice of such changed address to the other party hereto.
Section
9.5 Waivers. No waiver by either party of any default with respect to any provision, condition or requirement of this Agreement
shall be deemed to be a continuing waiver in the future or a waiver of any other provisions, condition or requirement hereof nor shall
any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right accruing to it
thereafter. No provision of this Agreement may be waived other than in a written instrument signed by the party against whom enforcement
of such waiver is sought.
Section
9.6 Headings; Construction. The article, section and subsection headings in this Agreement are for convenience only and shall
not constitute a part of this Agreement for any other purpose and shall not be deemed to limit or affect any of the provisions hereof.
Unless the context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine, feminine, neuter, singular
and plural forms thereof. The terms “including,” “includes,” “include” and words of like import shall
be construed broadly as if followed by the words “without limitation.” The terms “herein,” “hereunder,”
“hereof” and words of like import refer to this entire Agreement instead of just the provision in which they are found. The
parties agree that each of them and their respective counsel has reviewed and had an opportunity to revise this Agreement and, therefore,
the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed
in the interpretation of this Agreement. In addition, each and every reference to share prices and number of shares of Common Stock in
this Agreement shall, in all cases, be subject to adjustment for any stock splits, stock combinations, stock dividends, recapitalizations,
reorganizations and other similar transactions that occur on or after the date of this Agreement. Any reference in this Agreement to “Dollars”
or “$” shall mean the lawful currency of the United States of America. Any references to “Section” or “Article”
in this Agreement shall, unless otherwise expressly stated herein, refer to the applicable Section or Article of this Agreement.
Section
9.7 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective
successors. Neither the Company nor the Investor may assign this Agreement or any of their respective rights or obligations hereunder
to any Person.
Section
9.8 Governing Law. This Agreement shall be governed by and construed in accordance with the internal procedural and substantive
laws of the State of New York, without giving effect to the choice of law provisions of such state that would cause the application of
the laws of any other jurisdiction.
Section
9.9 Survival. The representations, warranties, covenants and agreements of the Company and the Investor contained in this
Agreement shall survive the execution and delivery hereof until the termination of this Agreement; provided, however, that (a) the
provisions of Article VII (Termination), Article VIII (Indemnification), Section 9.1 (Fees and Expenses), Section 9.2 (Specific
Enforcement, Consent to Jurisdiction, Waiver of Jury Trial), Section 9.4 (Notices), Section 9.8 (Governing Law), Section 9.11
(Publicity), Section 9.12 (Severability) and this Section 9.9 (Survival) shall remain in full force and effect notwithstanding such
termination, (b) if the Investor owns any Securities at the time of such termination, the covenants and agreements of the Company
and the Investor, as applicable, contained in Section 5.1(a) (Securities Compliance), Section 5.3 (Compliance with Laws), Section
5.6 (Stop Orders), Section 5.7 (Amendments to the Registration Statement; Prospectus Supplements; Free Writing Prospectuses),
Section 5.8 (Prospectus Delivery), Section 5.9 (Selling Restrictions) Section 5.10 (Effective Registration Statement), Section 5.11
(Non-Public Information) and Section 5.12 (Broker/Dealer) shall remain in full force and effect notwithstanding such termination for
a period of six (6) months following such termination, and (c) if the Investor owns any Securities at the time of such termination,
the covenants and agreements of the Company contained in Section 5.2 (Registration and Listing) shall remain in full force and
effect notwithstanding such termination for a period of thirty (30) days following such termination.
Section
9.10 Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided
that a facsimile signature or signature delivered by e-mail in a “.pdf” format data file, including any electronic signature
complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com, www.echosign.adobe.com, etc., shall be considered due execution
and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original signature.
Section 9.11 Publicity.
The Company shall afford the Investor and its counsel with a reasonable opportunity to review and comment upon, shall consult with the
Investor and its counsel on the form and substance of, and shall give due consideration to all such comments from the Investor or its
counsel on, any press release, Commission filing or any other public disclosure made by or on behalf of the Company relating to the Investor,
its purchases hereunder or any aspect of this Agreement or the transactions contemplated hereby, prior to the issuance, filing or public
disclosure thereof. For the avoidance of doubt, the Company shall not be required to submit for review any such disclosure (i) contained
in periodic reports filed with the Commission under the Exchange Act if it shall have previously provided the same disclosure to the
Investor or its counsel for review in connection with a previous filing or (ii) any Prospectus Supplement if it contains disclosure that
does not reference the Investor, its purchases hereunder or any aspect of this Agreement or the transactions contemplated hereby. The
Company agrees and acknowledges that its failure to comply with this provision in all material respects constitutes a Material Adverse
Effect for purposes of Section 6.3(k).
Section
9.12 Severability. The provisions of this Agreement are severable and, in the event that any court of competent jurisdiction
shall determine that any one or more of the provisions or part of the provisions contained in this Agreement shall, for any reason, be
held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other
provision or part of a provision of this Agreement, and this Agreement shall be reformed and construed as if such invalid or illegal or
unenforceable provision, or part of such provision, had never been contained herein, so that such provisions would be valid, legal and
enforceable to the maximum extent possible.
Section
9.13 No Third Party Beneficiaries. Except as expressly provided in Article VIII, this Agreement is intended only for the benefit
of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof
be enforced by, any other Person.
Section
9.14 Further Assurances. From and after the date of this Agreement, upon the request of the Investor or the Company, each of
the Company and the Investor shall execute and deliver such instrument, documents and other writings as may be reasonably necessary or
desirable to confirm and carry out and to effectuate fully the intent and purposes of this Agreement.
[Signature Page Follows]
IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be duly executed by their respective authorized officer as of the date first above written.
|
SPECTAIRE HOLDINGS, INC.: |
|
|
|
|
By: |
/s/ Leonardo Fernandes |
|
|
Name: |
Leonardo Fernandes |
|
|
Title: |
Chief Financial Officer |
|
KEYSTONE CAPITAL PARTNERS, LLC: |
|
|
|
By: |
/s/ Fredric G. Zaino |
|
|
Name: |
Fredric G. Zaino |
|
|
Title: |
Authorized Signatory |
[Signature Page to Common Stock Purchase Agreement]
ANNEX I TO THE
COMMON STOCK PURCHASE AGREEMENT
DEFINITIONS
“Additional VWAP
Purchase” shall have the meaning assigned to such term in Section 2.3.
“Additional VWAP
Purchase Confirmation” shall have the meaning assigned to such term in Section 2.3.
“Additional VWAP
Purchase Commencement Time” means, with respect to an Additional VWAP Purchase made pursuant to Section 2.3, the time that is
ten (10) minutes after the latest of: (i) the VWAP Purchase Ending Time of the VWAP Purchase Period for the VWAP Purchase preceding
the Additional VWAP Purchase Period for such Additional VWAP Purchase occurring on the same Trading Day as such preceding VWAP Purchase,
(ii) the Additional VWAP Purchase Termination Time of the Additional VWAP Purchase Period for the most recent prior Additional VWAP Purchase,
if any, occurring on the same Trading Day as such Additional VWAP Purchase, and (iii) the Investor’s timely receipt from the Company
of the applicable Additional VWAP Purchase Notice for such Additional VWAP Purchase occurring on the same Trading Day as the VWAP Purchase
preceding such Additional VWAP Purchase.
“Additional VWAP
Purchase Date” means, with respect to an Additional VWAP Purchase made pursuant to Section 2.3, the Trading Day (i) that is
also the VWAP Purchase Date for the corresponding VWAP Purchase referred to in clause (i) of the second sentence of Section 2.3 and (ii)
on which the Investor receives, prior to 2:00 p.m., New York City time, on such Trading Day, a valid Additional VWAP Purchase Notice for
such Additional VWAP Purchase in accordance with this Agreement.
“Additional VWAP
Purchase Maximum Amount” means, with respect to an Additional VWAP Purchase made pursuant to Section 2.3, a number of shares
of Common Stock equal to the lesser of (i) 300% of the number of Shares directed by the Company to be purchased by the Investor pursuant
to the corresponding Fixed Purchase Notice for the corresponding Fixed Purchase referred to in clause (i) of the second sentence of Section
2.2 and (ii) a number of Shares equal to (A) the Additional VWAP Purchase Share Percentage multiplied by (B) the total number (or volume)
of shares of Common Stock traded on the Trading Market (or, if the Common Stock is then listed on an Eligible Market, on such Eligible
Market) during the applicable Additional VWAP Purchase Period on the applicable Additional VWAP Purchase Date for such Additional VWAP
Purchase.
“Additional VWAP
Purchase Notice” means, with respect to an Additional VWAP Purchase made pursuant to Section 2.3, an irrevocable written notice,
substantially in the form of Exhibit D, delivered by the Company to the Investor, prior to 2:00 p.m., New York City time, on the
applicable Additional VWAP Purchase Date for such Additional VWAP Purchase, directing the Investor to purchase a specified Additional
VWAP Purchase Share Amount (such specified Additional VWAP Purchase Share Amount subject to adjustment as set forth in Section 2.3 as
necessary to give effect to the Additional VWAP Purchase Maximum Amount), at the applicable Additional VWAP Purchase Price therefor on
the applicable Additional VWAP Purchase Date for such Additional VWAP Purchase in accordance with this Agreement.
“Additional VWAP
Purchase Period” means, with respect to an Additional VWAP Purchase made pursuant to Section 2.3, the period on the applicable
Additional VWAP Purchase Date for such Additional VWAP Purchase beginning at the applicable Additional VWAP Purchase Commencement Time
and ending at the applicable Additional VWAP Purchase Termination Time.
“Additional VWAP
Purchase Price” means, with respect to an Additional VWAP Purchase made pursuant to Section 2.3, the purchase price per Share
to be purchased by the Investor in such Additional VWAP Purchase equal the lower of (i) of the Closing Sale Price of the Common Stock
on such applicable Additional VWAP Purchase Date for such Additional VWAP Purchase and (ii) ninety-five percent (95%) of the VWAP for
the applicable Additional VWAP Purchase Period on the applicable Additional VWAP Purchase Date for such Additional VWAP Purchase (to be
appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar
transaction).
“Additional VWAP
Purchase Settlement Date” shall have the meaning assigned to such term in Section 2.4.
“Additional VWAP
Purchase Share Amount” means, with respect to an Additional VWAP Purchase made pursuant to Section 2.3, the number of Shares
to be purchased by the Investor in such Additional VWAP Purchase as specified by the Company in the applicable Additional VWAP Purchase
Notice, which number of Shares shall not exceed the applicable Additional VWAP Purchase Maximum Amount.
“Additional VWAP
Purchase Share Delivery Date” shall have the meaning assigned to such term in Section 2.4.
“Additional VWAP
Purchase Share Percentage” means, with respect to an Additional VWAP Purchase made pursuant to Section 2.3, thirty percent (30%).
“Additional VWAP
Purchase Share Volume Maximum” means, with respect to an Additional VWAP Purchase made pursuant to Section 2.3, a number of
shares of Common Stock equal to (i) the number of Shares specified by the Company in the applicable Additional VWAP Purchase Notice as
the Additional VWAP Purchase Share Amount to be purchased by the Investor in such Additional VWAP Purchase, divided by (ii) the Additional
VWAP Purchase Share Percentage (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split,
reverse stock split or other similar transaction).
“Additional VWAP
Purchase Termination Time” means, with respect to an Additional VWAP Purchase made pursuant to Section 2.3, the earliest of
(i) 4:00 p.m., New York City time, on the applicable Additional VWAP Purchase Date, or such other time publicly announced by the Trading
Market as the official close of trading on the Trading Market (or, if the Common Stock is then listed on an Eligible Market, by such Eligible
Market as the official close of trading on such Eligible Market) on such applicable Additional VWAP Purchase Date and (ii) such time,
from and after the Additional VWAP Purchase Commencement Time for such Additional VWAP Purchase, that the total number (or volume) of
shares of Common Stock traded on the Trading Market (or, if the Common Stock is then listed on an Eligible Market, on such Eligible Market)
has exceeded the applicable Additional VWAP Purchase Share Volume Maximum.
“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control
with a Person, as such terms are used in and construed under Rule 144.
“Aggregate Limit”
shall have the meaning assigned to such term in Section 1.1.
“Agreement” shall have the meaning assigned to such term
in the Preamble.
“Average Price”
means a price per Share (rounded to the nearest tenth of a cent) equal to the quotient obtained by dividing (i) the aggregate gross purchase
price paid by the Investor for all Shares purchased pursuant to this Agreement, by (ii) the aggregate number of Shares issued pursuant
to this Agreement.
“Bankruptcy Law”
means Title 11, U.S. Code, or any similar U.S. federal or state law for the relief of debtors.
“Base Prospectus”
shall mean the Company’s prospectus, dated December 31, 2020, a preliminary form of which is included in the Registration Statement,
including the documents incorporated by reference therein.
“Base Price”
means a price per Share equal to $2.23.
“Beneficial Ownership
Limitation” shall have the meaning assigned to such term in Section 2.7.
“BHCA”
shall have the meaning assigned to such term in Section 4.34.
“Bloomberg”
means Bloomberg, L.P.
“Broker-Dealer”
shall have the meaning assigned to such term in Section 5.12.
“Bylaws” shall have the meaning assigned to such term
in Section 4.3.
“Charter” shall have the meaning assigned to such term in Section 4.3.
“Cleansing Date”
shall have the meaning assigned to such term in Section 5.11.
“Closing Date” shall have the meaning assigned to such
term in Section 2.7.
“Closing Sale
Price” means, for the Common Stock as of any date, the last closing trade price for the Common Stock on the Trading Market
(or if the Common Stock is then traded on an Eligible Market, on such Eligible Market), as reported by Bloomberg, or, if the Trading
Market (or such Eligible Market, as applicable) begins to operate on an extended hours basis and does not designate the closing
trade price for the Common Stock, then the last trade price for the Common Stock prior to 4:00 p.m., New York City time, as reported
by Bloomberg, or, if the foregoing do not apply, the last trade price for the Common Stock in the over-the-counter market on the
electronic bulletin board for the Common Stock as reported by Bloomberg, or, if no last trade price is reported for the Common Stock
by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such security as reported by
OTC Markets Group Inc. All such determinations shall be appropriately adjusted for any stock splits, stock dividends, stock
combinations, recapitalizations or other similar transactions during such period.
“Code”
shall have the meaning assigned to such term in Section 4.24.
“Commencement” shall have the meaning assigned to such
term in Section 2.1.
“Commencement Date” shall have the meaning assigned to such term in Section 1.2.
“Commission”
means the U.S. Securities and Exchange Commission or any successor entity.
“Commission Documents”
shall mean (1) all reports, schedules, registrations, forms, statements, information and other documents filed with or furnished to the
Commission by the Company pursuant to the reporting requirements of the Exchange Act, including all material filed with or furnished to
the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, since December 31, 2022, including, without limitation,
the Annual Report on Form 10-K filed by the Company for its fiscal year ended December 31, 2022 (the “2022 Form 10-K”),
and which hereafter shall be filed with or furnished to the Commission by the Company during the Investment Period, including, without
limitation, the Current Report, (2) the Registration Statement, as the same may be amended from time to time, the Prospectus and each
Prospectus Supplement, and each Permitted Free Writing Prospectus and (3) all information contained in such filings and all documents
and disclosures that have been and heretofore shall be incorporated by reference therein.
“Commitment Note”
shall have the meaning assigned to such term in Section 2.7.
“Common Stock”
shall have the meaning assigned to such term in the Recitals.
“Common Stock Equivalents” means any securities of the
Company or its Subsidiaries which entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt,
preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for,
or otherwise entitles the holder thereof to receive, Common Stock.
“Company”
shall have the meaning assigned to such term in the Preamble.
“Cover Price” shall have the meaning assigned to such
term in Section 2.4.
“Current Report” shall have the meaning assigned to such term in Section 1.3.
“Custodian”
shall mean any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.
“Dilutive Issuance”
shall have the meaning assigned to such term in Section 5.5(c).
“DTC” means
The Depository Trust Company, a subsidiary of The Depository Trust & Clearing Corporation, or any successor thereto.
“DWAC”
shall have the meaning assigned to such term in Section 4.28.
“DWAC Shares”
means shares of Common Stock issued pursuant to this Agreement that are (i) issued in electronic form, (ii) freely tradable and transferable
and without restriction on resale and without stop transfer instructions maintained against the transfer thereof and (iii) timely credited
by the Company’s transfer agent to the Investor’s (or its designee’s) specified DWAC account with DTC under its Fast
Automated Securities Transfer (FAST) Program, or any similar program hereafter adopted by DTC performing substantially the same function.
“EDGAR”
shall have the meaning assigned to such term in Section 4.3.
“Eligible Market”
means the New York Stock Exchange, The Nasdaq Global Market, The Nasdaq Global Select Market or the NYSE American (or any nationally recognized
successor to any of the foregoing).
“EMEA”
shall have the meaning assigned to such term in Section 4.42(b).
“Environmental Laws” shall have the meaning assigned
to such term in Section 4.17.
“ERISA” shall have the meaning assigned to such term in Section 4.24.
“Evaluation Date”
shall have the meaning assigned to such term in Section 4.6(c).
“Exchange Act”
shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder.
“Exchange Cap”
shall have the meaning assigned to such term in Section 2.5(a).
“Exempt Issuance”
means the issuance of (a) Common Stock, options or other equity incentive awards to employees, officers, directors or vendors of the Company
pursuant to any equity incentive plan duly adopted for such purpose, by the Company’s Board of Directors or a majority of the members
of a committee of the Board of Directors established for such purpose, (b) (1) any Securities issued to the Investor pursuant to this
Agreement, (2) any equity or debt securities of the Company issued to the Investor, Keystone Capital Partners, LLC or any of their respective
Affiliates pursuant to any contract or arrangement other than this Agreement or the transactions contemplated hereby, by and between the
Company, on the one hand, and the Investor and/or any of its Affiliates, on the other hand, or by and between the Company, on the one
hand, and Keystone Capital Partners, LLC and/or any of its Affiliates, on the other hand, (3) any securities issued upon the exercise
or exchange of or conversion of any shares of Common Stock or Common Stock Equivalents held by the Investor, Keystone Capital Partners,
LLC or any of their respective Affiliates at any time, or (4) any securities issued upon the exercise or exchange of or conversion of
any Common Stock Equivalents issued and outstanding on the date of this Agreement, provided that such securities referred to in this clause
(4) have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price,
exchange price or conversion price of such securities, or (c) securities issued pursuant to acquisitions, divestitures, licenses, partnerships,
collaborations or strategic transactions approved by the Company’s Board of Directors or a majority of the members of a committee
of directors established for such purpose, which acquisitions, divestitures, licenses, partnerships, collaborations or strategic transactions
can have a Variable Rate Transaction component, provided that any such issuance shall only be to a Person (or to the equity holders of
a Person) which is, itself or through its subsidiaries, an operating company or an asset in a business synergistic with the business of
the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction
in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing
in securities.
“FCPA”
shall have the meaning assigned to such term in Section 4.29.
“FDA” shall have the meaning assigned to such term in
Section 4.42(a).
“Federal Reserve”
shall have the meaning assigned to such term in Section 4.24
“FINRA” means the Financial Industry Regulatory Authority.
“Fixed Purchase”
shall have the meaning assigned to such term in Section 2.1.
“Fixed Purchase Date”
means, with respect to a Fixed Purchase made pursuant to Section 2.1, the Trading Day on which the Investor receives, after 4:00 p.m.,
New York City time, but prior to 5:30 p.m., New York City time, on such Trading Day, a valid Fixed Purchase Notice for such Fixed Purchase
in accordance with this Agreement.
“Fixed Purchase Maximum
Amount” means, with respect to a Fixed Purchase made pursuant to Section 2.1, $50,000 of shares of Common Stock (to be appropriately
adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction that occurs on or after
the date of this Agreement).
“Fixed Purchase Notice”
means, with respect to a Fixed Purchase pursuant to Section 2.1, an irrevocable written notice, substantially in the form of Exhibit
A, timely delivered by the Company to the Investor on the applicable Fixed Purchase Date for such Fixed Purchase, directing the Investor
to purchase a specified Fixed Purchase Share Amount (such specified Fixed Purchase Share Amount subject to adjustment as set forth in
Section 2.1 as necessary to give effect to the Fixed Purchase Maximum Amount), at the applicable Fixed Purchase Price therefor on the
applicable Fixed Purchase Date for such Fixed Purchase in accordance with this Agreement.
“Fixed Purchase Price”
means, with respect to a Fixed Purchase made pursuant to Section 2.1, the purchase price per Share to be purchased by the Investor in
such Fixed Purchase equal to ninety-five percent (95%) of the lower of: (i) the Closing Sale Price on the applicable Fixed Purchase Date
for such Fixed Purchase and (ii) the daily volume weighted average price for the Common Stock on the NASDAQ, as reported by Bloomberg
Financial LP through its “AQR” function for the five (5) consecutive trading days immediately preceding the applicable Fixed
Purchase Date for such Fixed Purchase (in each case, to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend,
stock split or other similar transaction that occurs on or after the date of this Agreement).
“Fixed Purchase Settlement
Date” shall have the meaning assigned to such term in Section 2.4.
“Fixed Purchase Share
Amount” means, with respect to a Fixed Purchase made pursuant to Section 2.1, the number of Shares to be purchased by the Investor
in such Fixed Purchase as specified by the Company in the applicable Fixed Purchase Notice, which number of Shares shall not exceed the
applicable Fixed Purchase Maximum Amount (calculated as of the applicable Fixed Purchase Date).
“Fixed Purchase Share
Delivery Date” shall have the meaning assigned to such term in Section 2.4.
“Free Writing Prospectus”
shall mean a “free writing prospectus” as defined in Rule 405 promulgated under the Securities Act.
“Fundamental Transaction”
means that (i) the Company shall, directly or indirectly, in one or more related transactions, (1) consolidate or merge with or into (whether
or not the Company is the surviving corporation) another Person, with the result that the holders of the Company’s capital stock
immediately prior to such consolidation or merger together beneficially own less than 50% of the outstanding voting power of the surviving
or resulting corporation, or (2) sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of the
properties or assets of the Company to another Person, or (3) take action to facilitate a purchase, tender or exchange offer by another
Person that is accepted by the holders of more than 50% of the outstanding shares of Common Stock (excluding any shares of Common Stock
held by the Person or Persons making or party to, or associated or affiliated with the Persons making or party to, such purchase, tender
or exchange offer), or (4) consummate a stock or share purchase agreement or other business combination (including, without limitation,
a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than
50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making
or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business
combination), or (5) reorganize, recapitalize or reclassify its Common Stock, or (ii) any “person” or “group”
(as these terms are used for purposes of Sections 13(d) and 14(d) of the Exchange Act) is or shall become the “beneficial owner”
(as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of 50% of the aggregate ordinary voting power represented by
issued and outstanding Common Stock.
“GAAP”
shall have the meaning assigned to such term in Section 4.6(b).
“GDPR”
shall have the meaning assigned to such term in Section 4.35.
“Governmental Entity”
means any nation, state, county, city, town, village, district, or other political jurisdiction of any nature, federal, state, local,
municipal, foreign, or other government, governmental or quasi-governmental authority of any nature (including any governmental agency,
branch, department, official, or entity and any court or other tribunal), multi-national organization or body; or body exercising, or
entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature
or instrumentality of any of the foregoing, including any entity or enterprise owned or controlled by a government or a public international
organization or any of the foregoing.
“HIPPA”
shall have the meaning assigned to such term in Section 4.35.
“Indebtedness” shall have the meaning assigned to such
term in Section 4.11.
“Intellectual Property”
shall have the meaning assigned to such term in Section 4.16(b).
“Investment Period”
means the period commencing on the Commencement Date and expiring on the date this Agreement is terminated pursuant to Article VII.
“Investor”
shall have the meaning assigned to such term in the Preamble.
“Investor Expense
Reimbursement” shall have the meaning assigned to such term in Section 9.1.
“Issuer Free Writing
Prospectus” shall mean an “issuer free writing prospectus,” as defined in Rule 433 promulgated under the Securities
Act, relating to the Shares that (i) is required to be filed with the Commission by the Company or (ii) is exempt from filing pursuant
to Rule 433(d)(5)(i) under the Securities Act, in each case, in the form filed or required to be filed with the Commission or, if not
required to be filed, in the form retained in the Company’s records pursuant to Rule 433(g) under the Securities Act.
“IT Systems”
shall have the meaning assigned to such term in Section 4.35.
“Knowledge” means the actual knowledge of the Company’s
Chief Executive Officer and Chief Financial Officer, after reasonable inquiry of all officers, directors and employees of the Company
and its Subsidiaries under their direct supervision who would reasonably be expected to have knowledge or information with respect to
the matter in question.
“Material
Adverse Effect” means (i) any condition, occurrence, state of facts or event having, or insofar as reasonably can be
foreseen would likely have, any material adverse effect on the legality, validity or enforceability of this Agreement or the
transactions contemplated hereby, (ii) any condition, occurrence, state of facts or event having, or insofar as reasonably can be
foreseen would likely have, any effect on the business, operations, properties or financial condition of the Company that is
material and adverse to the Company and its Subsidiaries, taken as a whole, and/or (iii) any condition, occurrence, state of facts
or event that would, or insofar as reasonably can be foreseen would likely, prohibit or otherwise materially interfere with or delay
the ability of the Company to perform any of its obligations under this Agreement; provided, however, that no facts,
circumstances, changes or effects exclusively and directly resulting from, relating to or arising out of the following, individually
or in the aggregate, shall be taken into account in determining whether a Material Adverse Effect has occurred or insofar as
reasonably can be foreseen would likely occur: (a) changes in conditions in the U.S. or global capital, credit or financial markets
generally, including changes in the availability of capital or currency exchange rates, provided such changes shall not have
affected the Company in a materially disproportionate manner as compared to other similarly situated companies; (b) changes
generally affecting the industries in which the Company and its Subsidiaries operate, provided such changes shall not have affected
the Company and its Subsidiaries, taken as a whole, in a materially disproportionate manner as compared to other similarly situated
companies; (c) any effect of the announcement of, or the consummation of the transactions contemplated by, this Agreement on the
Company’s relationships, contractual or otherwise, with customers, suppliers, vendors, bank lenders, strategic venture
partners or employees; (d) changes arising in connection with earthquakes, pandemics, hostilities, acts of war, sabotage or
terrorism or military actions or any escalation or material worsening of any such pandemic, hostilities, acts of war, sabotage or
terrorism or military actions; (e) any action taken by the Investor with respect to the transactions contemplated by this Agreement;
and (f) the effect of any changes in applicable laws or accounting rules, provided such changes shall not have affected the Company
in a materially disproportionate manner as compared to other similarly situated companies.
“Material Agreements”
shall have the meaning assigned to such term in Section 4.18.
“Minimum Price”
means 85% of the Closing Sale Price of the Company’s Common Stock on the Trading Day on which the Company properly delivered the
applicable VWAP Purchase Notice to the Investor simultaneously with the corresponding Fixed Purchase Notice representing the Nasdaq official
closing price of the Common Stock on the Trading Market (as reflected on Nasdaq.com) on the date of this Agreement (subject to adjustment
for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction that occurs
on or after the date of this Agreement).
“Money Laundering
Laws” shall have the meaning assigned to such term in Section 4.30.
“MPA Period”
means the period commencing at 9:30 a.m., New York City time, on the Trading Day immediately prior to the Trading Day on which the Company
makes a public disclosure of material information concerning the Company, its business or its securities (whether via issuance of a press
release, filing of a Commission Document with the Commission, or otherwise), and ending at 9:30 a.m., New York City time, on the first
(1st) Trading Day immediately following the Trading Day on which the Company has made such public disclosure of material information.
“NOLs”
shall have the meaning assigned to such term in Section 4.25.
“Note Shares”
shall have the meaning assigned to such term in Section 2.7.
“OFAC”
shall have the meaning assigned to such term in Section 4.31.
“Permits” shall have the meaning assigned to such term
in Section 4.16(a).
“Permitted Free Writing
Prospectus” shall have the meaning assigned to such term in Section 5.7(b).
“Person”
means any person or entity, whether a natural person, trustee, corporation, partnership, limited partnership, limited liability company,
trust, unincorporated organization, business association, firm, joint venture, governmental agency or authority.
“Personal Data”
shall have the meaning assigned to such term in Section 4.35.
“Policies”
shall have the meaning assigned to such term in Section 4.36.
“Potential Product”
shall have the meaning assigned to such term in Section 4.42(b).
“Privacy Laws”
shall have the meaning assigned to such term in Section 4.36.
“Prospectus” shall mean the Base Prospectus, as supplemented
by any Prospectus Supplement, including the documents incorporated by reference therein, together with any Permitted Free Writing Prospectus.
“Prospectus Supplement”
shall mean any prospectus supplement to the Base Prospectus (including the Registration Statement) filed with the Commission pursuant
to Rule 424(b) under the Securities Act, including the documents incorporated by reference therein.
“Purchase Condition
Satisfaction Time” shall mean (i) with respect to each Fixed Purchase, at the time of delivery of the applicable Fixed Purchase
Notice to the Investor on the applicable Fixed Purchase Date for such Fixed Purchase, (ii) with respect to each VWAP Purchase, both (A)
at the time of delivery of the applicable VWAP Purchase Notice to the Investor on the applicable VWAP Purchase Exercise Date for such
VWAP Purchase and (B) immediately prior to the applicable VWAP Purchase Commencement Time on the applicable VWAP Purchase Date for such
VWAP Purchase, and (iii) with respect to each Additional VWAP Purchase, both (A) at the time of delivery of the applicable Additional
VWAP Purchase Notice to the Investor on the applicable Additional VWAP Purchase Date for such Additional VWAP Purchase and (B) immediately
prior to the applicable Additional VWAP Purchase Commencement Time on the applicable Additional VWAP Purchase Date for such Additional
VWAP Purchase.
“Reference Period”
shall have the meaning assigned to such term in Section 5.5(c).
“Reference Price” shall have the meaning assigned to
such term in Section 5.5(c).
“Registration Period” shall have the meaning assigned to such term in Section 5.10.
“Registration
Statement” shall mean the registration statement on Form S-1, filed by the Company with the Commission under the Securities
Act for the registration of the Securities, as such Registration Statement may be amended and supplemented from time to time (including
any related abbreviated registration statement to register additional shares of Common Stock filed by the Company pursuant to Rule 462(b)
under the Securities Act), including all documents filed as part thereof or incorporated by reference therein, and including all information
deemed to be a part thereof at the time of effectiveness pursuant to Rule 430B under the Securities Act, including any comparable successor
registration statement filed by the Company with the Commission under the Securities Act for the registration of shares of its Common
Stock, including the Shares.
“Representation Date”
shall have the meaning assigned to such term in Section 6.3(l).
“Restricted Period”
shall have the meaning assigned to such term in Section 5.9.
“Restricted Person”
shall have the meaning assigned to such term in Section 5.9.
“Restricted Persons”
shall have the meaning assigned to such term in Section 5.9.
“Sale Price”
means any trade price for a share of Common Stock on the Trading Market (or if the Common Stock is then traded on an Eligible Market,
on such Eligible Market), as reported by Bloomberg.
“Sanctions”
shall have the meaning assigned to such term in Section 4.31.
“Sanctioned Countries”
shall have the meaning assigned to such term in Section 4.31.
“Sanctioned Country”
shall have the meaning assigned to such term in Section 4.31.
“Sanctioned Persons”
shall have the meaning assigned to such term in Section 4.31.
“Sarbanes-Oxley Act”
shall have the meaning assigned to such term in Section 4.6(c).
“Securities” shall mean, collectively, the Shares and
the Note Shares.
“Securities Act”
shall mean the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder.
“Shares”
shall mean the shares of Common Stock that are and/or may be purchased by the Investor under this Agreement pursuant to one or more Fixed
Purchase Notices, one or more VWAP Purchase Notices and/or one or more Additional VWAP Purchase Notices, but not including the Note Shares.
“Short Sales”
means “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act.
“Subsidiary”
shall mean any corporation or other entity of which at least a majority of the securities or other ownership interest having ordinary
voting power (absolutely or contingently) for the election of directors or other Persons performing similar functions are at the time
owned directly or indirectly by the Company and/or any of its other Subsidiaries.
“Threshold Price”
means, with respect to a Fixed Purchase, a VWAP Purchase and an Additional VWAP Purchase (as applicable), $1.00, which shall be appropriately
adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction and, effective upon the
consummation of any such reorganization, recapitalization, non-cash dividend, stock split or other similar transaction, the “Threshold
Price” shall mean the lower of (i) the adjusted price and (ii) $1.00.
“Total Commitment”
shall have the meaning assigned to such term in Section 1.1.
“Trading Day”
shall mean any day on which the Trading Market or, if the Common Stock is then listed on an Eligible Market, such Eligible Market is open
for trading, including any day on which the Trading Market (or such Eligible Market, as applicable) is open for trading for a period of
time less than the customary time.
“Trading Market”
means The Nasdaq Capital Market (or any nationally recognized successor thereto).
“Transfer Agent”
means Securities Transfer Corporation, 2901 N. Dallas Parkway, Suite 380, Plano, TX 75093, or such other Person who is then serving as
the Transfer Agent for the Company in respect of the Common Stock.
“UKBA”
shall have the meaning assigned to such term in Section 4.29.
“Variable Rate Transaction”
means a transaction in which the Company (i) issues or sells any equity or debt securities that are convertible into, exchangeable or
exercisable for, or include the right to receive additional shares of Common Stock or Common Stock Equivalents either (A) at a conversion
price, exercise price, exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the
Common Stock at any time after the initial issuance of such equity or debt securities, or (B) with a conversion, exercise or exchange
price that is subject to being reset at some future date after the initial issuance of such equity or debt security or upon the occurrence
of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock (including,
without limitation, any “full ratchet” or “weighted average” anti-dilution provisions, but not including any standard
anti-dilution protection for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction), (ii)
issues or sells any equity or debt securities, including without limitation, Common Stock or Common Stock Equivalents, either (A) at a
price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence
of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock (other
than standard anti-dilution protection for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction),
or (B) that are subject to or contain any put, call, redemption, buy-back, price-reset or other similar provision or mechanism (including,
without limitation, a “Black-Scholes” put or call right, other than in connection with a “fundamental transaction”)
that provides for the issuance of additional equity securities of the Company or the payment of cash by the Company, or (iii) enters into
any agreement, including, but not limited to, an “equity line of credit” (other than with the Investor or an Affiliate of
the Investor) or “at the market offering” or other continuous offering or similar offering of Common Stock or Common Stock
Equivalents, whereby the Company may sell Common Stock or Common Stock Equivalents at a future determined price.
“VWAP”
means, for the Common Stock for a specified period, the dollar volume-weighted average price for the Common Stock on the Trading Market
(or, if the Common Stock is then listed on an Eligible Market, on such Eligible Market), for such period, as reported by Bloomberg through
its “AQR” function. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination,
recapitalization or other similar transaction during such period.
“VWAP Purchase”
shall have the meaning assigned to such term in Section 2.2.
“VWAP Purchase Confirmation”
shall have the meaning assigned to such term in Section 2.2.
“VWAP Purchase Commencement
Time” means, with respect to a VWAP Purchase made pursuant to Section 2.2, 9:30:01 a.m., New York City time, on the VWAP Purchase
Date for such VWAP Purchase, or such later time on such VWAP Purchase Date publicly announced by the Trading Market (or, if the Common
Stock is then listed on an Eligible Market, by such Eligible Market) as the official open of the primary (or “regular) trading session
on the Trading Market (or on such Eligible Market, as applicable) on such VWAP Purchase Date.
“VWAP Purchase Date”
means, with respect to a VWAP Purchase made pursuant to Section 2.2, the Trading Day immediately following the VWAP Purchase Exercise
Date for such VWAP Purchase.
“VWAP Purchase Exercise
Date” means, with respect to a VWAP Purchase made pursuant to Section 2.2, the Trading Day on which the Investor receives, after
4:00 p.m., New York City time, but prior to 5:30 p.m., New York City time, on such Trading Day, a valid VWAP Purchase Notice for such
VWAP Purchase, simultaneously with the delivery to the Investor of a valid Fixed Purchase Notice for a Fixed Purchase directing the Investor
to purchase a specified Fixed Purchase Share Amount equal to the Fixed Purchase Maximum Amount, in accordance with this Agreement.
“VWAP Purchase Maximum
Amount” means, with respect to a VWAP Purchase made pursuant to Section 2.2, a number of shares of Common Stock equal to the
lesser of (i) 300% of the number of Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Fixed
Purchase Notice for the corresponding Fixed Purchase referred to in clause (i) of the second sentence of Section 2.2 and (ii) a number
of Shares equal to (A) the VWAP Purchase Share Percentage multiplied by (B) the total number (or volume) of shares of Common Stock traded
on the Trading Market (or, if the Common Stock is then listed on an Eligible Market, on such Eligible Market) during the applicable VWAP
Purchase Period on the applicable VWAP Purchase Date for such VWAP Purchase.
“VWAP Purchase Minimum
Price Threshold” means, with respect to a VWAP Purchase made pursuant to Section 2.2, eighty-five percent (85%) of the Closing
Sale Price of the Common Stock on the applicable VWAP Purchase Exercise Date with respect to such VWAP Purchase.
“VWAP Purchase Notice”
means, with respect to a VWAP Purchase made pursuant to Section 2.2, an irrevocable written notice, substantially in the form of Exhibit
B, timely delivered by the Company to the Investor on the applicable VWAP Purchase Exercise Date for such VWAP Purchase (simultaneously
with the delivery to the Investor of a valid Fixed Purchase Notice for a Fixed Purchase directing the Investor to purchase a specified
Fixed Purchase Share Amount equal to the Fixed Purchase Maximum Amount), directing the Investor to purchase a specified VWAP Purchase
Share Amount (such specified VWAP Purchase Share Amount subject to adjustment as set forth in Section 2.2 as necessary to give effect
to the VWAP Purchase Maximum Amount), at the applicable VWAP Purchase Price therefor on the applicable VWAP Purchase Date for such VWAP
Purchase in accordance with this Agreement.
“VWAP Purchase Period”
means, with respect to a VWAP Purchase made pursuant to Section 2.2, the period on the applicable VWAP Purchase Date for such VWAP Purchase
beginning at the applicable VWAP Purchase Commencement Time and ending at the applicable VWAP Purchase Termination Time.
“VWAP Purchase Price”
means, with respect to a VWAP Purchase made pursuant to Section 2.2, the purchase price per Share to be purchased by the Investor in such
VWAP Purchase equal to the lesser of ninety-five percent (95%) of (i) of the lowest intraday sale price of the Common Stock on the applicable
VWAP Purchase Date and (ii) the VWAP during the period on the applicable VWAP Zurchase Date (to be appropriately adjusted for any reorganization,
recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction).
“VWAP Purchase Settlement
Date” shall have the meaning assigned to such term in Section 2.4.
“VWAP Purchase Share
Amount” means, with respect to a VWAP Purchase made pursuant to Section 2.2, the number of Shares to be purchased by the Investor
in such VWAP Purchase as specified by the Company in the applicable VWAP Purchase Notice, which number of Shares shall not exceed the
applicable VWAP Purchase Maximum Amount.
“VWAP Purchase Share
Delivery Date” shall have the meaning assigned to such term in Section 2.4.
“VWAP Purchase Share
Percentage” means, with respect to a VWAP Purchase made pursuant to Section 2.2, thirty percent (30%).
“VWAP Purchase Share
Volume Maximum” means, with respect to a VWAP Purchase made pursuant to Section 2.2, a number of shares of Common Stock equal
to (i) the number of Shares specified by the Company in the applicable VWAP Purchase Notice as the VWAP Purchase Share Amount to be purchased
by the Investor in such VWAP Purchase, divided by (ii) the VWAP Purchase Share Percentage (to be appropriately adjusted for any reorganization,
recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction).
“VWAP Purchase Termination
Time” means, with respect to an VWAP Purchase made pursuant to Section 2.2, the earliest of (i) 4:00 p.m., New York City time,
on the applicable VWAP Purchase Date, or such other time publicly announced by the Trading Market as the official close of trading on
the Trading Market (or, if the Common Stock is then listed on an Eligible Market, by such Eligible Market as the official close of trading
on such Eligible Market) on such applicable VWAP Purchase Date, (ii) such time, from and after the VWAP Purchase Commencement Time for
such VWAP Purchase, that the total number (or volume) of shares of Common Stock traded on the Trading Market (or, if the Common Stock
is then listed on an Eligible Market, on such Eligible Market) has exceeded the applicable VWAP Purchase Share Volume Maximum, and (iii)
such time, from and after the VWAP Purchase Commencement Time for such VWAP Purchase, that the Sale Price has fallen below the applicable
VWAP Purchase Minimum Price Threshold.
EXHIBIT A TO THE
COMMON STOCK PURCHASE AGREEMENT
FORM OF FIXED PURCHASE NOTICE
Reference is made to the Common
Stock Purchase Agreement dated as of November 17, 2023, (the “Purchase Agreement”) between Spectaire Holdings, Inc.,
a Delaware corporation (the “Company”), and Keystone Capital Partners, LLC, a Delaware limited liability company. Capitalized
terms used and not otherwise defined herein shall have the meanings given such terms in the Purchase Agreement.
In accordance with and pursuant
to Section 2.1 of the Purchase Agreement, the Company hereby issues this Fixed Purchase Notice to exercise a Fixed Purchase for the Fixed
Purchase Share Amount indicated below.
Fixed Purchase Share Amount (number of Shares): |
|
|
|
Fixed Purchase Exercise Date: |
|
|
|
Fixed Purchase Price (per Share): |
|
|
|
Total Aggregate Fixed Purchase Price: |
|
|
|
Fixed Purchase Share Delivery Date: |
|
|
|
Fixed Purchase Settlement Date: |
|
|
|
Dollar Amount of Common Stock Currently Available under the Aggregate Limit: |
|
Dated: |
|
|
SPECTAIRE HOLDINGS, INC. |
|
|
|
|
|
|
|
|
By: |
|
|
|
|
Name: |
|
|
|
Title: |
|
|
|
|
|
|
|
|
Address: |
|
|
|
Email: |
AGREED AND ACCEPTED: |
|
|
|
|
|
KEYSTONE CAPITAL PARTNERS, LLC |
|
|
|
|
|
|
By: |
|
|
|
|
Name: |
|
|
|
Title: |
|
|
EXHIBIT B TO THE
COMMON STOCK PURCHASE AGREEMENT
FORM OF VWAP PURCHASE NOTICE
Reference is made to the Common
Stock Purchase Agreement dated as of November 17, 2023, (the “Purchase Agreement”) between Spectaire Holdings, Inc.,
a Delaware corporation (the “Company”), and Keystone Capital Partners, LLC, a Delaware limited liability company. Capitalized
terms used and not otherwise defined herein shall have the meanings given such terms in the Purchase Agreement.
In accordance with and pursuant
to Section 2.2 of the Purchase Agreement, the Company hereby issues this VWAP Purchase Notice to exercise a VWAP Purchase for the VWAP
Purchase Share Amount indicated below.
VWAP Purchase Share Amount (number of Shares): |
|
|
|
VWAP Purchase Exercise Date: |
|
|
|
VWAP Purchase Date: |
|
|
|
VWAP Purchase Share Delivery Date: |
|
|
|
VWAP Purchase Settlement Date: |
|
|
|
Dollar Amount of Common Stock Currently Available under the Aggregate Limit: |
|
Dated: |
|
|
SPECTAIRE HOLDINGS, INC. |
|
|
|
|
|
|
|
|
By: |
|
|
|
|
Name: |
|
|
|
Title: |
|
|
|
|
|
|
|
|
|
Address: |
|
|
|
Email: |
|
AGREED AND ACCEPTED: |
|
|
|
|
|
KEYSTONE CAPITAL PARTNERS, LLC |
|
|
|
|
|
|
By: |
|
|
|
|
Name: |
|
|
|
Title |
|
|
EXHIBIT C TO THE
COMMON STOCK PURCHASE AGREEMENT
FORM OF VWAP PURCHASE CONFIRMATION
Reference is made to the Common
Stock Purchase Agreement dated as of November 17, 2023, (the “Purchase Agreement”) between Spectaire Holdings, Inc.,
a Delaware corporation (the “Company”), and Keystone Capital Partners, LLC, a Delaware limited liability company. Capitalized
terms used and not otherwise defined herein shall have the meanings given such terms in the Purchase Agreement.
In accordance with and pursuant
to Section 2.2 of the Purchase Agreement, the Investor hereby issues this VWAP Purchase Confirmation for the VWAP Purchase Share Amount
indicated below.
VWAP Purchase Share Amount (number of Shares): |
|
|
|
VWAP Purchase Exercise Date: |
|
|
|
VWAP Purchase Date: |
|
|
|
VWAP Purchase Commencement Time: |
|
|
|
VWAP Purchase Termination Time: |
|
|
|
VWAP during the VWAP Purchase Period: |
|
|
|
Closing Sale Price on the VWAP Purchase Date: |
|
|
|
VWAP Purchase Price (per Share) (95% of lower of two line items immediately above): |
|
|
|
Total Aggregate VWAP Purchase Price: |
|
|
|
VWAP Purchase Share Delivery Date: |
|
|
|
VWAP Purchase Settlement Date: |
|
Dated: |
|
|
KEYSTONE CAPITAL PARTNERS, LLC |
|
|
|
|
|
|
|
|
By: |
|
|
|
|
Name: |
|
|
|
Title: |
|
|
|
|
|
|
|
|
|
Address: |
|
|
|
Email: |
|
AGREED AND ACCEPTED: |
|
|
|
|
|
SPECTAIRE HOLDINGS, INC. |
|
|
|
|
|
|
By: |
|
|
|
|
Name: |
|
|
|
Title: |
|
|
EXHIBIT D TO THE
COMMON STOCK PURCHASE AGREEMENT
FORM OF ADDITIONAL VWAP PURCHASE NOTICE
Reference is made to the Common
Stock Purchase Agreement dated as of November 17, 2023, (the “Purchase Agreement”) between Spectaire Holdings, Inc.,
a Delaware corporation (the “Company”), and Keystone Capital Partners, LLC, a Delaware limited liability company. Capitalized
terms used and not otherwise defined herein shall have the meanings given such terms in the Purchase Agreement.
In accordance with and pursuant
to Section 2.3 of the Purchase Agreement, the Company hereby issues this Additional VWAP Purchase Notice to exercise an Additional VWAP
Purchase for the Additional VWAP Purchase Share Amount indicated below.
Additional VWAP Purchase Share Amount (number of Shares): |
|
|
|
Additional VWAP Purchase Date (indicate whether this is for the first, second, third, etc. Additional VWAP exercised by the Company on such Additional VWAP Purchase Date): |
|
|
|
Additional VWAP Purchase Share Delivery Date: |
|
|
|
Additional VWAP Purchase Settlement Date: |
|
|
|
Dollar Amount of Common Stock Currently Available under the Aggregate Limit: |
|
Dated: |
|
|
SPECTAIRE HOLDINGS, INC. |
|
|
|
|
|
|
|
|
By: |
|
|
|
|
Name: |
|
|
|
Title: |
|
|
|
|
|
|
|
|
|
Address: |
|
|
|
Email: |
|
AGREED AND ACCEPTED: |
|
|
|
|
|
KEYSTONE CAPITAL PARTNERS, LLC |
|
|
|
|
|
|
By: |
|
|
|
|
Name: |
|
|
|
Title |
|
|
EXHIBIT E TO THE
COMMON STOCK PURCHASE AGREEMENT
FORM OF ADDITIONAL VWAP PURCHASE CONFIRMATION
Reference is made to the Common
Stock Purchase Agreement dated as of November 17, 2023, (the “Purchase Agreement”) between Spectaire Holdings, Inc.,
a Delaware corporation (the “Company”), and Keystone Capital Partners, LLC, a Delaware limited liability company. Capitalized
terms used and not otherwise defined herein shall have the meanings given such terms in the Purchase Agreement.
In accordance with and pursuant
to Section 2.3 of the Purchase Agreement, the Investor hereby issues this Additional VWAP Purchase Confirmation for the Additional VWAP
Purchase Share Amount indicated below.
Additional VWAP Purchase Share Amount (number of Shares): |
|
|
|
Additional VWAP Purchase Date (indicate whether this is for the first, second, third, etc. Additional VWAP exercised by the Company on such Additional VWAP Purchase Date): |
|
|
|
Additional VWAP Purchase Commencement Time: |
|
|
|
Additional VWAP Purchase Termination Time: |
|
|
|
VWAP during the Additional VWAP Purchase Period: |
|
|
|
Closing Sale Price on the Additional VWAP Purchase Date: |
|
|
|
Additional VWAP Purchase Price (per Share) (95% of lower of two line items immediately above): |
|
|
|
Total Aggregate Additional VWAP Purchase Price: |
|
|
|
Additional VWAP Purchase Share Delivery Date: |
|
|
|
Additional VWAP Purchase Settlement Date: |
|
Dated: |
|
|
KEYSTONE CAPITAL PARTNERS, LLC |
|
|
|
|
|
|
|
|
By: |
|
|
|
|
Name: |
|
|
|
Title: |
|
|
|
|
|
|
|
|
Address: |
|
|
|
Email: |
|
AGREED AND ACCEPTED: |
|
|
|
|
|
SPECTAIRE HOLDINGS, INC. |
|
|
|
|
|
|
By: |
|
|
|
|
Name: |
|
|
|
Title: |
|
|
EXHIBIT F TO THE
COMMON STOCK PURCHASE AGREEMENT
FORM OF COMMITMENT NOTE
EXHIBIT G TO THE
COMMON STOCK PURCHASE AGREEMENT
CERTIFICATE OF THE COMPANY
COMMENCEMENT CERTIFICATE
_________, 2023
The undersigned, the [●]
of Spectaire Holdings, Inc., a Delaware corporation (the “Company”), delivers this certificate in connection with the
Common Stock Purchase Agreement, dated as of November 17, 2023 (the “Agreement”), by and between the Company and Keystone
Capital Partners, LLC, a Delaware limited liability company (the “Investor”), and hereby certifies on the date hereof
that (capitalized terms used herein without definition have the meanings assigned to them in the Agreement):
1. Attached
hereto as Exhibit A is a true, complete and correct copy of the Certificate of Incorporation of the Company as amended through,
and as in full force and effect on, the date hereof. The Certificate of Incorporation of the Company has not been further amended or restated,
and no action has been taken by the Company in contemplation of any such amendment or the dissolution, merger or consolidation of the
Company.
2. Attached
hereto as Exhibit B is a true and complete copy of the Bylaws of the Company, as amended and restated through, and as in full force
and effect on, the date hereof, and no proposal for any amendment, repeal or other modification to the Bylaws of the Company has been
taken or is currently pending before the Board of Directors or stockholders of the Company.
3. The
Board of Directors of the Company has approved the transactions contemplated by the Agreement; said approval has not been amended, rescinded
or modified and remains in full force and effect as of the date hereof.
4. Each
person who, as an officer of the Company, or as attorney-in-fact of an officer of the Company, signed (i) the Agreement and (ii) any other
document delivered prior hereto or on the date hereof in connection with the transactions contemplated by the Agreement, was duly elected,
qualified and acting as such officer or duly appointed and acting as such attorney-in-fact, and the signature of each such person appearing
on any such document is his genuine signature.
IN WITNESS WHEREOF,
I have signed my name as of the date first above written.
EXHIBIT H TO THE
COMMON STOCK PURCHASE AGREEMENT
COMPLIANCE CERTIFICATE
In connection with the issuance
of shares of common stock of Spectaire Holdings, Inc., a Delaware corporation (the “Company”), pursuant to the VWAP
Purchase Notice, dated [●], 202[●], delivered by the Company to Keystone Capital Partners, LLC, a Delaware limited liability
company (the “Investor”), pursuant to Article II of the Common Stock Purchase Agreement, dated as of November 17, 2023,
by and between the Company and the Investor (the “Agreement”), the undersigned hereby certifies as follows:
1. The
undersigned is the duly elected [●] of the Company.
2. The
representations and warranties of the Company set forth in Article IV of the Agreement (i) that are not qualified by “materiality”
or “Material Adverse Effect” are true and correct in all material respects as of the date hereof and as of [insert Purchase
Condition Satisfaction Time] with the same force and effect as if made on such date and at such time, except to the extent such representations
and warranties are as of another date or time, in which case, such representations and warranties are true and correct in all material
respects as of such other date or time and (ii) that are qualified by “materiality” or “Material Adverse Effect”
are true and correct as of the date hereof and as of [insert Purchase Condition Satisfaction Time] with the same force and effect as if
made on such date and at such time, except to the extent such representations and warranties are as of another date or time, in which
case, such representations and warranties are true and correct as of such other date or time.
3. The
Company has performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by the Agreement
to be performed, satisfied or complied with by the Company at or prior to the date hereof and at or prior to [insert Purchase Condition
Satisfaction Time].
4. As of the date
hereof and as of [insert Purchase Condition Satisfaction Time], (i) the Registration Statement did not and does not contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the
statements therein not misleading, (ii) the Prospectus did not and does not contain any untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading and (iii) no event has occurred as a result of which it is necessary to
amend or supplement the Registration Statement or the Prospectus in order to make the statements therein not untrue or misleading
for clauses (i) and (ii) above, respectively, to be true and correct.
5. As
of the date hereof and as of [insert Purchase Condition Satisfaction Time], the Company did not and does not possess any material non-public
information.
Capitalized terms used but
not otherwise defined herein shall have the meanings assigned to them in the Agreement.
The undersigned has executed
this Certificate this [●] day of [●], 20[●].
Exhibit 10.2
Execution Version
THIS CONVERTIBLE PROMISSORY NOTE
(AS MAY BE AMENDED FROM TIME TO TIME, THE “NOTE”) AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR UNDER THE SECURITIES
LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE. THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT
ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF OR EXEMPTION UNDER THE SECURITIES
ACT.
CONVERTIBLE PROMISSORY
NOTE
Aggregate Principal Amount: $300,000 |
|
Dated
as of November 17, 2023 |
FOR VALUE
RECEIVED, and subject to the terms and conditions set forth herein, Spectaire Holdings, Inc., a Delaware corporation (the “Company”),
hereby promises to pay to the order of Keystone Capital Partners, LLC, a Delaware limited liability company (the “Holder”),
the principal sum of THREE HUNDRED THOUSAND DOLLARS ($300,000) or such lesser amount as shall remain unpaid under this Convertible Promissory
Note (this “Note”) on the Maturity Date (as defined herein), together with any accrued and unpaid interest,
if any, thereon. Subject to Section 10, all payments on this Note shall be made by check or wire transfer of immediately available
funds to such account as the Holder may from time to time designate by written notice in accordance with the provisions of this Note.
Contemporaneously
with the issuance of this Note, the Company and the Holder have entered into a registration rights agreement relating to the registration
and subsequent sale by the Holder of the Conversion Shares (as defined herein) (the “Registration Rights Agreement”).
1.
Principal. Subject to Sections 9 and 10, the entire unpaid principal balance of this Note, together with any
accrued and unpaid interest, if any, thereon, shall be due and payable on May 17, 2024 (the “Maturity Date”).
Under no circumstances shall any individual, including but not limited to any officer, director, employee or equityholder of the Company,
be obligated personally for any obligations or liabilities of the Company hereunder.
2.
Prepayment. At any time and from time to time, the principal balance of this Note, together with any accrued and unpaid
interest, if any, thereon, may be prepaid, in whole or in part, without the prior written consent of the Holder.
3.
Interest. Commencing on the date hereof, simple interest shall accrue on the unpaid principal balance of this Promissory
Note at a rate equal to five percent (5%) per annum, computed on the basis of the actual number of days elapsed and a year of 365 days
from the date hereof until the principal balance and all interest accrued thereon are paid or satisfied, as provided herein. Accrued interest
on this Note shall be due and payable on the Maturity Date; provided that in the event of any prepayment of the Promissory Note, accrued
interest on the principal amount prepaid shall be payable on the date of such prepayment.
4.
Application of Payments. All payments shall be applied first to any accrued but unpaid interest and then to the reduction
of the unpaid principal balance of this Note.
5. Security. This Note is a general unsecured obligation of the Company.
6.
Representations and Warranties of the Company. The Company hereby represents and warrants to the Holder as of the date hereof
as follows:
a. Organization,
Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the
laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as now conducted. The
Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would
have a material adverse effect on its business or properties.
b. Due Authorization.
All corporate action on the part of the Company’s directors and shareholders necessary for the authorization, execution,
delivery of, and the performance of all obligations of the Company under this Note has been taken and this Note constitutes the
valid and legally binding obligations of the Company, enforceable against the Company in accordance with its terms, except as may be
limited by (i) applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other similar laws relating
to or affecting the enforcement of creditor’s rights generally and (ii) general principles of equity.
c. Corporate Power.
The Company has the requisite corporate power and authority to execute and deliver this Note to the Holder and to issue, and carry
out and perform all of its obligations under, this Note.
d. Valid Issuance.
i.
The Conversion Shares, when issued in accordance with the terms of this Note, will be duly and validly issued, fully paid and nonassessable
and will be free of any liens, encumbrances, or restrictions on transfer other than restrictions on under applicable state and federal
securities laws or as contemplated thereby.
ii.
Assuming the accuracy of the representations made by the Holder in Section 7, the offer and sale of the Note and the Conversion
Shares to the Holder in accordance with this Note are exempt from the registration and prospectus delivery requirements of the Securities
Act, and the securities registration and qualification requirements of the currently effective provisions of the securities laws of the
states in which the Holder is resident based upon its addresses set forth on the signature page, and neither the Company nor any authorized
agent acting on its behalf will take any action hereafter that would cause the loss of such exemption.
7. Representations, Warranties
and Certain Agreements of the Holder. The Holder hereby represents and warrants to the Company as of the date hereof as follows:
a. Organization, Good
Standing and Qualification. The Holder is a limited liability company duly formed, validly existing and in good standing under
the laws of the State of Delaware.
b. Authorization.
This Note constitutes the Holder’s valid and legally binding obligation, enforceable in accordance with its terms except as
may be limited by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other similar laws relating to or
affecting the enforcement of creditor’s rights generally and (ii) general principles of equity. The Holder represents that it
has full power and authority to enter into this Note.
c. Purchase for Own
Account. This Note and the Conversion Shares, if and when acquired, are being acquired for investment for the Holder’s own
account, not as a nominee or agent, and not with a view to the public resale or distribution thereof within the meaning of the
Securities Act, and the Holder has no present intention of selling, granting any participation in, or otherwise distributing the
same.
d. Disclosure of
Information. The Holder has received or has had full access to all the information it considers necessary or appropriate to make
an informed investment decision with respect to this Note and the Conversion Shares. The Holder further has had an opportunity to
ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Note and the
Conversion Shares and to obtain additional information (to the extent the Company possessed such information or could acquire it
without unreasonable effort or expense) necessary to verify any information furnished to the Holder or to which the Holder had
access. The foregoing, however, does not in any way limit or modify the representations and warranties made by the Company in Section
6.
e. Investment
Experience. The Holder understands that the purchase of this Note and the Conversion Shares involves substantial risk. The
Holder also understands that there can be no assurances that the Company will be able to repay this Note. The Holder has experience
as an investor in securities of companies in the development stage and acknowledges that it is able to fend for itself, can bear the
economic risk of its investment in this Note and the Conversion Shares and has such knowledge and experience in financial or
business matters that it is capable of evaluating the merits and risks of this investment in this Note and the Conversion Shares and
protecting its own interests in connection with this investment.
f. Accredited Investor
Status. The Holder is an “accredited investor” within the meaning of Rule 501 of Regulation D promulgated under the
Securities Act.
g. Restricted
Securities. The Holder understands that this Note and the Conversion Shares are characterized as “restricted
securities” under the Securities Act and Rule 144 promulgated thereunder inasmuch as they are being acquired from the Company
in a transaction not involving a public offering, and that under the Securities Act and applicable regulations thereunder such
securities may be resold without registration under the Securities Act only in certain limited circumstances. In this connection,
the Holder represents that it is familiar with Rule 144 of the SEC, as presently in effect, and understands the resale limitations
imposed thereby and by the Securities Act. The Holder understands that the Company is under no obligation to register this Note or
the Conversion Shares other than pursuant to the Registration Rights Agreement.
h. No Solicitation.
At no time was the Holder presented with or solicited by any publicly issued or circulated newspaper, mail, radio, television or
other form of general advertising or solicitation in connection with the offer, sale and purchase of this Note or the Conversion
Shares.
i. Further Limitations on
Disposition. Without in any way limiting the representations set forth above, the Holder further agrees not to make any disposition
of all or any portion of this Note or the Conversion Shares, and acknowledges and agrees that the legends included in this Note and the
legends described in Section 7.j to be applied to the Conversion Shares will not be removed by the Company from any certificate
or book entry evidencing this Note and/or the Conversion Shares, unless there is then in effect a registration statement under the Securities
Act covering such proposed disposition and such disposition is made in accordance with such registration statement or the Holder will
have notified the Company of the proposed disposition, and will have furnished the Company with a statement of the circumstances surrounding
the proposed disposition, and, at the expense of the Holder or its transferee, with an opinion of counsel, reasonably satisfactory to
the Company, that such disposition will not require registration of such securities under the Securities Act; provided, that,
notwithstanding the foregoing, no such registration statement will be required: (x) for any transfer of this Note or the Conversion Shares
in reliance on an exemption from the registration requirements under the Securities Act; or (y) for any transfer of this Note or the
Conversion Shares by the Holder to its “affiliates” (as such term is defined in Rule 405 under the Securities Act), or by
the Holder to (A) one or more of partners of the Holder as of the time of such transfer, (B) one or more retired partners of the Holder
who retires after the date hereof, or (C) the estate of any such partner; provided, further, that in each of the foregoing cases
such transfer is made in compliance with the Securities Act and the transferee agrees in writing to be subject to the terms hereof to
the same extent as if the transferee were the Holder hereunder, to the extent the terms continue to be applicable following such transfer.
j. Legends. It is
understood that the certificates or book entries evidencing the Conversion Shares will bear (1) any legend required by the laws of
the State of Delaware, including any legend required by the General Corporation Law of the State of Delaware, or any other state
securities law and (2) the following legend:
THE SECURITIES REPRESENTED HEREBY
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS
OF ANY STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT
AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD
BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.
k. No “Bad
Actor” Disqualification. No “bad actor” disqualifying event is applicable to the Holder. The Holder has
exercised reasonable care to determine whether any disqualification event is applicable to the Holder.
8.
Events of Default. Each of the following shall constitute an event of default (“Event of Default”):
a. Failure to Pay. The
Company’s failure to pay all or a portion of the unpaid principal balance of this Note, together with any accrued and unpaid interest,
if any, thereon, to the Holder when due, whether at maturity, as a result of acceleration or otherwise.
b. Voluntary
Bankruptcy. The commencement by the Company or any of its Significant Subsidiaries (as defined below) of a voluntary case under
any applicable bankruptcy, insolvency, reorganization, rehabilitation or other similar law, or the consent by it to the appointment
of or taking possession by a receiver, liquidator, assignee, trustee, custodian, sequestrator (or other similar official) of the
Company or any of its Significant Subsidiaries or for any substantial part of its property, or the making by it of any assignment
for the benefit of creditors, or the failure of the Company or any of its Significant Subsidiaries generally to pay its debts as
such debts become due, or the taking of corporate action by the Company or any of its Significant Subsidiaries in furtherance of any
of the foregoing. As used herein, “Significant Subsidiary” shall have the meaning set forth in Article I,
Rule 1-02(w) of Regulation S-X promulgated by the SEC (or any successor rule); provided, that in each instance in such definition in
which the term “10 percent” is used, the term “5 percent” shall be substituted therefor.
c. Involuntary
Bankruptcy. The entry of a decree or order for relief by a court having jurisdiction in the premises in respect of the Company
or any of its Significant Subsidiaries in an involuntary case under any applicable bankruptcy, insolvency or other similar law, or
appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) of the Company or any of its
Significant Subsidiaries or for any substantial part of its property, or ordering the winding-up or liquidation of its affairs, and
the continuance of any such decree or order unstayed and in effect for a period of sixty (60) consecutive days.
d. Change of Control.
(i) The holders of the outstanding voting securities of the Company cease to beneficially own (as defined in Rules 13d-3 and 13d-5
of Regulation 13D under the Exchange Act), in the aggregate, directly or indirectly, a majority of the aggregate voting power
represented by the issued and outstanding voting securities of the Company or (ii) the Company consummates a sale, lease or transfer
of all or substantially all of the assets, lines of business or divisions of the Company and its subsidiaries in a single
transaction or series of related transactions, taken as a whole, to any person or persons, other than solely to one or more of the
Company’s wholly owned subsidiaries; provided, that, in no event shall the consummation of any transaction with the Holder or
any of its affiliates constitute an Event of Default pursuant to this Section 8.d.
e. Delisting of the
Company’s Common Stock. At any time after the date hereof, the common stock, par value $0.0001 per share, of the Company
(“Common Stock”) is no longer listed, or is suspended from trading for a period of five or more
consecutive trading days, on any national securities exchange.
f. Representations and Warranties.
Any representation or warranty made by the Company in this Note shall be untrue or incorrect in any material respect as of the date
when made or deemed made.
g. Breach. The
Company’s failure to observe or perform any covenant or agreement contained in this Note.
9. Remedies.
a. Upon the occurrence of an
Event of Default specified in Section 8.a, Section 8.f or Section 8.g, the Holder may, by written notice to the
Company, declare this Note to be due immediately and payable, whereupon the unpaid principal balance of this Note, together with any
accrued and unpaid interest, if any, thereon, shall become immediately due and payable without presentment, demand, protest or other
notice of any kind, all of which are hereby expressly waived, anything contained herein or in the documents evidencing the same to the
contrary notwithstanding.
b.
Upon the occurrence of an Event of Default specified in Section 8.b, Section 8.c or Section 8.d, or Section
8.e, the unpaid principal balance of this Note, together with any accrued and unpaid interest, if any, thereon, shall automatically
and immediately become due and payable, in all cases without any action on the part of the Holder.
c. The Company will furnish to
the Holder prompt written notice of the occurrence of any Event of Default.
10. Conversion.
a. The Holder may, in its sole
discretion and upon written notice to the Company delivered at least three (3) business days and no more than ten (10) business days
prior to the Maturity Date (a “Conversion Notice”), convert all or a portion of the entire unpaid principal
balance of this Note, together with all accrued and unpaid interest, if any, thereon, as of such time (the “Conversion Amount”)
into a number of Conversion Shares equal to (x) the Conversion Amount divided by (y) the average VWAP of a share of Common Stock
during the five (5) trading day period ending on the trading day immediately prior to the date of the Conversion Notice (the “VWAP
Price”); provided, that if the VWAP Price is less than $1.00, the VWAP Price shall be deemed to be $1.00.
b.
Upon delivery of any Conversion Notice, all interest on the Conversion Amount specified therein shall stop accruing as of the date
of such Conversion Notice.
c. If at any time during the
period between the date of this Note and any conversion of all or any portion of the unpaid principal balance of this Note, together
with all accrued and unpaid interest, if any, thereon, in accordance with this Section 10, any change in the outstanding shares
of Common Stock shall occur by reason of any stock split, reverse stock split, stock dividend, cash dividend, reorganization, recapitalization,
reclassification, combination, exchanges of shares, rights, options, warrants, distributions, spin-off, tender offer, exchange offer
or other change or transaction with respect to the Common Stock (each, an “Adjustment Event”), any number or
amount contained in this Section 10 that is based on the price of a share of Common Stock or a number of shares of Common Stock
shall be equitably adjusted to the extent necessary to provide the Holder the same economic effect with respect to the Common Stock as
contemplated by this Section 10 with respect to such conversion as of immediately prior to such Adjustment Event.
d.
Upon any conversion of the principal balance of this Note, together with accrued and unpaid interest, if any, thereon, (i) the
Holder shall surrender and deliver this Note, duly endorsed, to the Company against delivery of the Conversion Shares, (ii) in exchange
for, and within one (1) business day following the receipt of, the surrendered Note, the Company shall, at the direction of the Holder,
deliver (or cause to be delivered) to the Holder the Conversion Shares, which shall bear such legends as are required in the opinion of
counsel to the Company, by applicable state and federal securities laws or by any other agreement between the Company and the Holder and
the Company will pay any documentary, stamp or similar issue or transfer tax or duty due on the issue or delivery of any Conversion Share
upon such conversion. Upon such delivery of the Conversion Shares to the Holder, the converted portion of this Note shall automatically
become fully paid and satisfied.
e.
For purposes of this Note: (i) “Conversion Shares” means any shares of Common Stock issued upon conversion
of the principal balance of this Note, together with accrued and unpaid interest, if any, thereon, in accordance with this Section
10; and (ii) “VWAP” means, as of any day or multi-day period, the dollar volume-weighted average price for
a share of Common Stock on the principal securities exchange or securities market on which the Common Stock is then traded during the
period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg through its “HP”
function (set to weighted average).
f. Authorized Shares.
So long as this Note is outstanding, the Company shall take all action necessary, including amending the Company’s governing
documents to authorize and reserve the requisite number of shares of Common Stock, solely for the purpose of effecting the
conversion of this Note, such that the number of shares of Conversion Shares shall be duly and validly authorized, reserved and
available for issuance at the time of the conversion of this Note, and upon issuance in accordance with the terms of this Note, the
Conversion Shares will be duly and validly issued, fully paid and nonassessable and free of restrictions on transfer other than
restrictions on transfer under applicable federal and state securities laws or liens or encumbrances created by or imposed by the
Holder.
11. Notices. Any notice
or communication by the Company or the Holder to the other will be deemed to have been duly given if in writing and delivered in person
or by first class mail (registered or certified, return receipt requested), electronic transmission or other similar means of unsecured
electronic communication or overnight air courier guaranteeing next day delivery, or to the other’s address included on the signature
page hereto. The Company or the Holder, by notice to the other, may designate additional or different addresses (including facsimile
numbers and electronic addresses) for subsequent notices or communications. All notices and communications will be deemed to have been
duly given: (a) at the time delivered by hand, if personally delivered; (b) five (5) business days after being deposited in the mail,
postage prepaid, if mailed; (c) when transmitted, if transmitted by facsimile, electronic transmission or other similar means of unsecured
electronic communication; and (d) the next business day after timely delivery to the courier, if sent by overnight air courier guaranteeing
next day delivery.
12. Governing Law. THIS
NOTE AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS PROMISSORY NOTE WILL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE
WITH THE LAWS OF THE STATE OF NEW YORK. EACH OF THE COMPANY, AND THE HOLDER BY ITS ACCEPTANCE THEREOF IRREVOCABLY WAIVES, TO THE FULLEST
EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS NOTE
OR THE TRANSACTIONS CONTEMPLATED BY THIS NOTE.
13. Severability. Any
provision contained in this Note that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective
to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition
or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.
14. Amendment; Waiver. Any
amendment hereto or waiver of any provision hereof may be made with, and only with, the written consent of the Company and the Holder.
No failure to exercise or delay in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any
single or partial exercise of any right, power or privilege hereunder preclude any further exercise thereof or of any other right, power
or privilege. The rights and remedies herein provided are cumulative and are not exclusive of rights available in law or in equity. Each
party hereto acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the other party hereto and
that the remedy at law for any such breach would be inadequate. Each party hereto therefore agrees that, in the event of any such breach
or threatened breach, the other party hereto shall be entitled, in addition to all other available remedies, to an injunction restraining
any such breach or any such threatened breach, without the necessity of showing economic loss and without any bond or other security
being required.
15. Assignment. No assignment
or transfer of this Note or any rights or obligations hereunder may be made by any party hereto (by operation of law or otherwise) without
the prior written consent of the other party hereto (such consent not to be unreasonably withheld, conditioned or delayed) and any attempted
assignment without the required consent shall be void.
16. Transfer Procedures.
If this Note is to be transferred as permitted under this Note, in whole or in part, the Holder shall surrender this Note to the
Company, whereupon the Company will issue and deliver a new Note to the transferee and, if less than the entire unpaid principal balance
of this Note held by the Holder is being transferred, a new Note to the Holder, representing the portion of the unpaid principal balance
not being transferred.
17. Lost, Stolen, Destroyed
or Mutilated Note. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction
or mutilation of this Note and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Company
in customary form and, in the case of mutilation, upon surrender and cancellation of this Note, the Company shall execute and deliver
to the Holder a replacement Note.
18. Issuance of
Replacement Notes. Whenever the Company is required to issue a new or replacement Note (a “Replacement
Note”) pursuant to the terms of this Note, such Replacement Note (i) shall be of like tenor with this Note, (ii) shall
represent, as indicated on the face of such Replacement Note, the outstanding principal balance of this Note (or, in the case of a
Replacement Note being issued pursuant to Section 17, the outstanding principal balance of this Note designated by the Holder
which, when added to the aggregate outstanding principal balance represented by the other Replacement Notes issued in connection
with such issuance, does not exceed the outstanding principal balance under this Note immediately prior to such issuance of
Replacement Notes), (iii) shall have an issuance date, as indicated on the face of such Replacement Note, which is the same as the
issuance date of this Note, (iv) still be deemed to have accrued its proportional share of interest under this Note from the
issuance date of this Note to the extent unpaid, (v) shall have the same rights and conditions as this Note and (vi) shall be timely
prepared and issued by the Company, but in any event the Company shall issue such Replacement Note not later than five (5) business
days after surrender of this Note or the receipt of the evidence reasonably satisfactory to the Company in accordance with Section
17, as the case may be.
19. Counterparts.
This Note may be executed in any number of counterparts, each of which shall be enforceable against the parties actually executing
such counterparts, and all of which together shall constitute one instrument. The exchange of copies of this Note and signature
pages by email in .pdf or .tif format (and including any electronic signature complying with the U.S. ESIGN Act of 2000, e.g.,
www.docusign.com), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a
document, or by combination of such means, shall constitute effective execution and delivery of this Note as to the parties hereto
and may be used in lieu of the original Note for all purposes. Such execution and delivery shall be considered valid, binding and
effective for all purposes.
[Signature page follows]
IN WITNESS WHEREOF, the parties
to this Note have caused this Note to be duly executed as of the date first written above.
|
SPECTAIRE HOLDINGS INC. |
|
|
|
|
|
By: |
/s/ Leonardo Fernandes |
|
|
Name: |
Leonardo Fernandes |
|
|
Title: |
Chief Financial Officer |
|
|
Address: |
155 Arlington St.,
Watertown, MA 02472 |
|
|
Email: |
lfernandes@spectaire.com |
Accepted and agreed as of the date first written above.
KEYSTONE CAPITAL PARTNERS, LLC |
|
|
|
|
|
By: |
/s/ Fredric Zaino |
|
|
Name: |
Fredric Zaino |
|
|
Title: |
CIO |
|
|
Address: |
139 Fulton Street, NY NY 10038 |
|
|
Email: |
fz@keystone-cp.com |
|
[Signature Page to Convertible Promissory Note]
10
Exhibit 10.3
Execution Version
REGISTRATION RIGHTS AGREEMENT
This REGISTRATION RIGHTS
AGREEMENT (this “Agreement”), dated as of November 17, 2023, is by and between Keystone Capital Partners,
LLC, a Delaware limited liability company (the “Investor”), and Spectaire Holdings, Inc., a Delaware corporation
(the “Company”).
RECITALS
A. The
Company and the Investor have entered into that certain Common Stock Purchase Agreement, dated as of the date hereof (the “Purchase
Agreement”), pursuant to which, from time to time, the Company may issue and sell to the Investor, and the Investor shall
purchase from the Company, up to the lesser of (i) $20,000,000 in aggregate gross purchase price of duly authorized, validly issued, fully
paid and non-assessable shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”)
and (ii) the Exchange Cap, on the terms and subject to the conditions set forth therein.
B. Pursuant
to the terms of, and in consideration for the Investor entering into, the Purchase Agreement, and to induce the Investor to execute and
deliver the Purchase Agreement, the Company has agreed to provide the Investor with certain registration rights with respect to the Registrable
Securities (as defined herein) as set forth herein.
AGREEMENT
NOW, THEREFORE, in consideration
of the representations, warranties, covenants and agreements contained herein and in the Purchase Agreement, and for other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, intending to be legally bound hereby, the Company and the
Investor hereby agree as follows:
1. Definitions.
Capitalized terms used herein
and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement. As used in this Agreement, the
following terms shall have the following meanings:
(a) “Agreement”
shall have the meaning assigned to such term in the preamble of this Agreement
(b) “Allowable Grace Period”
shall have the meaning assigned to such term in Section 3(n).
(c) “Blue Sky Filing” shall have the meaning assigned to such term in Section 6(a).
(d) “Business
Day” means any day other than Saturday, Sunday or any other day on which commercial banks in New York, New York are authorized
or required by law to remain closed.
(e) “Claims” shall have the meaning assigned to such term in Section 6(a).
(f) “Closing Date” shall mean the date of this Agreement.
(g) “Commission”
means the U.S. Securities and Exchange Commission or any successor entity.
(h) “Common
Stock” shall have the meaning assigned to such term in the recitals to this Agreement.
(i) “Company”
shall have the meaning assigned to such term in the preamble of this Agreement.
(j) “Effective
Date” means the date that the applicable Registration Statement has been declared effective by the Commission.
(k) “Filing
Deadline” means (i) with respect to the Initial Registration Statement required to be filed to pursuant to Section 2(a),
the first Business Day that is not less than 10 business days after the date of this Agreement and (ii) with respect to any New Registration
Statements that may be required to be filed by the Company pursuant to this Agreement, the first Business Day that is not less than 30
calendar days following the sale of substantially all of the Registrable Securities included in the Initial Registration Statement or
the most recent prior New Registration Statement, as applicable, or such other date as permitted by the Commission.
(l) “Indemnified
Damages” shall have the meaning assigned to such term in Section 6(a).
(m) “Initial
Registration Statement” shall have the meaning assigned to such term in Section 2(a).
(n) “Investor”
shall have the meaning assigned to such term in the preamble of this Agreement.
(o) “Investor
Party” and “Investor Parties” shall have the meaning assigned to such terms in Section 6(a).
(p) “Legal Counsel” shall have the meaning assigned to such term in Section 2(b).
(q) “New
Registration Statement” shall have the meaning assigned to such term in Section 2(c).
(r) “Person”
means any person or entity, whether a natural person, trustee, corporation, partnership, limited partnership, limited liability company,
trust, unincorporated organization, business association, firm, joint venture, governmental agency or authority.
(s) “Prospectus”
means the prospectus in the form included in the Registration Statement, as supplemented from time to time by any Prospectus Supplement,
including the documents incorporated by reference therein.
(t) “Prospectus
Supplement” means any prospectus supplement to the Prospectus filed with the Commission from time to time pursuant to Rule
424(b) under the Securities Act, including the documents incorporated by reference therein.
(u) “Purchase
Agreement” shall have the meaning assigned to such term in the recitals to this Agreement.
(v) “register,”
“registered,” and “registration” refer to a registration effected by preparing and
filing one or more Registration Statements in compliance with the Securities Act and pursuant to Rule 415 and the declaration of effectiveness
of such Registration Statement(s) by the Commission.
(w)
“Registrable Securities” means all of (i) the Shares, (ii) the Note Shares, and (iii) any capital stock of
the Company issued or issuable with respect to such Shares or Note Shares, including, without limitation, (1) as a result of any
stock split, stock dividend, recapitalization, exchange or similar event or otherwise and (2) shares of capital stock of the Company
into which the shares of Common Stock are converted or exchanged and shares of capital stock of a successor entity into which the
shares of Common Stock are converted or exchanged, in each case until such time as such securities cease to be Registrable
Securities; provided, however, that, as to any particular Registrable Security, such securities shall cease to be Registrable
Securities upon the earliest to occur of: (A) a Registration Statement with respect to the sale of such securities shall have become
effective under the Securities Act and such securities shall have been sold, transferred, disposed of or exchanged in accordance
with such Registration Statement by the Investor; (B)(i) such securities shall have been otherwise transferred, (ii) new
certificates for such securities not bearing (or book-entry positions not subject to) a legend restricting further transfer shall
have been delivered by the Company and (iii) subsequent public distribution of such securities shall not require registration under
the Securities Act; (C) such securities shall have ceased to be outstanding; (D) such securities may be sold without registration
pursuant to Rule 144 or any successor rule promulgated under the Securities Act (but with no limitation as to volume or manner of
sale); (E) such securities have been sold to, or through, a broker, dealer or underwriter in a public distribution or other public
securities transaction; and (F) the date that is the later of (A) the first (1st) anniversary of the date of termination
of the Purchase Agreement in accordance with Article VIII of the Purchase Agreement and (B) the first (1st) anniversary
of the date of the last sale of any Registrable Securities to the Investor pursuant to the Purchase Agreement.
(x) “Registration
Statement” means a registration statement or registration statements of the Company filed under the Securities Act covering
the resale by the Investor of Registrable Securities, as such registration statement or registration statements may be amended and supplemented
from time to time, including all documents filed as part thereof or incorporated by reference therein.
(y) “Registration Period” shall have the meaning assigned to such term in Section 3(a).
(z) “Rule
144” means Rule 144 promulgated by the Commission under the Securities Act, as such rule may be amended from time to time,
or any other similar or successor rule or regulation of the Commission that may at any time permit the Investor to sell securities of
the Company to the public without registration.
(aa) “Rule 415”
means Rule 415 promulgated by the Commission under the Securities Act, as such rule may be amended from time to time, or any other similar
or successor rule or regulation of the Commission providing for offering securities on a delayed or continuous basis.
(bb) “Staff” shall have the meaning assigned
to such term in Section 2(e).
(cc) “Violations” shall have the meaning
assigned to such term in Section 6(a).
2. Registration.
(a) Mandatory
Registration. The Company shall prepare and, as soon as reasonably practicable, but in no event later than the Filing Deadline,
file with the Commission an initial Registration Statement on Form S-1 (or any successor form) covering the resale by the Investor
of (i) all of the Note Shares then issued and (ii) the maximum number of additional Registrable Securities as shall be permitted to
be included thereon in accordance with applicable Commission rules, regulations and interpretations so as to permit the resale of
such Registrable Securities by the Investor under Rule 415 under the Securities Act at then prevailing market prices (and not fixed
prices) (the “Initial Registration Statement”). Unless otherwise agreed in writing (email being
sufficient) by the Company and the Investor, such initial Registration Statement shall contain the “Selling Stockholder”
and “Plan of Distribution” sections in substantially the form attached hereto as Exhibit A. The Company shall use
its commercially reasonable efforts to have the Initial Registration Statement declared effective by the Commission as soon as
reasonably practicable. With regard to each comment letter or telephonic comment received from the SEC regarding the Initial
Registration Statement, the Company shall prepare and file an appropriate amendment to the Registration Statement and an appropriate
comment response letter within ten (10) business days following the date such comments are received.
(b) Legal
Counsel. Subject to Section 5 hereof, the Investor shall have the right to select one legal counsel to review and oversee, solely
on its behalf, any registration pursuant to this Section 2 (“Legal Counsel”), which shall be McMurdo Law Group,
LLC, or such other counsel as thereafter designated by the Investor. Except as provided under Section 10.1(i) of the Purchase Agreement,
the Investor shall be solely responsible for all (and the Company shall have no obligation to reimburse the Investor for any) legal fees
and expenses of the Legal Counsel incurred in connection with the transactions contemplated hereby.
(c) Sufficient Number
of Shares Registered. If at any time all Registrable Securities are not covered by the Initial Registration Statement filed
pursuant to Section 2(a) as a result of Section 2(e) or otherwise, and if the Company desires to sell additional Shares to the
Investor under the Agreement, the Company shall then use its commercially reasonable efforts to file with the Commission one or more
additional Registration Statements so as to cover all of the Registrable Securities not covered by such initial Registration
Statement, in each case, as soon as practicable (taking into account any position of the staff of the Commission
(“Staff”) with respect to the date on which the Staff will permit such additional Registration
Statement(s) to be filed with the Commission and the rules and regulations of the Commission) (each such additional Registration
Statement, a “New Registration Statement”), but in no event later than the applicable Filing Deadline for
such New Registration Statement(s). The Company shall use its commercially reasonable efforts to cause each such New Registration
Statement to become effective as soon as practicable following the filing thereof with the Commission. With regard to each comment
letter or telephonic comment received from the SEC regarding the New Registration Statement, the Company shall prepare and file an
appropriate amendment to the Registration Statement and an appropriate comment response letter within ten (10) business days
following the date such comments are received.
(d) No
Inclusion of Other Securities. In no event shall the Company include any securities other than Registrable Securities on any Registration
Statement pursuant to Section 2(a) or Section 2(c) without consulting the Investor and Legal Counsel prior to filing such Registration
Statement with the Commission.
(e) Offering.
If the Staff or the Commission seeks to characterize any offering pursuant to a Registration Statement filed pursuant to this Agreement
as constituting an offering of securities that does not permit such Registration Statement to become effective and be used for resales
by the Investor on a delayed or continuous basis under Rule 415 at then-prevailing market prices (and not fixed prices), or if after the
filing of any Registration Statement pursuant to Section 2(a) or Section 2(c), the Company is otherwise required by the Staff or the Commission
to reduce the number of Registrable Securities included in such Registration Statement, then the Company shall reduce the number of Registrable
Securities to be included in such Registration Statement (after consultation with the Investor and Legal Counsel as to the specific Registrable
Securities to be removed therefrom) until such time as the Staff and the Commission shall so permit such Registration Statement to become
effective and be used as aforesaid. Notwithstanding anything in this Agreement to the contrary, if after giving effect to the actions
referred to in the immediately preceding sentence, the Staff or the Commission does not permit such Registration Statement to become effective
and be used for resales by the Investor on a delayed or continuous basis under Rule 415 at then-prevailing market prices (and not fixed
prices), the Company shall not request acceleration of the Effective Date of such Registration Statement, the Company shall promptly (but
in no event later than 48 hours) request the withdrawal of such Registration Statement pursuant to Rule 477 under the Securities Act.
In the event of any reduction in Registrable Securities pursuant to this paragraph, if the Company desires to sell any Shares to the Investor
that are not covered by a Registration Statement or New Registration Statement, the Company shall then use its commercially reasonable
efforts to file one or more New Registration Statements with the Commission in accordance with Section 2(c) until such time as all Registrable
Securities have been included in Registration Statements that have been declared effective and the Prospectuses contained therein are
available for use by the Investor.
3. Related Obligations.
The Company shall use its
commercially reasonable efforts to effect the registration of the Registrable Securities in accordance with the intended method of disposition
thereof, and, pursuant thereto, the Company shall have the following obligations:
(a) The Company shall
promptly prepare and file with the Commission the Initial Registration Statement pursuant to Section 2(a) hereof and one or more New
Registration Statements pursuant to Section 2(c) hereof with respect to the Registrable Securities, but in no event later than the
applicable Filing Deadline therefor, and the Company use its commercially reasonable efforts to cause each such Registration
Statement to become effective as soon as practicable after such filing. Subject to Allowable Grace Periods, the Company shall keep
each Registration Statement effective (and the Prospectus contained therein available for use) pursuant to Rule 415 for resales by
the Investor on a continuous basis at then-prevailing market prices (and not fixed prices) at all times until the earlier of (i) the
date on which the Investor shall have sold all of the Registrable Securities covered by such Registration Statement and (ii) the
date of termination of the Purchase Agreement if as of such termination date the Investor holds no Registrable Securities (or, if
applicable, the date on which such securities cease to be Registrable Securities after the date of termination of the Purchase
Agreement) (the “Registration Period”). Notwithstanding anything to the contrary contained in this
Agreement (but subject to the provisions of Section 3(o) hereof), the Company shall ensure that, when filed and at all times while
effective, each Registration Statement (including, without limitation, all amendments and supplements thereto) and the Prospectus
(including, without limitation, all amendments and supplements thereto) used in connection with such Registration Statement shall
not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to
make the statements therein (in the case of Prospectuses, in the light of the circumstances in which they were made) not misleading.
The Company shall submit to the Commission, as soon as reasonably practicable after the date that the Company learns that no review
of a particular Registration Statement will be made by the Staff or that the Staff has no further comments on a particular
Registration Statement (as the case may be), a request for acceleration of effectiveness of such Registration Statement to a time
and date as soon as reasonably practicable in accordance with Rule 461 under the Securities Act.
(b) Subject to Section 3(o)
of this Agreement, the Company shall use its commercially reasonable efforts to prepare and file with the Commission such amendments
(including, without limitation, post-effective amendments) and supplements to each Registration Statement and the Prospectus used in
connection with each such Registration Statement, which Prospectus is to be filed pursuant to Rule 424 promulgated under the Securities
Act, as may be necessary to keep each such Registration Statement effective (and the Prospectus contained therein current and available
for use) at all times during the Registration Period for such Registration Statement, and, during such period, comply with the provisions
of the Securities Act with respect to the disposition of all Registrable Securities of the Company required to be covered by such Registration
Statement until such time as all of such Registrable Securities shall have been disposed of in accordance with the intended methods of
disposition by the Investor. Without limiting the generality of the foregoing, the Company covenants and agrees that (i) at or before
5:30 p.m. (New York City time) on the second (2nd) Trading Day immediately following the Effective Date of the Initial Registration
Statement and any New Registration Statement (or any post-effective amendment thereto), the Company shall file with the Commission in
accordance with Rule 424(b) under the Securities Act the final Prospectus to be used in connection with sales pursuant to such Registration
Statement (or post-effective amendment thereto), and (ii) if the transactions contemplated by any Fixed Purchase are material to the
Company (individually or collectively with all other prior Fixed Purchases, the consummation of which have not previously been reported
in any Prospectus Supplement filed with the Commission under Rule 424(b) under the Securities Act or in any report, statement or other
document filed by the Company with the Commission under the Exchange Act), or if otherwise required under the Securities Act (or the
interpretations of the Commission thereof), in each case as reasonably determined by the Company and the Investor, then, at or before
8:30 a.m., New York City time, on the first (1st) Trading Day immediately following the Fixed Purchase Date with respect to
such Fixed Purchase, the Company shall file with the Commission a Prospectus Supplement pursuant to Rule 424(b) under the Securities
Act with respect to the applicable Fixed Purchase(s), disclosing the total number of Shares that are to be (and, if applicable, have
been) issued and sold to the Investor pursuant to such Fixed Purchase(s), the total purchase price for the Shares subject to such Fixed
Purchase(s), the applicable purchases price(s) for such Shares and the net proceeds that are to be (and, if applicable, have been) received
by the Company from the sale of such Shares. To the extent not previously disclosed in the Prospectus or a Prospectus Supplement, the
Company shall disclose in its Quarterly Reports on Form 10-Q and in its Annual Reports on Form 10-K the information described in the
immediately preceding sentence relating to all Fixed Purchase(s) consummated during the relevant fiscal quarter and shall file such Quarterly
Reports and Annual Reports with the Commission within the applicable time period prescribed for such report under the Exchange Act. In
the case of amendments and supplements to any Registration Statement on Form S-1 or Prospectus related thereto which are required to
be filed pursuant to this Agreement (including, without limitation, pursuant to this Section 3(b)) by reason of the Company filing a
report on Form 8-K, Form 10-Q or Form 10-K or any analogous report under the Exchange Act, the Company shall have incorporated such report
by reference into such Registration Statement and Prospectus, if applicable, or shall file such amendments or supplements to the Registration
Statement or Prospectus with the Commission on the same day on which the Exchange Act report is filed which created the requirement for
the Company to amend or supplement such Registration Statement or Prospectus, for the purpose of including or incorporating such report
into such Registration Statement and Prospectus. The Company consents to the use of the Prospectus (including, without limitation, any
supplement thereto) included in each Registration Statement in accordance with the provisions of the Securities Act and with the securities
or “Blue Sky” laws of the jurisdictions in which the Registrable Securities may be sold by the Investor, in connection with
the resale of the Registrable Securities and for such period of time thereafter as such Prospectus (including, without limitation, any
supplement thereto) (or in lieu thereof, the notice referred to in Rule 173(a) under the Securities Act) is required by the Securities
Act to be delivered in connection with resales of Registrable Securities.
(c) The Company shall
(A) permit Legal Counsel an opportunity to review and comment upon (i) each Registration Statement at least two (2) Business Days
prior to its filing with the Commission (or such shorter period as required by applicable securities laws) and (ii) all amendments
and supplements to each Registration Statement (including, without limitation, the Prospectus contained therein) (except for Annual
Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any similar or successor reports or
Prospectus Supplements the contents of which is limited to that set forth in such reports) within a reasonable number of days prior
to their filing with the Commission, and (B) shall reasonably consider any comments of the Investor and Legal Counsel on any such
Registration Statement or amendment or supplement thereto or to any Prospectus contained therein. The Company shall promptly furnish
to Legal Counsel, without charge, (i) electronic copies of any correspondence from the Commission or the Staff to the Company or its
representatives relating to each Registration Statement (which correspondence shall be redacted to exclude any material, non-public
information regarding the Company or any of its Subsidiaries), (ii) after the same is prepared and filed with the Commission, one
(1) electronic copy of each Registration Statement and any amendment(s) and supplement(s) thereto, including, without limitation,
financial statements and schedules, all documents incorporated therein by reference, if requested by the Investor, and all exhibits
and (iii) upon the effectiveness of each Registration Statement, one (1) electronic copy of the Prospectus included in such
Registration Statement and all amendments and supplements thereto; provided, however, the Company shall not be required to furnish
any document (other than the Prospectus, which may be provided in .PDF format) to Legal Counsel to the extent such document is
available on EDGAR).
(d) Without
limiting any obligation of the Company under the Purchase Agreement, the Company shall promptly furnish to the Investor, without charge,
(i) after the same is prepared and filed with the Commission, at least one (1) electronic copy of each Registration Statement and any
amendment(s) and supplement(s) thereto, including, without limitation, financial statements and schedules, all documents incorporated
therein by reference, if requested by the Investor, all exhibits thereto, (ii) upon the effectiveness of each Registration Statement,
one (1) electronic copy of the Prospectus included in such Registration Statement and all amendments and supplements thereto (or such
other number of copies as the Investor may reasonably request from time to time) and (iii) such other documents, including, without limitation,
copies of any final Prospectus and any Prospectus Supplement thereto, as the Investor may reasonably request from time to time in order
to facilitate the disposition of the Registrable Securities owned by the Investor; provided, however, the Company shall not be required
to furnish any document (other than the Prospectus, which may be provided in .PDF format) to the Investor to the extent such document
is available on EDGAR).
(e) The
Company shall take such action as is reasonably necessary to (i) register and qualify, unless an exemption from registration and qualification
applies, the resale by the Investor of the Registrable Securities covered by a Registration Statement under such other securities or “Blue
Sky” laws of all applicable jurisdictions in the United States, (ii) prepare and file in those jurisdictions, such amendments (including,
without limitation, post-effective amendments) and supplements to such registrations and qualifications as may be necessary to maintain
the effectiveness thereof during the Registration Period, (iii) take such other actions as may be reasonably necessary to maintain such
registrations and qualifications in effect at all times during the Registration Period, and (iv) take all other actions reasonably necessary
or advisable to qualify the Registrable Securities for sale in such jurisdictions; provided, however, the Company shall
not be required in connection therewith or as a condition thereto to (x) qualify to do business in any jurisdiction where it would not
otherwise be required to qualify but for this Section 3(e), (y) subject itself to general taxation in any such jurisdiction, or (z) file
a general consent to service of process in any such jurisdiction. The Company shall promptly notify Legal Counsel and the Investor of
the receipt by the Company of any notification with respect to the suspension of the registration or qualification of any of the Registrable
Securities for sale under the securities or “Blue Sky” laws of any jurisdiction in the United States or its receipt of actual
notice of the initiation or threatening of any proceeding for such purpose.
(f) The Company shall
notify Legal Counsel and the Investor in writing of the happening of any event, as promptly as reasonably practicable after becoming
aware of such event, as a result of which the Prospectus included in a Registration Statement, as then in effect, includes an untrue
statement of a material fact or omission to state a material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading (provided that in no event shall such notice
contain any material, non-public information regarding the Company or any of its Subsidiaries), and, subject to Section 3(o),
promptly prepare a supplement or amendment to such Registration Statement and such Prospectus contained therein to correct such
untrue statement or omission and deliver one (1) electronic copy of such supplement or amendment to Legal Counsel and the Investor
(or such other number of copies as Legal Counsel or the Investor may reasonably request). The Company shall also promptly notify
Legal Counsel and the Investor in writing (i) when a Prospectus or any Prospectus Supplement or post-effective amendment has been
filed, when a Registration Statement or any post-effective amendment has become effective (notification of such effectiveness shall
be delivered to Legal Counsel and the Investor by facsimile or e-mail on the same day of such effectiveness and by overnight mail),
and when the Company receives written notice from the Commission that a Registration Statement or any post-effective amendment will
be reviewed by the Commission, (ii) of any request by the Commission for amendments or supplements to a Registration Statement or
related Prospectus or related information, (iii) of the Company’s reasonable determination that a post-effective amendment to
a Registration Statement would be appropriate and (iv) of the receipt of any request by the Commission or any other federal or state
governmental authority for any additional information relating to the Registration Statement or any amendment or supplement thereto
or any related Prospectus. The Company shall respond as promptly as reasonably practicable to any comments received from the
Commission with respect to a Registration Statement or any amendment thereto. Nothing in this Section 3(f) shall limit any
obligation of the Company under the Purchase Agreement.
(g) The
Company shall (i) use its commercially reasonable efforts to prevent the issuance of any stop order or other suspension of effectiveness
of a Registration Statement or the use of any Prospectus contained therein, or the suspension of the qualification, or the loss of an
exemption from qualification, of any of the Registrable Securities for sale in any jurisdiction and, if such an order or suspension is
issued, to obtain the withdrawal of such order or suspension at the earliest possible time and (ii) notify Legal Counsel and the Investor
of the issuance of such order and the resolution thereof or its receipt of actual notice of the initiation or threat of any proceeding.
(h) The Company shall
hold in confidence and not make any disclosure of information concerning the Investor provided to the Company unless (i) disclosure
of such information is necessary to comply with federal or state securities laws, (ii) the disclosure of such information is
necessary to avoid or correct a misstatement or omission in any Registration Statement or is otherwise required to be disclosed in
such Registration Statement pursuant to the Securities Act, (iii) the release of such information is ordered pursuant to a subpoena
or other final, non-appealable order from a court or governmental body of competent jurisdiction, or (iv) such information has been
made generally available to the public other than by disclosure in violation of this Agreement or any other Transaction Document.
The Company agrees that it shall, upon learning that disclosure of such information concerning the Investor is sought in or by a
court or governmental body of competent jurisdiction or through other means, give prompt written notice to the Investor and allow
the Investor, at the Investor’s expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective
order for, such information.
(i) The Company shall
cooperate with the Investor and, to the extent applicable, facilitate the timely preparation and delivery of Registrable Securities,
as DWAC Shares, to be offered pursuant to a Registration Statement and enable such DWAC Shares to be in such denominations or
amounts (as the case may be) as the Investor may reasonably request from time to time and registered in such names as the Investor
may request. Investor hereby agrees that it shall cooperate with the Company, its counsel and Transfer Agent in connection with any
issuances of DWAC Shares, and hereby represents, warrants and covenants to the Company that that it will resell such DWAC Shares
only pursuant to the Registration Statement in which such DWAC Shares are included, in a manner described under the caption
“Plan of Distribution” in such Registration Statement, and in a manner in compliance with all applicable U.S. federal
and state securities laws, rules and regulations, including, without limitation, any applicable prospectus delivery requirements of
the Securities Act. DWAC Shares shall be free from all restrictive legends may be transmitted by the transfer agent to the Investor
by crediting an account at DTC as directed in writing by the Investor.
(j) The
Company shall use its commercially reasonable efforts to cause the Registrable Securities covered by a Registration Statement to be registered
with or approved by such other governmental agencies or authorities as may be necessary to consummate the disposition of such Registrable
Securities.
(l) The
Company shall otherwise use its commercially reasonable efforts to comply with all applicable rules and regulations of the Commission
in connection with any registration hereunder.
(m) Within
one (1) Business Day after each Registration Statement which covers Registrable Securities is declared effective by the Commission, the
Company shall deliver to the transfer agent for such Registrable Securities (with copies to the Investor) confirmation that such Registration
Statement has been declared effective by the Commission.
(n) Notwithstanding
anything to the contrary contained herein (but subject to the last sentence of this Section 3(n)), at any time after the Effective
Date of a particular Registration Statement, the Company may, upon written notice to Investor, suspend Investor’s use of any
prospectus that is a part of any Registration Statement (in which event the Investor shall discontinue sales of the Registrable
Securities pursuant to such Registration Statement contemplated by this Agreement, but shall settle any previously made sales of
Registrable Securities) if the Company (x) is pursuing an acquisition, merger, tender offer, reorganization, disposition or other
similar transaction and the Company determines in good faith that (A) the Company’s ability to pursue or consummate such a
transaction would be materially adversely affected by any required disclosure of such transaction in such Registration Statement or
other registration statement or (B) such transaction renders the Company unable to comply with Commission requirements, in each case
under circumstances that would make it impractical or inadvisable to cause any Registration Statement (or such filings) to be used
by Investor or to promptly amend or supplement any Registration Statement contemplated by this Agreement on a post effective basis,
as applicable, or (y) has experienced some other material non-public event the disclosure of which at such time, in the good faith
judgment of the Company, would materially adversely affect the Company (each, an “Allowable Grace
Period”); provided, however, that in no event shall the Investor be suspended from selling Registrable
Securities pursuant to any Registration Statement for a period that exceeds 60 consecutive calendar days or an aggregate of 120
calendar days in any 365-day period. Upon disclosure of such information or the termination of the condition described above, the
Company shall provide prompt notice, but in any event within one Business Day of such disclosure or termination, to the Investor and
shall promptly terminate any suspension of sales it has put into effect and shall take such other reasonable actions to permit
registered sales of Registrable Securities as contemplated in this Agreement (including as set forth in the first sentence of
Section 3(f) with respect to the information giving rise thereto unless such material, non-public information is no longer
applicable). Notwithstanding anything to the contrary contained in this Section 3(n), the Company shall cause its transfer agent to
deliver DWAC Shares to a transferee of the Investor in accordance with the terms of the Purchase Agreement in connection with any
sale of Registrable Securities with respect to which (i) the Company has made a sale to Investor and (ii) the Investor has entered
into a contract for sale, and delivered a copy of the Prospectus included as part of the particular Registration Statement to the
extent applicable, in each case prior to the Investor’s receipt of the notice of an Allowable Grace Period and for which the
Investor has not yet settled.
4. Obligations of the Investor.
(a) At
least two (2) Business Days prior to the first anticipated filing date of each Registration Statement (or such shorter period to which
the parties agree), the Company shall notify the Investor in writing of the information the Company requires from the Investor with respect
to such Registration Statement. It shall be a condition precedent to the obligations of the Company to complete the registration pursuant
to this Agreement with respect to the Registrable Securities of the Investor that the Investor shall furnish to the Company such information
regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it,
as shall be reasonably required to effect and maintain the effectiveness of the registration of such Registrable Securities and shall
execute such documents in connection with such registration as the Company may reasonably request.
(b) The
Investor, by its acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested by the Company
in connection with the preparation and filing of each Registration Statement hereunder, unless the Investor has notified the Company in
writing of the Investor’s election to exclude all of the Investor’s Registrable Securities from such Registration Statement.
(c) The
Investor agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Section 3(l)
or the first sentence of 3(f), the Investor shall immediately discontinue disposition of Registrable Securities pursuant to any Registration
Statement(s) covering such Registrable Securities until the Investor’s receipt of the copies of the supplemented or amended Prospectus
contemplated by Section 3(l) or the first sentence of Section 3(f) or receipt of notice that no supplement or amendment is required. Notwithstanding
anything to the contrary in this Section 4(c), the Company shall cause its transfer agent to deliver DWAC Shares to a transferee of the
Investor in accordance with the terms of the Purchase Agreement in connection with any sale of Registrable Securities with respect to
which the Investor has entered into a contract for sale prior to the Investor’s receipt of a notice from the Company of the happening
of any event of the kind described in Section 3(l) or the first sentence of Section 3(f) and for which the Investor has not yet settled.
(d) The
Investor covenants and agrees that it shall comply with the prospectus delivery and other requirements of the Securities Act as applicable
to it in connection with sales of Registrable Securities pursuant to a Registration Statement.
5. Expenses of Registration.
All reasonable expenses of
the Company, other than sales or brokerage commissions and fees and disbursements of counsel for, and other expenses of, the Investor,
incurred in connection with registrations, filings or qualifications pursuant to Sections 2 and 3, including, without limitation, all
registration, listing and qualifications fees, printers and accounting fees, and fees and disbursements of counsel for the Company, shall
be paid by the Company.
6. Indemnification.
(a) In the event any Registrable
Securities are included in any Registration Statement under this Agreement, to the fullest extent permitted by law, the Company will,
and hereby does, indemnify, hold harmless and defend the Investor, each of its directors, officers, shareholders, members, partners,
employees, agents, advisors, representatives (and any other Persons with a functionally equivalent role of a Person holding such titles
notwithstanding the lack of such title or any other title) and each Person, if any, who controls the Investor within the meaning of the
Securities Act or the Exchange Act and each of the directors, officers, shareholders, members, partners, employees, agents, advisors,
representatives (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding the lack of
such title or any other title) of such controlling Persons (each, an “Investor Party” and collectively, the
“Investor Parties”), against any losses, obligations, claims, damages, liabilities, contingencies, judgments,
fines, penalties, charges, costs (including, without limitation, court costs, reasonable attorneys’ fees, costs of defense and
investigation), amounts paid in settlement or expenses, joint or several, (collectively, “Claims”) reasonably
incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the
foregoing by or before any court or governmental, administrative or other regulatory agency, body or the Commission, whether pending
or threatened, whether or not an Investor Party is or may be a party thereto (“Indemnified Damages”), to which
any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect thereof)
arise out of or are based upon: (i) any untrue statement or alleged untrue statement of a material fact in a Registration Statement or
any post-effective amendment thereto or in any filing made in connection with the qualification of the offering under the securities
or other “Blue Sky” laws of any jurisdiction in which Registrable Securities are offered (“Blue Sky Filing”),
or the omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein
not misleading or (ii) any untrue statement or alleged untrue statement of a material fact contained in any Prospectus (as amended or
supplemented) or in any Prospectus Supplement or the omission or alleged omission to state therein any material fact necessary to make
the statements made therein, in light of the circumstances under which the statements therein were made, not misleading (the matters
in the foregoing clauses (i) and (ii) being, collectively, “Violations”). Subject to Section 6(c), the Company
shall reimburse the Investor Parties, promptly as such expenses are incurred and are due and payable, for any legal fees or other reasonable
expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained
herein, the indemnification agreement contained in this Section 6(a): (i) shall not apply to a Claim by an Investor Party arising out
of or based upon a Violation which occurs in reliance upon and in conformity with information furnished in writing to the Company by
such Investor Party for such Investor Party expressly for use in connection with the preparation of such Registration Statement, Prospectus
or Prospectus Supplement or any such amendment thereof or supplement thereto (it being hereby acknowledged and agreed that the written
information set forth on Exhibit B attached hereto is the only written information furnished to the Company by or on behalf of
the Investor expressly for use in any Registration Statement, Prospectus or Prospectus Supplement); (ii) shall not be available to the
Investor to the extent such Claim is based on a failure of the Investor to deliver or to cause to be delivered the Prospectus (as amended
or supplemented) made available by the Company (to the extent applicable), including, without limitation, a corrected Prospectus, if
such Prospectus (as amended or supplemented) or corrected Prospectus was timely made available by the Company pursuant to Section 3(d)
and then only if, and to the extent that, following the receipt of the corrected Prospectus no grounds for such Claim would have existed;
and (iii) shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent
of the Company, which consent shall not be unreasonably withheld or delayed. Such indemnity shall remain in full force and effect regardless
of any investigation made by or on behalf of the Investor Party and shall survive the transfer of any of the Registrable Securities by
the Investor pursuant to Section 9.
(b) In
connection with any Registration Statement in which the Investor is participating, the Investor agrees to severally and not jointly indemnify,
hold harmless and defend, to the same extent and in the same manner as is set forth in Section 6(a), the Company, each of its directors,
each of its officers who signs the Registration Statement and each Person, if any, who controls the Company within the meaning of the
Securities Act or the Exchange Act (each, an “Company Party”), against any Claim or Indemnified Damages to which
any of them may become subject, under the Securities Act, the Exchange Act or otherwise, insofar as such Claim or Indemnified Damages
arise out of or are based upon any Violation, in each case, to the extent, and only to the extent, that such Violation occurs in reliance
upon and in conformity with written information relating to the Investor furnished to the Company by the Investor expressly for use in
connection with such Registration Statement, the Prospectus included therein or any Prospectus Supplement thereto (it being hereby acknowledged
and agreed that the written information set forth on Exhibit B attached hereto is the only written information furnished to the
Company by or on behalf of the Investor expressly for use in any Registration Statement, Prospectus or Prospectus Supplement); and, subject
to Section 6(c) and the below provisos in this Section 6(b), the Investor shall reimburse a Company Party any legal or other expenses
reasonably incurred by such Company Party in connection with investigating or defending any such Claim; provided, however,
the indemnity agreement contained in this Section 6(b) and the agreement with respect to contribution contained in Section 7 shall not
apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Investor, which
consent shall not be unreasonably withheld or delayed; and provided, further that the Investor shall be liable under this Section
6(b) for only that amount of a Claim or Indemnified Damages as does not exceed the net proceeds to the Investor as a result of the applicable
sale of Registrable Securities pursuant to such Registration Statement, Prospectus or Prospectus Supplement. Such indemnity shall remain
in full force and effect regardless of any investigation made by or on behalf of such Company Party and shall survive the transfer of
any of the Registrable Securities by the Investor pursuant to Section 9.
(c) Promptly after
receipt by an Investor Party or Company Party (as the case may be) under this Section 6 of notice of the commencement of any action
or proceeding (including, without limitation, any governmental action or proceeding) involving a Claim, such Investor Party or
Company Party (as the case may be) shall, if a Claim in respect thereof is to be made against any indemnifying party under this
Section 6, deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the
right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly
noticed, to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and the Investor
Party or the Company Party (as the case may be); provided, however, an Investor Party or Company Party (as the case
may be) shall have the right to retain its own counsel with the fees and expenses of such counsel to be paid by the indemnifying
party if: (i) the indemnifying party has agreed in writing to pay such fees and expenses; (ii) the indemnifying party shall have
failed promptly to assume the defense of such Claim and to employ counsel reasonably satisfactory to such Investor Party or Company
Party (as the case may be) in any such Claim; or (iii) the named parties to any such Claim (including, without limitation, any
impleaded parties) include both such Investor Party or Company Party (as the case may be) and the indemnifying party, and such
Investor Party or such Company Party (as the case may be) shall have been advised by counsel that a conflict of interest is likely
to exist if the same counsel were to represent such Investor Party or such Company Party and the indemnifying party (in which case,
if such Investor Party or such Company Party (as the case may be) notifies the indemnifying party in writing that it elects to
employ separate counsel at the expense of the indemnifying party, then the indemnifying party shall not have the right to assume the
defense thereof on behalf of the indemnified party and such counsel shall be at the expense of the indemnifying party, provided
further that in the case of clause (iii) above the indemnifying party shall not be responsible for the reasonable fees and
expenses of more than one (1) separate legal counsel for all Investor Parties or Company Parties (as the case may be). The Company
Party or Investor Party (as the case may be) shall reasonably cooperate with the indemnifying party in connection with any
negotiation or defense of any such action or Claim by the indemnifying party and shall furnish to the indemnifying party all
information reasonably available to the Company Party or Investor Party (as the case may be) which relates to such action or Claim.
The indemnifying party shall keep the Company Party or Investor Party (as the case may be) reasonably apprised at all times as to
the status of the defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable for any
settlement of any action, claim or proceeding effected without its prior written consent; provided, however, the
indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without the prior
written consent of the Company Party or Investor Party (as the case may be), consent to entry of any judgment or enter into any
settlement or other compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff to
such Company Party or Investor Party (as the case may be) of a release from all liability in respect to such Claim or litigation,
and such settlement shall not include any admission as to fault on the part of the Company Party. For the avoidance of doubt, the
immediately preceding sentence shall apply to Sections 6(a) and 6(b) hereof. Following indemnification as provided for hereunder,
the indemnifying party shall be subrogated to all rights of the Company Party or Investor Party (as the case may be) with respect to
all third parties, firms or corporations relating to the matter for which indemnification has been made. The failure to deliver
written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve such
indemnifying party of any liability to the Investor Party or Company Party (as the case may be) under this Section 6, except to the
extent that the indemnifying party is materially and adversely prejudiced in its ability to defend such action.
(d) No Person involved in the sale of
Registrable Securities who is guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) in
connection with such sale shall be entitled to indemnification from any Person involved in such sale of Registrable Securities who
is not guilty of fraudulent misrepresentation.
(e) The
indemnification required by this Section 6 shall be made by periodic payments of the amount thereof during the course of the investigation
or defense, as and when bills are received or Indemnified Damages are incurred; provided that any Person receiving any payment
pursuant to this Section 6 shall promptly reimburse the Person making such payment for the amount of such payment to the extent a court
of competent jurisdiction determines that such Person receiving such payment was not entitled to such payment.
(f) The indemnity and
contribution agreements contained herein shall be in addition to (i) any cause of action or similar right of the Company Party or
Investor Party against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject to pursuant
to the law.
7. Contribution.
To the extent any
indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum
contribution with respect to any amounts for which it would otherwise be liable under Section 6 to the fullest extent permitted by
law; provided, however: (i) no contribution shall be made under circumstances where the maker would not have been
liable for indemnification under the fault standards set forth in Section 6 of this Agreement, (ii) no Person involved in the sale
of Registrable Securities which Person is guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the
Securities Act) in connection with such sale shall be entitled to contribution from any Person involved in such sale of Registrable
Securities who was not guilty of fraudulent misrepresentation; and (iii) contribution by any seller of Registrable Securities shall
be limited in amount to the amount of net proceeds received by such seller from the applicable sale of such Registrable Securities
pursuant to such Registration Statement. Notwithstanding the provisions of this Section 7, the Investor shall not be required to
contribute, in the aggregate, any amount in excess of the amount by which the net proceeds actually received by the Investor from
the applicable sale of the Registrable Securities subject to the Claim exceeds the amount of any damages that the Investor has
otherwise been required to pay, or would otherwise be required to pay under Section 6(b), by reason of such untrue or alleged untrue
statement or omission or alleged omission.
8. Reports Under the Exchange Act.
With a view to making available
to the Investor the benefits of Rule 144, the Company agrees to:
(a) so
long as the Investor owns Registrable Securities, use its reasonable best efforts to make and keep public information available, as those
terms are understood and defined in Rule 144;
(b) so long as the
Investor owns Registrable Securities, use its reasonable best efforts to file with the Commission in a timely manner all reports and
other documents required of the Company under the Securities Act and the Exchange Act so long as the Company remains subject to such
requirements (it being understood that nothing herein shall limit any of the Company’s obligations under the Purchase
Agreement) and the filing of such reports and other documents is required for the applicable provisions of Rule 144;
(c) furnish to the
Investor so long as the Investor owns Registrable Securities, promptly upon request, (i) a written statement by the Company, if
true, that it has complied with the reporting, submission and posting requirements of Rule 144 and the Exchange Act, if applicable
(ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the
Company with the Commission if such reports are not publicly available via EDGAR, and (iii) such other information as may be
reasonably requested to permit the Investor to sell such securities pursuant to Rule 144 without registration; and
(d) take
such additional action as is reasonably requested by the Investor to enable the Investor to sell the Registrable Securities pursuant to
Rule 144, including, without limitation, delivering all such legal opinions, consents, certificates, resolutions and instructions to the
Company’s Transfer Agent as may be reasonably requested from time to time by the Investor and otherwise fully cooperate with Investor
and Investor’s broker to effect such sale of securities pursuant to Rule 144.
9. Assignment of Registration Rights.
The Company shall not assign
this Agreement or any rights or obligations hereunder without the prior written consent of the Investor; provided, however, that any transaction,
whether by merger, reorganization, restructuring, consolidation, financing or otherwise, whereby the Company remains the surviving entity
immediately after such transaction shall not be deemed an assignment. The Investor may not assign its rights under this Agreement without
the prior written consent of the Company, other than to an affiliate of the Investor controlled by Melissa Welner, in which case the assignee
must agree in writing to be bound by the terms and conditions of this Agreement.
10. Amendment or Waiver.
No provision of this Agreement
may be (i) amended other than by a written instrument signed by both parties hereto or (ii) waived other than in a written instrument
signed by the party against whom enforcement of such waiver is sought. Failure of any party to exercise any right or remedy under this
Agreement or otherwise, or delay by a party in exercising such right or remedy, shall not operate as a waiver thereof.
11. Miscellaneous.
(a) Solely
for purposes of this Agreement, a Person is deemed to be a holder of Registrable Securities whenever such Person owns or is deemed to
own of record such Registrable Securities. If the Company receives conflicting instructions, notices or elections from two or more Persons
with respect to the same Registrable Securities, the Company shall act upon the basis of instructions, notice or election received from
such record owner of such Registrable Securities.
(b) Any notices, consents,
waivers or other communications required or permitted to be given under the terms of this Agreement shall be given in accordance with
Section 10.4 of the Purchase Agreement.
(c) Failure
of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy,
shall not operate as a waiver thereof. The Company and the Investor acknowledge and agree that irreparable damage would occur in the event
that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It
is accordingly agreed that either party shall be entitled to an injunction or injunctions to prevent or cure breaches of the provisions
of this Agreement by the other party and to enforce specifically the terms and provisions hereof (without the necessity of showing economic
loss and without any bond or other security being required), this being in addition to any other remedy to which either party may be entitled
by law or equity.
(d) All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws
of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New
York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. Each
party hereby irrevocably submits to the exclusive jurisdiction of the federal courts sitting in The City of New York, Borough of Manhattan,
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein,
and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject
to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such
suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being
served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any manner permitted by law. If any provision of this Agreement shall
be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of
the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other
jurisdiction. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION
OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.
(e) The
Transaction Documents set forth the entire agreement and understanding of the parties solely with respect to the subject matter thereof
and supersedes all prior and contemporaneous agreements, negotiations and understandings between the parties, both oral and written, solely
with respect to such matters. There are no promises, undertakings, representations or warranties by either party relative to subject matter
hereof not expressly set forth in the Transaction Documents. Notwithstanding anything in this Agreement to the contrary and without implication
that the contrary would otherwise be true, nothing contained in this Agreement shall limit, modify or affect in any manner whatsoever
(i) the conditions precedent to a Fixed Purchase contained in Article VII of the Purchase Agreement or (ii) any of the Company’s
obligations under the Purchase Agreement.
(f) This Agreement shall
inure to the benefit of and be binding upon the parties hereto and their respective successors. This Agreement is not for the
benefit of, nor may any provision hereof be enforced by, any Person, other than the parties hereto, their respective successors and
the Persons referred to in Sections 6 and 7 hereof.
(g) The
headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof. Unless the
context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine, feminine, neuter, singular and plural
forms thereof. The terms “including,” “includes,” “include” and words of like import shall be construed
broadly as if followed by the words “without limitation.” The terms “herein,” “hereunder,” “hereof”
and words of like import refer to this entire Agreement instead of just the provision in which they are found.
(h) This
Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall
become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature
or signature delivered by e-mail in a “.pdf” format data file, including any electronic signature complying with the U.S.
federal ESIGN Act of 2000, e.g., www.docusign.com, www.echosign.adobe.com, etc., shall be considered due execution and shall be binding
upon the signatory thereto with the same force and effect as if the signature were an original signature.
(i) Each
party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such
other agreements, certificates, instruments and documents as any other party may reasonably request in order to carry out the intent and
accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.
(j) The
language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent and no rules of
strict construction will be applied against any party.
[Signature Pages Follow]
IN WITNESS WHEREOF,
Investor and the Company have caused their respective signature page to this Registration Rights Agreement to be duly executed as of the
date first written above.
|
COMPANY: |
|
|
|
SPECTAIRE HOLDINGS INC. |
|
|
|
|
|
By: |
/s/ Leonardo Fernandes |
|
|
Name: |
Leonardo Fernandes |
|
|
Title: |
Chief Financial Officer |
[Signature Page to Registration Rights Agreement]
IN WITNESS WHEREOF,
Investor and the Company have caused their respective signature page to this Registration Rights Agreement to be duly executed as of the
date first written above.
|
INVESTOR: |
|
|
|
KEYSTONE CAPITAL PARTNERS, LLC |
|
|
|
|
|
By: |
/s/ Fredric G. Zaino |
|
|
Name: |
Fredric G. Zaino |
|
|
Title: |
CIO |
EXHIBIT A
SELLING STOCKHOLDER
This prospectus relates to
the possible resale from time to time by Keystone Capital Partners, LLC Partners of any or all of the shares of common stock that may
be issued by us to Keystone Capital Partners, LLC Partners under the Purchase Agreement. For additional information regarding the issuance
of common stock covered by this prospectus, see the section titled “Keystone Capital Partners, LLC Partners Committed Equity Financing”
above. We are registering the shares of common stock pursuant to the provisions of the Registration Rights Agreement we entered into with
Keystone Capital Partners, LLC Partners on November 17, 2023 in order to permit the selling stockholder to offer the shares for resale
from time to time. Except for the transactions contemplated by the Purchase Agreement and the Registration Rights Agreement, Keystone
Capital Partners, LLC has not had any material relationship with us within the past three years. As used in this prospectus, the term
“selling stockholder” means Keystone Capital Partners, LLC
The table below presents information
regarding the selling stockholder and the shares of common stock that it may offer from time to time under this prospectus. This table
is prepared based on information supplied to us by the selling stockholder, and reflects holdings as of November 17, 2023. The number
of shares in the column “Maximum Number of Shares of Common Stock to be Offered Pursuant to this Prospectus” represents all
of the shares of common stock that the selling stockholder may offer under this prospectus. The selling stockholder may sell some, all
or none of its shares in this offering. We do not know how long the selling stockholder will hold the shares before selling them, and
we currently have no agreements, arrangements or understandings with the selling stockholder regarding the sale of any of the shares.
Beneficial ownership is determined
in accordance with Rule 13d-3(d) promulgated by the SEC under the Exchange Act, and includes shares of common stock with respect to which
the selling stockholder has voting and investment power. The percentage of shares of common stock beneficially owned by the selling stockholder
prior to the offering shown in the table below is based on an aggregate of [●] shares of our common stock outstanding on November
17, 2023. Because the purchase price of the shares of common stock issuable under the Purchase Agreement is determined on each Fixed Purchase
Date, the number of shares that may actually be sold by the Company under the Purchase Agreement may be fewer than the number of shares
being offered by this prospectus. The fourth column assumes the sale of all of the shares offered by the selling stockholder pursuant
to this prospectus.
|
|
Number of Shares of
Common Stock Owned
Prior to Offering |
|
Maximum Number of
Shares of Common Stock
to be Offered Pursuant
to this Prospectus |
|
Number of Shares of
Common Stock Owned
After Offering |
Name
of Selling Stockholder |
|
Number(1) |
|
Percent(2) |
|
|
|
Number(3) |
|
Percent(2) |
Keystone Capital Partners, LLC(4) |
|
[_____] |
|
* |
|
[●] |
|
0 |
|
-- |
| * | Represents beneficial ownership of less than [_]% of the outstanding
shares of our common stock. |
| (1) | This number represents the [_____] shares of common stock we may issue to Keystone Capital Partners,
LLC Partners upon conversion of the Commitment Note as Note Shares in consideration for entering into the Purchase Agreement with us.
In accordance with Rule 13d-3(d) under the Exchange Act, we have excluded from the number of shares beneficially owned prior to the offering
all of the shares that Keystone Capital Partners, LLC may be required to purchase under the Purchase Agreement, because the issuance of
such shares is solely at our discretion and is subject to conditions contained in the Purchase Agreement, the satisfaction of which are
entirely outside of Keystone Capital Partners, LLC’s control, including the registration statement that includes this prospectus
becoming and remaining effective. Furthermore, the Fixed Purchases of common stock are subject to certain agreed upon maximum amount limitations
set forth in the Purchase Agreement. Also, the Purchase Agreement prohibits us from issuing and selling any shares of our common stock
to Keystone Capital Partners, LLC to the extent such shares, when aggregated with all other shares of our common stock then beneficially
owned by Keystone Capital Partners, LLC, would cause Keystone Capital Partners, LLC’s beneficial ownership of our common stock to
exceed the 4.99% Beneficial Ownership Cap. |
| (2) | Applicable percentage ownership is based on [●] shares of our common stock outstanding as of November
17, 2023. |
| (3) | Assumes the sale of all shares being offered pursuant to this prospectus. |
| (4) | The business address of Keystone Capital Partners, LLC is 139 Fulton Street, Suite 412, New York, NY 10038.
Keystone Capital Partners, LLC’s principal business is that of a private investor. Ranz Group, LLC, a Delaware limited liability
company, is the managing member of Keystone Capital Partners, LLC and the beneficial owner of 97% of the membership interests in Keystone
Capital Partners, LLC. Fredric G. Zaino is the managing member of Ranz Group, LLC and has sole voting control and investment discretion
over securities beneficially owned directly by Keystone Capital, LLC and indirectly by Ranz Group, LLC. We have been advised that none
of Mr. Zaino, Ranz Group, LLC or Keystone Capital Partners, LLC is a member of the Financial Industry Regulatory Authority, or FINRA,
or an independent broker-dealer, or an affiliate or associated person of a FINRA member or independent broker-dealer. The foregoing should
not be construed in and of itself as an admission by Mr. Zaino as to beneficial ownership of the securities beneficially owned directly
by Keystone Capital Partners, LLC and indirectly by Ranz Group, LLC. |
PLAN OF DISTRIBUTION
The shares of common stock
offered by this prospectus are being offered by the selling stockholder, Keystone Capital Partners, LLC. The shares may be sold or distributed
from time to time by the selling stockholder directly to one or more purchasers or through brokers, dealers, or underwriters who may act
solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market prices, at negotiated prices,
or at fixed prices, which may be changed. The sale of the shares of our common stock offered by this prospectus could be effected in one
or more of the following methods:
| ● | ordinary brokers’ transactions; |
| ● | transactions involving cross or block trades; |
| ● | through brokers, dealers, or underwriters who may act solely as agents; |
| ● | “at the market” into an existing market for our common stock; |
| ● | in other ways not involving market makers or established business markets, including direct sales to purchasers or sales effected
through agents; |
| ● | in privately negotiated transactions; or |
| ● | any combination of the foregoing. |
In order to comply with the
securities laws of certain states, if applicable, the shares may be sold only through registered or licensed brokers or dealers. In addition,
in certain states, the shares may not be sold unless they have been registered or qualified for sale in the state or an exemption from
the state’s registration or qualification requirement is available and complied with.
Keystone Capital Partners,
LLC is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act.
Keystone Capital Partners,
LLC has informed us that it intends to use one or more registered broker-dealers to effectuate all sales, if any, of our common stock
that it has acquired and may in the future acquire from us pursuant to the Purchase Agreement. Such sales will be made at prices and at
terms then prevailing or at prices related to the then current market price. Each such registered broker-dealer will be an underwriter
within the meaning of Section 2(a)(11) of the Securities Act. Keystone Capital Partners, LLC has informed us that each such broker-dealer
will receive commissions from Keystone Capital Partners, LLC that will not exceed customary brokerage commissions.
Brokers, dealers,
underwriters or agents participating in the distribution of the shares of our common stock offered by this prospectus may receive
compensation in the form of commissions, discounts, or concessions from the purchasers, for whom the broker-dealers may act as
agent, of the shares sold by the selling stockholder through this prospectus. The compensation paid to any such particular
broker-dealer by any such purchasers of shares of our common stock sold by the selling stockholder may
be less than or in excess of customary commissions. Neither we nor the selling stockholder can presently estimate the amount
of compensation that any agent will receive from any purchasers of shares of our common stock sold by the selling stockholder.
We know of no existing arrangements
between the selling stockholder or any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of
the shares of our common stock offered by this prospectus.
We may from time to time file
with the SEC one or more supplements to this prospectus or amendments to the registration statement of which this prospectus forms a part
to amend, supplement or update information contained in this prospectus, including, if and when required under the Securities Act, to
disclose certain information relating to a particular sale of shares offered by this prospectus by the selling stockholder, including
the names of any brokers, dealers, underwriters or agents participating in the distribution of such shares by the selling stockholder,
any compensation paid by the selling stockholder to any such brokers, dealers, underwriters or agents, and any other required information.
We will pay the expenses
incident to the registration under the Securities Act of the offer and sale of the shares of our common stock covered by this
prospectus by the selling stockholder. As consideration for its irrevocable commitment to purchase our common stock under the
Purchase Agreement, we have reserved for Keystone Capital Partners, LLC ________ ___________shares of our common stock we may issue in as Note
Shares in accordance with the Purchase Agreement.
We also have agreed to indemnify
Keystone Capital Partners, LLC and certain other persons against certain liabilities in connection with the offering of shares of our
common stock offered hereby, including liabilities arising under the Securities Act or, if such indemnity is unavailable, to contribute
amounts required to be paid in respect of such liabilities. Keystone Capital Partners, LLC has agreed to indemnify us against liabilities
under the Securities Act that may arise from certain written information furnished to us by Keystone Capital Partners, LLC specifically
for use in this prospectus or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling
persons, we have been advised that in the opinion of the SEC this indemnification is against public policy as expressed in the Securities
Act and is therefore, unenforceable.
We estimate that the total expenses for the offering will be approximately
$[●].
Keystone Capital Partners,
LLC has represented to us that at no time prior to the date of the Purchase Agreement has Keystone Capital Partners, LLC or its agents,
representatives or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term
is defined in Rule 200 of Regulation SHO of the Exchange Act) of our common stock or any hedging transaction, which establishes a net
short position with respect to our common stock. Keystone Capital Partners, LLC has agreed that during the term of the Purchase Agreement,
neither Keystone Capital Partners, LLC, nor any of its agents, representatives or affiliates will enter into or effect, directly or indirectly,
any of the foregoing transactions.
We have advised the
selling stockholder that it is required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions,
Regulation M precludes the selling stockholder, any affiliated purchasers, and any broker-dealer or other person who participates in
the distribution from bidding for or purchasing, or attempting to induce any person to bid for or purchase any security which is the
subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in
order to stabilize the price of a security in connection with the distribution of that security. All of the foregoing may affect the
marketability of the securities offered by this prospectus.
This offering will terminate on the date that all
shares of our common stock offered by this prospectus have been sold by the selling stockholder.
Our common stock is currently listed on OTC Markets under the symbol
“SPEC”.
EXHIBIT B
The business address of Keystone Capital
Partners, LLC is____________. Keystone Capital Partners, LLC’s principal business is that of a private investor. ___________,
is the managing member of Keystone Capital Partners, LLC and the beneficial owner of __% of the membership interests in Keystone
Capital Partners, LLC. ________ is the managing member of ___________ and has sole voting control and investment discretion over
securities beneficially owned directly by Keystone Capital Partners, LLC and indirectly by ___________. We have been advised that
none of ___________, ________ or Keystone Capital Partners, LLC is a member of the Financial Industry Regulatory Authority, or
FINRA, or an independent broker-dealer, or an affiliate or associated person of a FINRA member or independent broker-dealer. The
foregoing should not be construed in and of itself as an admission by ___________as to beneficial ownership of the securities
beneficially owned directly by Keystone Capital Partners, LLC and indirectly by ____________.
23
Exhibit 10.4
FORWARD PURCHASE AGREEMENT CONFIRMATION AMENDMENT
THIS FORWARD PURCHASE AGREEMENT CONFIRMATION AMENDMENT, dated as of
November 17, 2023 (this “Amendment”), is entered into by and among (i) Meteora Special Opportunity Fund I, LP
(“MSOF”), (ii) Meteora Capital Partners, LP (“MCP”), (iii) Meteora Select Trading
Opportunities Master, LP (“MSTO”), (iv) Meteora Strategic Capital, LLC (“MSC”) (with MSOF,
MCP, MSTO and MSC collectively as “Seller”) and (v) Spectaire Inc., a private Delaware corporation
(“Spectaire”).
Reference is
hereby made to the OTC Equity Prepaid Forward Transaction, dated as of January 14, 2023 (amended on October 16, 2023 and as amended from
time to time, the “Confirmation”), by and among Seller, Perception Capital Corp. II, a Cayman Islands exempted company
(“PCCT”) and Spectaire. Capitalized terms not defined herein shall have the meanings assigned to such terms in the Confirmation.
On October 19,
2023, PCCT and Spectaire completed the Business Combination, and accordingly, the Seller delivered a Pricing Date Notice to commence the
Transaction.
1. Amendment: The parties hereto agree to amend the Confirmation as follows:
a. The section titled “Reset
Price” shall be deleted in its entirety and replaced with the following:
Reset Price: |
The Reset Price shall be $1.75; provided that the Reset Price may be
reduced pursuant to a Dilutive Offering Reset or an Equity Line Reset. |
b. The Section titled Share
Consideration shall be deleted in its entirety and replaced with the following:
Share Consideration: |
In addition to the Prepayment Amount, Counterparty shall pay to Seller, directly from the Trust Account, on the Prepayment Date, an amount
equal to the product of (x) the number of Recycled Shares, if any, up to a maximum of 150,000 (the “Share Consideration Shares”)
multiplied by (y) the Initial Price. Additionally, 125,000 Recycled Shares shall be released to the Seller as additional Share Consideration
Shares. The Share Consideration Shares shall not be included in the Number of Shares in this Transaction. The Seller and the Share Consideration
Shares shall be free and clear of all obligations with respect to the Seller and such Share Consideration Shares in connection with this
Confirmation. |
c. The
Counterparty and the Seller acknowledge and agree that the execution of this Amendment shall discharge any obligation of the Counterparty
to deliver cash to the Seller pursuant to the “Shortfall Sales” section.
2. No Other Amendments.
All other terms and conditions of the Confirmation shall remain in full force and effect and the Confirmation shall be read and construed
as if the terms of this Amendment were included therein by way of addition or substitution, as the case may be.
3. Execution
in Counterparts. This Amendment may be executed in any number of counterparts, each of which when so executed shall be deemed to be
an original and all of which when taken together shall constitute one and the same agreement.
4. Ratification.
The terms and provisions set forth in this Amendment modify and supersede all inconsistent terms and provisions set forth in the Confirmation
and, except as expressly modified and superseded by this Amendment, the terms and provisions of the Confirmation are ratified and confirmed
and continue in full force and effect. All parties hereby agree that the Confirmation and Amendment, as amended by this Amendment, shall
continue to be legal, valid, binding and enforceable in accordance with their terms.
5. THIS
AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK (WITHOUT GIVING EFFECT
TO THE CONFLICT OF LAWS PROVISIONS THEREOF).
IN WITNESS WHEREOF, the parties
hereto have caused this Amendment to be executed and delivered by their duly authorized officers as of the date first above written.
|
METEORA SPECIAL OPPORTUNITY FUND I, LP; |
|
|
|
METEORA STRATEGIC CAPITAL, LLC; |
|
|
|
METEORA SELECT TRADING OPPORTUNITIES MASTER, LP; AND |
|
|
|
METEORA CAPITAL PARTNERS, LP |
|
|
|
|
By: |
/s/ Vik Mittal |
|
|
Name: |
Vik Mittal |
|
|
Title: |
Managing Member |
|
|
|
|
SPECTAIRE INC. |
|
|
|
By: |
/s/ Brian Semkiw |
|
|
Name: |
Brian Semkiw |
|
|
Title: |
Chief Executive Officer |
v3.23.3
Cover
|
Nov. 17, 2023 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Nov. 17, 2023
|
Entity File Number |
001-40976
|
Entity Registrant Name |
Spectaire Holdings Inc.
|
Entity Central Index Key |
0001844149
|
Entity Tax Identification Number |
98-1578608
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
155 Arlington St.
|
Entity Address, City or Town |
Watertown
|
Entity Address, State or Province |
MA
|
Entity Address, Postal Zip Code |
02472
|
City Area Code |
508
|
Local Phone Number |
213-8991
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Common stock, par value $0.0001 per share |
|
Title of 12(b) Security |
Common stock, par value $0.0001 per share
|
Trading Symbol |
SPEC
|
Security Exchange Name |
NASDAQ
|
Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 |
|
Title of 12(b) Security |
Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50
|
Trading Symbol |
SPECW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=SPEC_CommonStockParValue0.0001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=SPEC_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Spectaire (NASDAQ:SPEC)
過去 株価チャート
から 4 2024 まで 5 2024
Spectaire (NASDAQ:SPEC)
過去 株価チャート
から 5 2023 まで 5 2024